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Hydrogen sulfide (H2S) is an important gasotransmitter exhibits many 
physiological and pathophysiological functions. Increasing number of reports 
over the past two decades had uncovered many important roles of this gas 
molecule in inflammation, cardiology, neurology, and oxidative biology. 
However, little is known for its role in cancer. Most studies have used the 
simplest sulfide salt, sodium hydrosulfide (NaHS) as the H2S donor but 
ambiguous results were reported, partly due to the concentration used and 
different modes of exposure to H2S. The current study aimed to evaluate the 
effects of H2S on cancer cell viability, metastasis and angiogenesis, and to 
study its underlying mechanisms. 
We previously observed that the slow-releasing H2S donor GYY4137 
but not NaHS, decreased cancer cell viability (Lee et al., 2011). The 
differential effects of NaHS and GYY4137 on cancer may be due to their 
different manner of H2S release. 400 μM of NaHS instantaneously released the 
full amount of H2S in aqueous but was non-detectable after 2 hours. In 
contrast, the same concentration of GYY4137 produced only low amount of 
H2S (≤ 30 μM) that was sustainably detected at least up to 7 days in culture 
media. Importantly, non-cancer cells tested were minimally affected by 
GYY4137. We therefore hypothesized that a continual exposure to low 
concentration of H2S exhibited a selective anti-cell viability effect on cancer 
but not non-cancer cells. To attribute the observed effects were indeed caused 
by H2S, we used NaHS as the H2S donor. Cancer and non-cancer cells were 
treated with either single or continual exposure of NaHS (fresh solution 
changed every 2 hours) and the cell viability was examined. While single 
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exposure of NaHS spared cancer and non-cancer cells, continual exposure to 
NaHS at low micromolar concentrations (5-20 μM) selectively exhibited 
cytotoxicity on cancer but not non-cancer cells. The data showed clearly that 
prolonged exposure to low concentration of H2S possessed selective anti-
cancer cell viability property. 
As selective effects by H2S were observed on cancer but not non-
cancer cells, we then speculated that H2S may target on cancer-addicted 
glucose metabolism and pH homeostasis. Using GYY4137 that acts as a slow-
releasing H2S donor, an increased glucose uptake, glucose utilization and 
lactate overproduction were observed in cancer cells. H2S induced a thiol-
sensitive protein oligomerization of glucose transporter (Glut) 1 that promoted 
increased glucose uptake by the cells. Furthermore, coupled with an H2S-
induced impaired pH regulator activity, a significant intracellular acidification 
was observed in the cancer cells. These mechanisms were absented in the non-
cancer cells. Invasive cancers and cancer-activated endothelial cells were 
recognized to exhibit glycolytic adaptation. Hence, we proposed that H2S will 
effectively target these cell types. Intriguingly, the invasive cancer cell lines 
evidenced with higher basal intracellular lactate production and ECAR/OCR 
ratio showed lower sensitivity towards H2S as compared to their less invasive 
comparisons. It was then found that their basal glycolytic adaptation confers 
lower magnitude of H2S-induced intracellular pH (pHi) reduction thus 
determined their lower sensitivity to H2S. By perturbing intracellular lactate 
accumulation using monocarboxylate transporter 4 inhibitor simvastatin and 
glycolysis booster metformin, an enhanced sensitivity to H2S was observed. 
Taken together, we hereby demonstrated that H2S dysregulated cancer glucose 
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metabolism and pHi homeostasis of cancer cells thence induced cancer cell 
death. 
We next investigated the effects of H2S on cancer metastasis and 
observed a significant inhibitory activity of H2S on cancer cell motility, 
transwell chemoinvasion and anchorage independent colony formation. The 
data indicated that H2S effectively inhibited the cancer metastasis. A cancer-
activated endothelial cell (EC) model was established by culturing the EC in 
the cancer-conditioned media (CM), in contrast to under normal DMEM 
condition. The CM-activated EC showed a glycolytic switch, as evidenced by 
a greater lactate production as compared to the DMEM-cultured EC. H2S 
treatment significantly decreased the cell viability of CM-activated EC via 
induction of lactate overproduction and pHi acidification. DMEM-cultured EC 
was not affected by H2S. More importantly, EC cell migration in response to 
cancer spheroid attraction and tube differentiation were inhibited by H2S 
treatment. The inhibitory effects of H2S on cancer metastasis and angiogenesis 
may partly cause by a H2S-induced disruption on protein conformation and 
activity of vascular endothelial growth factor (VEGF). In vivo mouse study 
showed that GYY4137 increased circulatory sulfide concentration and 
intratumoral sulfide. Significant reduction in tumor growth, volumes and gross 
mass were measured with GYY4137 administration. Lung macrometastasis 
was observed in non-treated control mice but none was observed in 
GYY4137-treated groups. Mechanistically, intratumoral lactate production 
was increased and pH was decreased by GYY4137 treatment, suggesting in 
vitro mechanisms were taking place in vivo too.  
12 
 
Taken together, this study provides strong evidences that H2S is a 
selective anti-cancer agent, which targets on glycolytic metabolism and pHi 
imbalance of cancer and cancer-activated endothelial cells. Advance 
investigations to identify molecular targets of H2S will warrant the 
development of H2S-based donor as an innovative cancer therapeutic strategy.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Hydrogen Sulfide (H2S) As A Biological Molecule 
Hydrogen sulfide (H2S) is a colorless, flammable and water soluble gas with 
its characterized pungent rotten egg smell (Li and Lancaster, 2013). It is long 
known to be produced naturally in sewages, swamps and hot spring sites by 
biodegradation of organic materials by sulfate-reducing bacteria (Barton and 
Fauque, 2009). These bacteria are able to utilize sulfate (SO4
2-
) or oxidized 
sulfur compounds for their energy production, excreting H2S as waste product. 
The sulfides produced has high reactivity with divalent ions such as zinc and 
iron, which give rise to the dark black color of sewage wastes and sludge 
(Poulton et al., 2003). The similar reaction of sulfide with iron/copper 
contributes to its strong inhibitory activity on mitochondrial cytochrome c 
oxidase (Dorman et al., 2002; Dorman et al., 2004). Notoriously, H2S is 
recognized as a toxic gas to all eukaryotes including human. Exposure to 5 
ppm of H2S may induce mitochondrial toxicity and higher doses (≥ 300 ppm) 
may result in immediate collapse and even death (Beauchamp et al., 1984; Li 
and Lancaster, 2013).  
 
1.1.1 Biogenesis of H2S: Mammalian reverse-transsulfuration pathway 
Several bacteria species make methionine from cysteine amino acid, a 
pathway being named as transsulfuration pathway (Ferla and Patrick, 2014). 
Interestingly, the reverse-transsulfuration pathway is identified in mammalian 
system and it is the dominant pathway that produce sulfide endogenously 
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(Finkelstein, 1990). In 1989, Goodwin and colleagues firstly detected sulfide 
in murine brain tissue, provided the first evidence of endogenous production 
of this gas molecule (Goodwin et al., 1989). It was until 1996 when Abe and 
Kimura demonstrated that cystathionine beta synthase (CBS) was the enzyme 
that responsible for H2S production in mammalian brain and exhibited 
neuromodulation activity (Abe and Kimura, 1996). A subsequent report 
identified another H2S-producing enzyme cystathionine gamma lyase (CSE) to 
be expressed in rat aorta, smooth muscle and guinea pig intestines (Hosoki et 
al., 1997). The reverse transsulfuration pathway is illustrated in Illus. 1. The 
importance of H2S produced by CSE as a smooth muscle relaxant was also 
highlighted in the same study. Subsequent from these landmark discoveries, 
several reports confirmed and established that H2S is an important vascular 
and gastrointestinal muscle relaxant in physiology (Teague et al., 2002; Zhao 
et al., 2001b). 
 
Illus. 1. H2S biogenesis pathways in mammalian cell. Endogenous 
production of H2S in mammalian cell by reverse transsulfuration pathway that 
takes place in cytosol and cysteine oxidation pathway that occurs in 
mitochondria. CBS, cystathionine beta synthase; CSE, cystathionine gamma 




Both CBS and CSE are pyridoxal-5’-phosphate (PLP)-dependent 
enzymes that utilize cysteine as major substrate in H2S production (Renga, 
2011). CBS is found to be expressed highly in the kidney and nervous system 
of mouse. Yet, its expression is also found in many organs such as liver, 
placenta, uterus, small intestines and pancreas. CBS produces H2S by β-
replacement reaction using cysteine, though it also involves in reverse-
transsulfuration pathway by catalyzes the conversion of homocysteine to 
cystathionine (Huang and Moore, 2015). On the other hand, CSE is the 
dominant H2S-producing enzyme in peripheral tissues including human 
placenta, amnion, chorion, myometrium, pancreas, smooth muscles, small 
intestines and stomach, utilizes homocysteine and cysteine as substrate (Kabil 
et al., 2011; Kamoun, 2004; Martin et al., 2010). Although CSE is able to use 
both sulfur-containing molecules as substrate, Chiku and colleagues showed 
that at physiological concentration of homocysteine and cysteine, α- and β-
elimination of cysteine by CSE contribute to nearly 70% of the H2S 
production (Chiku et al., 2009; Singh et al., 2009). While under condition of 
hyperhomocysteinemia, a condition of diseased state, α,γ-elimination of 
homocysteine by CSE accounts for about 90% of the H2S production. The 
study indicates clearly that the H2S production activity by CSE is highly 
regulated by the bioavailability of substrate in physiological system, 
highlighting the importance of substrate specificity in regulation of H2S-
producing enzymes (Chiku et al., 2009). The most recent discovered H2S-
producing enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) is 
mitochondrial localized and PLP-independent (Shibuya et al., 2009). 3-MST 
produces H2S through cysteine oxidation pathway (Illus. 1). Cysteine is first 
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converted to 3-mercaptopyruvate by cysteine aminotransferase (CAT). 3-MST 
then converts 3-mercaptopyruvate to pyruvate, producing H2S in mitochondria 
(Kamoun, 2004; Shibuya et al., 2008).  
With the discovery of endogenous production and revelation of its 
important biomedical and physiological functions, H2S is categorized as the 
latest member of gasotransmitters (Gadalla and Snyder, 2010; Wang, 2003). 
This group of gaseous molecules, including nitric oxide (NO) and carbon 
monoxide (CO), are produced endogenously and carry important signaling 
functions. Singly or interconnected, they serve as messengers that 
communicate signaling cascades and networks to activate downstream 
homeostatic responses. 
 
1.1.2 H2S and its donors 
In attempt to uncover importance of sulfide in biology, many investigations 
made use of exogenous sulfide donors to elucidate the actions of the molecule 
on a wide range of physiological responses. Briefly, the exogenous sulfide 
donors can be categorized into three major groups: organosulfur compounds 
(OSC), inorganic sulfide salts and synthetic H2S-releasing agents (Song et al., 




Table 1. Major classes of H2S donors 
 
Organosulfur Compounds (OSC) 
OSCs are sulfur-containing, naturally existed compounds that are abundantly 
found in Allium such as garlic, and Cruciferae vegetables such as broccoli, 
Brussel sprout and cabbages (Iciek et al., 2009). These vegetables are 
recognized to be health beneficial, especially garlic that is well described as 
“immune booster” dating back to records from ancient Egypt, Chinese and 
Hindu civilizations (Block, 1985). Reduced serum cholesterol and blood 
glucose levels were measured in individuals with consumption of garlic and 
other Allium vegetables (Lu et al., 2012; Nasri, 2013; Ried and Fakler, 2014). 
Furthermore, these vegetables was shown to stimulate immune responses 






 Diallyl sulfide (DAS), diallyl disulfide (DADS), 
diallyl trisulfide (DATS) 
Isothiocyanate:  
 Erucin, iberin, sulforaphane 
Inorganic Sulfide salts 
 Calcium sulfide (CaS) 
 Sodium hydrosulfide (NaHS) 
 Sodium sulfide (Na2S) 
Synthetic Anethole trithione (ADT-OH) derivatives: 
 ACS 5, ACS 48, ACS50 etc. 





 S-propyl cysteine, S-allyl cysteine, N-acetyl 
cysteine, S-propargyl cysteine 
Lawesson’s reagent: 
 (p-Methoxyphenyl) morpholino-
phosphinodithioic acid (GYY4137) 
 AP39 (mitochondria-targeted) 
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against microbial, viral and pathogen infection (Feng et al., 2012; Ghazanfari 
et al., 2000; Ghazanfari et al., 2006). 
Garlic oil is a mixture containing of different OSCs. γ-glutamyl-S-
alk(en)yl-L-cysteines and S-alk(en)yl-L-cysteine sulfoxides are two major 
OSCs in intact garlic (Block, 1985; Carson, 1987). They undergo hydrolysis 
and oxidation in exposed to atmospheric water and oxygen, result in formation 
of hundreds of thiosulfinates. Among these, nearly 70-80% is compound 
allicin. Yet, allicin is highly unstable and likely to be further oxidized forming 
oil-soluble volatiles including methyl allyl sulfides, ajoene, diallyl sulfides 
(DAS), diallyl disulfides (DADS) and diallyl trisulfides (DATS) (Amagase, 
2006; Carson, 1987; Fenwick and Hanley, 1985). 90% of allicin administered 
into rat liver disappeared within 3 minutes while less than 1% was detected 
after 6 minutes. The rapid decomposition of allicin produces the strong 
unpleasant odor of garlic.  
 
Inorganic sulfide salts 
The simplest form of sulfide donor is the inorganic salts including calcium 
sulfide (CaS), sodium hydrosulfide (NaHS) and sodium sulfide (Na2S). These 
water soluble salts dissolve readily in aqueous solution and produces only 
sulfide species, as opposed to in OSCs. The simple chemistry of sulfide salts 
enables scientists to conclude confidently the observed bioactivities with H2S. 
A major limitation of using sulfide salts as H2S donor is the instant, non-
controlled release of sulfide in aqueous. An instant production of sulfide does 
not mimic physiological H2S production. Moreover, due to its high volatility, 
most H2S-released by sulfide salts escapes to atmosphere within short 
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1,2-Dithiole-3-thiones (ADTs) is long well recognized as a core moiety acts as 
a H2S-donor. ADT can produce H2S spontaneously under heating at 120 °C in 
phosphate buffer, based on hydrolysis mechanism (Zanatta et al., 2010). In 
biological system, H2S was found to be released from ADT by metabolic 
activity of enzyme esterases (Li et al., 2007). The flexibility of this molecule 
moiety makes it a great candidate in developing H2S donor hybrids. Several 
non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and 
diclofenac have been conjugated to ADT-OH to form HS-NSAIDs (Kashfi, 
2014). Dopamine (DOPA) used in treating Parkinson’s disease was also 
conjugated with ADT (Lee et al., 2010). These H2S donor hybrids were found 
to be protective against pathological inflammation and oxidative stress.  
A Lawesson’s reagent based synthetic molecule, (p-methoxyphenyl) 
morpholino-phosphinodithioic acid (GYY4137) was designed and synthesized 
as the first slow-releasing H2S donor (Li et al., 2008; Rose et al., 2015). The 
novel H2S donor releases H2S by hydrolysis in aqueous in a very slow manner 
and the release is pH dependent with higher releasing rate at acidic pH. In the 
pilot study of GYY4137, sulfide concentration in rat plasma reached maximal 
level after 30 min of compound administration and was maintained at elevated 
level over 3 hours experimental duration (Li et al., 2008). Moreover, a recent 
study by Martelli and coworkers suggested that H2S-release from GYY4137 
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can be promoted by thiols abundantly present in physiological system 
(Martelli et al., 2013b).  
 
1.1.3 Physiological roles of H2S 
Inflammation 
Inflammation is a systemic response to insults from external environment or of 
internal origins. It is increasingly clear now that uncontrolled inflammation is 
responsible for many disease conditions including acute pancreatitis, arthritis, 
sepsis, neurodegeneration and even cancer (Coussens and Werb, 2002; Glass 
et al., 2010; Hansson 2005; Hotamisligil, 2006; Perry et al., 2007; Rittirsch et 
al., 2008). In a cerulein-induced acute pancreatitis mouse model, pre-treatment 
with H2S donor S-propargyl-cysteine (SPRC) resulted in marked reduction in 
myeloperoxidase (MPO) activity and well preserved pancreatic histology with 
lesser inflammatory cell infiltration (Sidhapuriwala et al., 2012). Li et al. 
reported that in lipopolysaccharide- (LPS) induced endotoxemia, an infection-
induced sepsis disease model, the rats treated with GYY4137 showed reduced 
production of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and 
reduced STAT3 and NF-kB activation (Li et al., 2009). H2S-conjugated 
mesalamine has also been developed and showed good protective effect 
against trinitrobenzene sulfonic-induced colitis (Fiorucci et al., 2007).  
 Contradictorily, a pro-inflammatory activity of H2S has also been 
documented in literatures. Plasma H2S concentration was measured to be 
higher in mice developing acute pancreatitis or LPS-induced endotoxemia 
(Bhatia et al., 2005; Li et al., 2005). CSE inhibitor PAG treatment was able to 
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reduce alveolar thickening and leucocyte infiltration to lung tissue as observed 
in histological examination. A marked reversion in acinar cell necrosis and 
pancreatic MPO activity were also evidenced with PAG treatment. Moreover, 
CSE knockout mice are protected from acute pancreatitis and lung injury 
suggesting a primarily pro-inflammation role of endogenous H2S (Ang et al., 
2013). Prophylactic administration of CBS inhibitor aminooxyacetatic acid 
(AOAA) into pancreas had shown protective effect against acute pancreatitis. 
An intraperitoneal administration of NaHS into mouse increased lung MPO 
activity and significant lung injury (Bhatia et al., 2006), markedly aggravated 
NF-kB activation and increased expression of TNF-α, IL-1β and IL-6 in 
human monocyte U937 (Zhang et al., 2007; Zhi et al., 2007).  
 The dual-roles of H2S in either pro- or anti-inflammation may be 
contributed by the different modes of H2S exposure or inhibition employed by 
the different studies. Increased expression of CSE or CBS, and higher H2S 
level are constantly being observed in many inflammation models. Yet, 
whether if the increased H2S concentration is the cause of inflammation or 
secondary protective mechanism activated by host cells to counter the 
inflammation is remained elusive. While exogenous NaHS shows pro-
inflammatory action, several other slow-releasing H2S donors are anti-
inflammatory. These compiled evidences indicate that the exposure manner to 





Complete deficiency of CSE in mice causes marked reduced endogenous H2S 
production with age-dependent development of hypertension (Yang et al., 
2008). A bolus injection of NaHS into rats showed a transient decrease of 
arterial blood pressure (Zhao et al., 2001a). Exogenously administered H2S 
donors GYY4137 and ACS14 also showed successful reduction of blood 
pressure in spontaneous hypertensive and buthionine sulfoximine-induced 
hypertensive rats (Li et al., 2008; Rossoni et al., 2010). The anti-hypertension 
effects of H2S observed in animal models may be contributed by its action on 
vascular smooth muscle.  
H2S was reported to be an important regulator in human aorta smooth 
muscle cell differentiation (Yang et al., 2011). Under serum-induced 
differentiation condition, H2S significantly induced expression of smooth 
muscle differentiation marker genes. Inhibition of CSE using PAG strikingly 
suppressed expression level of smooth muscle myosin heavy chain and 
calponin. However, exogenous H2S had no effect on expression of smooth 
muscle differentiation marker genes with the absence of serum (Yang et al., 
2011). The contractile status of smooth muscle is important in regulating 
blood pressure and blood flow. It was clearly demonstrated that physiological 
concentration of H2S induced opening of ATP-sensitive potassium (KATP) 
channels and caused relaxation of rat aortic ring (Siebert et al., 2008; Sun et 
al., 2011). The hyperpolarization of aortic smooth muscle cells resulted in 
transient decrease of blood pressure in animal. Moreover, preconditioning 
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isolated heart with NaHS showed attenuation of ischemia/reperfusion-induced 
arrhythmias, improvement in cardiac myocyte functions and cell viability 
mediated by opening of sarcolemmal KATP channels (Bian et al., 2006). Apart 
KATP channels, Kv7 voltage-gated potassium channel expressed on smooth 
muscle cells was identified to be another target of H2S, leading to its 
vasorelaxation effect (Martelli et al., 2013a).  
 Blocking of CSE activity using PAG or silencing of CSE expression 
using siRNA decreased cGMP accumulation in cells, while overexpression of 
CSE increased intracellular cGMP (Bucci et al., 2012). It was clearly 
demonstrated that H2S was not an activator of guanylyl cyclases but was 
capable to inhibit phophodiesterase activity at concentration as low as 10-30 
nM (Bucci et al., 2010). Phosphodiesterases involves in biodegradation of 
cyclic nucleotide secondary messengers including cGMP and cAMP 
(Rybalkin et al., 2003). H2S-induced accumulation of cGMP may contribute to 
smooth muscle relaxation while H2S-induced accumulation of cAMP may 
result in muscle contraction (Ali et al., 2006). The biphasic effect of H2S on 
muscle relaxation status appeared to be concentration dependent.  
 Another important aspect to be considered for cardioprotective effect 
of H2S is its interplay with another gaseous messenger nitric oxide (NO). NO 
acts as a vasodilator and directly activates guanylyl cyclase to produce 
increased level of cGMP intracellularly. It is known that H2S can interact with 
NO forming nitrosothiol, hence quenching NO from acting on guanylyl 
cyclases (Nagpure and Bian, 2016). In this term, H2S inhibited NO-induced 
vasodilation effect. However, studies had also reported that H2S stimulated 
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eNOS phosphorylation and promoted NO production in endothelial cells 
(Altaany et al., 2013; Predmore et al., 2011). These studies demonstrated that 
H2S can functionally interact with NO production to exhibit its 
cardioprotective effect.  
 
Nervous system 
Brain is one of the organs in mammalian body that is highly metabolically 
active. It consumes up to 20% of total oxygen and 25% of total body glucose 
for energy requirement (Uttara et al., 2009). Oxidative stress resulted from 
accumulation of reactive oxygen species (ROS) produced from high metabolic 
activity is detrimental especially in nervous system. In fact, it is the major 
etiologies of neurodegenerative diseases such as Parkinson’s and Alzheimer’s 
disease (Ogawa et al., 2002; Pimentel et al., 2012).  
Primary neurons are susceptible to high glutamate-induced toxicity, a 
condition termed oxytosis. Kimura and his co-workers showed that H2S 
protected neuron cells from glutamate-oxytosis by increasing cellular 
glutathione (GSH) level and cystine transport (Kimura et al., 2009; Kimura 
and Kimura, 2004). An increased activity of the rate-limiting enzyme in 
glutathione synthesis pathway gamma-glutamylcysteine synthetase was also 
observed with H2S treatment. Moreover, H2S increased glutamate transporter-
1activity in astrocytes, promoting clearance of glutamate in synaptic clefts 
thus preventing excitotoxicity (Lu et al., 2008). Mechanistically, H2S 
regulated mitoKATP channel and impeded cytochrome c release and caspase 
9/3 activation in rotenone-challenged neuroblastoma SH-SY5Y (Hu et al., 
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2009). Yet in a study by Tang, H2S protected PC12 cells from amyloid β-
induced apoptosis (Tang et al., 2008). Taken together, these studies showed 
the anti-oxidative and anti-apoptotic property of H2S on neurons. Besides, H2S 
was reported to induce hippocampal long-term potential by activating transient 
receptor potential ankyrin 1 (TRPA1) and N-methyl-D-aspartate (NMDA) 
receptors, partly by modulation of cysteine disulfide bond of the proteins (Abe 
and Kimura, 1996; Aizenman et al., 1989; Ogawa et al., 2012).  
 Neurodegenerative diseases such as Alzheimer’s and Parkinson’s 
disease are increasingly common in prevalence (Ferri et al., 2005; Reitz et al., 
2011). A clinical study done in 2008 reported that a lower plasma H2S level 
was positively correlated with severity of Alzheimer disease, suggesting H2S 
to be involved in Alzheimer pathogenesis (Liu et al., 2008). Indeed, H2S 
downregulated the generation of amyloid-β (Aβ) in primary neuron and SH-
SY5Y neuroblastoma cells (Nagpure and Bian, 2014; Zhu et al., 2014). H2S 
decreased expression of amyloid precursor protein and its cleaving enzymes β- 
and γ-secretase (Nagpure and Bian, 2014; Zhang et al., 2011). Interestingly, 
exogenous NaHS or treatment with H2S-rich Tabiano’s spa water was able to 
restore cognitive learning and memory in rat and mouse models of 
Alzheimer’s disease (Giuliani et al., 2013). A reduced amyloidogenesis, 
lowered phosphorylation status of Tau protein, JNK and p38 were observed in 
the same study. It is therefore possible to use H2S as an Aβ and Tau protein 
aggregation inhibitor to improve Alzheimer’s disease pathology. 
Parkinson’s disease is histopathologically identified by a progressive 
degeneration of neurons in substantia nigra of midbrain region (Fearnley and 
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Lees, 1991). Using neurotoxin 6-OHDA-induced disease model, Tiong 
demonstrated that H2S inhibited neuronal cell injury, partly by activation of 
pro-survival Akt signaling pathway (Tiong et al., 2010). NaHS administered 
into systemic circulation showed positive outcome by reversing progressive 
movement dysfunction and decreasing lipid peroxide malondialdehyde level in 
6-OHDA or rotenone-induced neuronal damage (Hu et al., 2010). H2S may 
also upregulated endogenous heme oxygenase 1 and glutamate-cysteine ligase 
for antioxidative defense mechanisms in a nuclear-factor-E2-related (Nrf2)-
dependent pathway (Calvert et al., 2009; Kida et al., 2010). These cell and 
animal studies have presented protective effects by H2S yet the use of H2S 
donors for long-term therapeutic purposes still requires further exploration.  
 
1.2 H2S In Cancer 
Research studies in the past decades recognized important functions of H2S in 
various physiological systems under healthy or disease condition. Perhaps 
intriguingly, study on the roles of H2S in cancer biology remains limited in 
number and is discussed only in recent years.  
 
1.2.1 Roles of endogenous H2S-synthesis enzymes in carcinogenesis 
A landmark discovery on the role of endogenous H2S-synthesis enzymes in 
cancer was done by Szabo (2013). They compared human colon cancer 
samples with adjacent normal mucosa tissue and found that CBS was highly 
upregulated in the cancer tissue. No difference was observed for expression 
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level of CSE and 3-MST. Similar observation was made in cancerous colon 
adenocarcinoma cell lines HCT116, HT29, LoVo as compared to non-
malignant NCM356 colon epithelial (Szabo et al., 2013). The upregulated 
CBS was localized both in cytosol and mitochondria in HCT116, suggesting 
its possible role in bioenergetics in cancer.  
 High CBS in colon cancer contributed to higher rate of H2S 
production and the increased production of H2S was inhibited by a CBS 
inhibitor AOAA. They author then studied the role of CBS in colon cancer cell 
proliferation and invasion. Either silencing of CBS expression by stably 
expression of shRNA or protein activity inhibition with AOAA suppressed 
HCT116 cell proliferation and invasion. Oppositely, S-adenosyl-methionine 
(SAM) acts as CBS activator increased cell proliferation (Módis et al., 2014). 
Furthermore, localization of CBS in mitochondria led the authors to 
investigate mitochondrial bioenergetics in loss of CBS. It was found that CBS 
inhibition caused decrease in basal mitochondria respiration, respiratory 
reserve capacity and glycolysis in HCT116. In HCT116 xenograft mouse 
model, silencing of CBS expression or inhibition of CBS activity reduced 
tumor growth and angiogenesis within tumor tissue. In addition, reduced 
number of metastatic lesions from cecum to liver was observed (Bohanon et 
al., 2014). The authors thus conclude that H2S production from CBS 
modulates colon cancer cell motility and promotes cancer cell proliferation by 
promoting mitochondria bioenergetics. 
 CSE is not involved in the pro-carcinogenesis activity in HCT116. 
However, in SW480 colon cancer cell line, expression level of CSE was 
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significantly high and was further upregulated by activation of Wnt signaling 
pathway (Fan et al., 2014). Inhibition of CSE activity using PAG or gene 
silencing significantly reduced SW480 cell proliferation and xenograft tumor 
growth. The findings from the abovementioned studies demonstrated that H2S 
from either CBS or CSE plays a pro-cancer role in colon cancer development 
and might be cancer cell line specific. 
 Also shown to be highly expressed in epithelial ovarian cancer 
particularly in serous histology subtype, CBS plays a role in ovarian cancer 
cell proliferation and invasion. Quantitative RT-PCR and protein 
immunoblotting showed increased expression level of CBS in ovarian cancer 
cell lines A2780, OV202 and SKOV3 as compared to control non-malignant 
ovarian surface epithelial cell line OSE (Bhattacharyya et al., 2013). Inhibition 
of CBS resulted in inhibition of cell proliferation and viability, coupled with a 
significant decrease of antioxidant glutathione level. It was then found that 
loss of CBS caused increase of ROS levels and induction of apoptosis in 
epithelial ovarian cancer cells. When CBS silencing and cisplatin treatment 
were applied on xenograft tumor harboring mice, marked reduction in tumor 
weight and decrease in number of metastatic nodules were observed 
(Bhattacharyya et al., 2013). Taken together, the authors claimed that CBS 
equips ovarian cancer cells with antioxidative defense that promotes their cell 
proliferation and cancer progression.  
 Another cancer type that showed altered expression level of CBS 
and CSE is prostatic tissue. Guo and colleagues reported that an androgen-
dependent prostate cancer cell line LnCaP expressed marked higher level of 
38 
 
CBS and CSE that were expressed in very low level in normal prostatic 
epithelial RWPE-1 (Guo et al., 2012). They tested if expression level of CBS 
and CSE in LnCaP is hormone responsive. Interestingly, dihydrotestosterone 
downregulated expression levels of both the H2S-synthesis enzymes. 
 While the above studies suggest a pro-cancer role of endogenous 
H2S, Takano and coworkers stably silenced CBS in U87-MG glioma cells and 
examined its tumorigenicity (Takano et al., 2014). Remarkably, the CBS-null 
subclone cell line showed increased cell proliferation rate and a faster tumor 
growth latency period. An overall faster tumor growth was observed with 
greater vascular density and depth of invasion. They also showed that the 
silencing of CBS in glioma increased HIF2a, VEGF and ANGPTL4 
expression that favored anchorage-independent cell growth in vitro. These 
findings reveal an opposite side of endogenous H2S-synthesis enzyme in 
carcinogenesis from what have been observed in colon and ovarian cancers.  
 
1.2.2 Effects of exogenous H2S donors on cancer 
Garlic extracts were firstly shown to be effective in inhibiting tumor growth of 
sarcoma 180 ascites in CFW Swiss mice (Weisberger and Pensky, 1957). The 
study marked a promising initiation of utilizing organosulfur as an anti-cancer 
agent. In a population-based case-control study, You et al. reported a nearly 
60% reduction in gastric cancer occurrence in the highest quartile of Chinese 
population who consumed highest intake of garlic and onions, as compared to 
those who was in the least quartile of Allium vegetables consumption (You et 
al., 1989). The same study also demonstrated significant tumor inhibition in 
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animal by administration of Allium extracts. Tanaka et al. reported that 
treatment with high dosages of aged garlic extracts significantly reduced 
colorectal adenomas in patients in a double-blind, randomized clinical trial 
study (Tanaka et al., 2004; Tanaka et al., 2006). Following that, increasing 
evidences had demonstrated the anti-cancer effect of OSC in pancreatic, liver, 
breast and prostate cancers (Howard et al., 2007; Lan et al., 2013; Modem et 
al., 2012; Zhang et al., 2013). 
The Allium extracts used is a complex mixture consists of hundreds of 
biologically active compounds. In order to identify the OSC that carries anti-
cancer activity, researchers purify and characterize some of the compounds. 
Interestingly, most of the OSC possesses anti-cancer effect even when singly 
administration (Nouroz et al., 2015; Thomson and Ali, 2003). Allicin 
produced secondarily from hydrolysis and oxidation of garlic extract 
effectively inhibited cell proliferation of colon cancer cells HCT116, LS174T, 
HT29 and Caco2 (Bat-Chen et al., 2010). Similar inhibitory effect was also 
evidenced in gastric cancer SGC7901 and lymphoma L5178Y (Padilla-
Camberos et al., 2010; Tao et al., 2013b). Adding on to the benefits and 
advantages of allicin, normal splenocytes were shown to be well tolerated with 
more than double the concentration of allicin used as compared to lymphoma 
(Padilla-Camberos et al., 2010). This finding thus suggests a low toxicity of 
allicin on non-cancer cells.  
Another major group of OSC present in Allium extracts is the allyl 
sulfides (Block, 1985; Fenwick and Hanley, 1985). It is characterized that the 
reactivity of allyl sulfides are directly determined by the number of sulfur 
atom present in the molecule (Munday et al., 2003). Tetrasulfides are highly 
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reactive, following with tri- and disulfides, while monosulfides are the least 
active form of all. Therefore, most studies utilized diallyl di- (DADS) or 
trisulfides (DATS) as OSC. DADS was reported to be active in causing G2/M 
cell cycle arrest and inducing apoptosis in various cancers including colon, 
pancreas, prostate, lung, brain and stomach (Aquilano et al., 2010; Bo et al., 
2014; Bottone et al., 2002; Gunadharini et al., 2006; Song et al., 2009; Wu et 
al., 2011). On the other hand, the more reactive DATS too showed inhibitory 
activity in cell proliferation of colon, gastric and prostate cancers (Ha et al., 
2005; Herman-Antosiewicz and Singh, 2005; Hosono et al., 2005). In 
particular, DATS was shown to selectively decreased cell viability of 
melanoma A375 and basal cell carcinoma BCC but not affecting human 
keratinocytes HaCaT (Wang et al., 2010).  These collective evidences clearly 
demonstrate the pan anti-cancer effects of OSC.  
 The use of NaHS in cancer study demonstrates ambiguous results. 
NaHS treatment decreased cell proliferation of breast cancer MCF7 and 
prostate cancer LnCaP, by induction of apoptosis (Lv et al., 2014; Zhao et al., 
2014a). On the other hand, a stimulated cell proliferation and cell cycle 
progression were observed in oral squamous carcinoma Cal27, GNM and 
WSU-HN6 cells (Ma et al., 2015). Though the differential effects may be 
explained by the different cell line models used by the studies, opposite effects 
of NaHS in either promoting or inhibiting cancer cell proliferation were 
reported in same colon cancer cell line too. A 200 μM NaHS treatment 
induced S-phase progression and cell proliferation but 1 mM inhibited cell 
migration and proliferation in HCT116 (Cai et al., 2010; Wu et al., 2012). It 
appeared that low micromolar concentration of NaHS induced activation of 
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pro-survival Akt and ERK signaling. However at higher milimolar 
concentration of NaHS, mTOR and S6 kinase activity were suppressed, 
causing autophagy and apoptosis. The elusive results may be due to the 
different concentration and duration of exposure to NaHS.  
 In fact, the studies by Cai and Wu clearly demonstrates the limitation 
of using NaHS as a H2S donor. Being a simple salt, NaHS or Na2S releases 
non-physiologically relevant, large amount of sulfide instantaneously into the 
system, possibly induces acute but false biological responses. In this context, 
synthetic H2S donors that exhibit slow and sustainable H2S release appear to 
be more appropriate agent. The slow-releasing H2S donor, GYY4137 was 
shown to be able to maintain prolonged and consistent H2S release as 
compared to the sulfide salts (Li et al., 2008). We had previously examined the 
releasing profile of NaHS and GYY4137 in culture media. 400 μM NaHS 
produced all sulfide and peaked at or before 15 min. No detectable sulfide was 
measured from NaHS after 2 hours. In contrast, GYY4137 at the same 
concentration maintained low but detectable amount of sulfide (less than 30 
μM) over 7 days in culture (Lee et al., 2011).   
The bioactivity of GYY4137 on cancer cells was systematically 
studied. A wide range of cell lines were treated with GYY4137 or NaHS and 
their cell viability was examined after 5 days (Lee et al., 2011). GYY4137 
reduced cell viability of cancer cell lines HeLa, HCT116, HepG2, HL60, 
MV4-11, MCF7 and U2OS but not the normal lung fibroblast WI38 and 
IMR90. NaHS had minimal effect on cell viability and was only observed at 
high concentration (800 μM). A GYY4137-concentration dependent reduction 
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in xenograft tumor volume was also reported. Lu et al. too showed that 
GYY4137 was active in suppressing cell proliferation and tumor growth of 
hepatocellular carcinoma HepG2 and Bel7402 (Lu et al., 2014). A decrease 
activation of STAT3 and HIF1a expression were observed in HepG2 treated 
with GYY4137.  
Synthetic H2S-releasing hybrids especially HS-NSAIDs are shown to 
exhibit good anti-cancer activity. Four HS-NSAIDs including sulindac, 
ibuprofen, naproxen and aspirin were used on leukemia, breast and colon 
cancer cell lines and showed significant reduction in cancer cell viability and 
proliferation (Chattopadhyay et al., 2012; Kashfi, 2014). Interestingly in these 
studies, the author also examined the anti-cancer effect of the respective 
parental NSAIDs and declared that HS-NSAIDs were 38-1300 times more 
effective. A total of 11 cancer cell lines were examined and all showed 
reduced cell growth with HS-NSAID treatment, with HS-aspirin being the 
most potent compound. The authors hence concluded that the potential of HS-
NSAID as anti-cancer agent was independent of cancer tissue types.  
 OSCs and synthetic GYY4137 and HS-NSAID have been reported by 
many independent groups to exhibit anti-cancer activity in various cancer cell 
lines and xenograft tumor animal models. This clearly creates an exciting 
research area in exploring utilization of H2S donors as innovative cancer 
therapeutic agent. Potentially, action of H2S on the fundamental differences 
between cancer and non-cancer cells, such as their differential glucose 




1.3 Glucose Metabolism and pH Homeostasis In Cancer Biology 
An increase in aerobic glycolysis is long recognized to be a metabolic 
hallmark of cancer (Gatenby and Gillies, 2004; Gillies et al., 2008). The 
phenomenon also known as the “Warburg effect”, describes a metabolic 
switch in energy production by cancer cells from mitochondrial oxidative 
phosphorylation towards glycolysis (Lunt and Vander Heiden, 2011; Warburg, 
1956). A significant increase in glucose uptake channeled into glycolytic 
pathway is used for ATP production and conversion to other metabolic 
intermediates as building blocks. These essentials promote tumor growth and 
proliferation. Yet so, addiction to glucose metabolism resulted in high 
production of metabolic acid lactate. In order to compensate for this 
acidification, cancer cells rely on a sophisticated pH homeostasis mechanism 
to maintain their physiological intracellular pH (pHi) (Brahimi-Horn and 
Pouysségur, 2007; Schornack and Gillies, 2003).  
 
1.3.1 Glycolytic adaptation and pH homeostasis for cancer survival 
As early in 1920s, Otto Warburg described an enhanced lactate production by 
tumor tissues and cancerous cells (Warburg, 1956). The metabolic activity was 
found to be secondary to high glucose consumption, even under aerobic 
condition. It is unusual in view that glycolysis produces only 2 ATP molecules 
per glucose as compared to 36 or 38 ATP molecules from mitochondrial 
oxidative respiration. Therefore, a logical postulation proposed is that cancer 
cells harbor defects in mitochondrial respiratory system that force them to 
utilize only glycolysis for energy production. Advances over the past 50 years 
reveal that impairment in mitochondrial respiration is rather rare in cancers 
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and cancer tissues in fact consume nearly similar level of oxygen as to 
surrounding normal tissues (Weinhouse, 1976). Despite the debatable cause of 
glucose addiction, this characteristic of elevated glucose uptake by cancer is 
employed in fluorodeoxyglucose-positron emission tomography (FDG-PET), 
a current clinical imaging technology for cancer diagnosis and staging (Rohren 
et al., 2004). 
Many alterations observed in cancer converged to a similar metabolic 
phenotype. The high rate of glucose metabolism and lactate production by 
cancer cells logically confers growth advantages. Firstly, a rather simple 
glycolysis pathway enables rapid production of ATP in cytosol to feed short-
term demand of energy. This is supported by biological modelling that 
suggests glycolysis serve as a flexible metabolic mechanism to provide ATP 
in correct subcellular compartment particularly to activate ATP-dependent 
membrane transporters (Epstein et al., 2014). The idea is particularly 
applicable in avascular tumor stage during cancer development, when 
availability of oxygen is limited and oxidative phosphorylation is suppressed 
(Gao et al., 2011).  
 Besides, metabolites generated along the glycolysis pathway serve as 
precursors for biosynthesis of other biomolecules required for cell replication 
and proliferation. One such very important intermediate molecule is glucose-
6-phosphate (G6P) that gets channeled into pentose phosphate pathway (PPP) 
(Patra and Hay, 2014). PPP is crucial to generate pentoses that then are used 
for nucleotide synthesis. NADPH, an important cellular reductant to counter 
ROS production was also an important anabolite produced from PPP. 
Shuttling of G6P into PPP not only ensures a continuous glycolysis process 
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but also feeds the new DNA synthesis needed for cell replication (Tong et al., 
2009). Moreover, pyruvate acts as important precursor in synthesis of amino 
acids and lipids. These comprehensive metabolic networks centered on 
glucose metabolism highlight the importance of glycolysis in cancer.  
The end product of aerobic glycolysis by cancer is metabolic acid 
lactate. Lactate accumulation intracellularly will bring to intracellular 
acidification that is disastrous to cancer cells. Therefore, cancer cells 
overexpress a range of transmembrane proteins that serve as pH regulators to 
compensate for the intracellular acidification. Among these, monocarboxylate 
transporters (MCTs), proton-pump vacuolar ATPase (V-ATPase), carbonic 
anhydrases (CAs), anion exchangers (AEs) and sodium/proton exchangers 
(NHEs) cooperatively form an efficient pH homeostasis network (Halestrap 
and Price, 1999; Mount and Romero, 2004; Orlowski and Grinstein, 2004; 
Pastorek et al., 1994; Pérez-Sayáns et al., 2009). In particular, AEs and NHEs 
are two major families of pH regulator that help to maintain a normal alkaline 
pHi for cancer cell survival (Illus. 2). 
Moreover, with the high activity of AEs and NHEs, cancer cells are 
able to excrete metabolic acid actively from cytoplasm into surrounding 
environment. An acidified extra-tumoral microenvironment confers 
advantageous conditions that facilitates in cancer cell proliferation and 
invasion. Rofstad and coworkers demonstrated that by pre-culturing human 
melanoma A-07, D-12, and T-22 in culture media at pH 6.8, cancer cells 
increased protein expression of matrix metalloproteinases (MMP)-2, MMP-9, 
cathepsin B, cathepsin L, VEGFA and IL-8 (Rofstad et al., 2006). These 
mechanisms contributed to an increased pulmonary metastasis as compared to 
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control melanoma cells cultured at pH 7.4. Besides, acidic tumor 
microenvironment was shown to inhibit the uptake of anti-cancer compounds 
such as mitoxantrone, paclitaxel and topotecan (Vukovic and Tannock, 1997). 
A suppressed host immune response, particularly a much reduced cytolytic 
function of natural killer (NK) cells was documented when NK cells were 
exposed to tumor-derived lactate (Husain et al., 2013; Lardner, 2001). Thence, 
strategies to manipulate cancer cell pH homeostasis could potentially an 
effective way to trigger cancer cell death (McCarty and Whitaker, 2010; Webb 
et al., 2011). 
 
 
Illus. 2. Glycolytic adaptation and pH homeostasis in cancer. Cancer cell 
exhibits enhanced glucose uptake that feeds its high glycolytic rate. Aerobic 
glycolysis produces metabolic acid that causes intracellular acidification. 
Cancer cell overexpresses many pH regulators, particularly NHEs and AEs 
that work cooperatively to maintain an alkaline physiological pHi that is 




1.3.2 Metabolic interplay between cancer and endothelial angiogenesis 
Cancer angiogenesis is one of the most important events in carcinogenesis. 
The formation of neo-blood vessels ensures a continuous supply of nutrient 
and oxygen to tumor mass that supports cancer growth (Carmeliet and Jain, 
2000). Cancer angiogenesis is activated by release of soluble factors from 
cancer cells. These factors activate the nearby endothelial cells and are found 
to induce metabolic changes in endothelial cells (Keeley et al., 2010; Shahi 
and Pineda, 2008).  
 During cancer angiogenesis, tip endothelial cells are actively 
proliferate and are highly motile evidenced by dynamic formation of filopodia 
and lamellipodia (De Bock et al., 2013; Gerhardt, 2008). Activated by the axis 
VEGF-VEGFR2 signaling, and partly by Wnt pathway, tip endothelial cells 
increased glycolysis especially when entering into S-phase (Almeida et al., 
2010). The high glycolysis by activated endothelial cells feeds the high ATP 
turnover in regulation of dynamic cytoskeleton rearrangement during cell 
migration. Remodeling of filopodia and lamellipodia involves rapid actin 
polymerization and depolymerization that require large amount of ATP 
(Romero et al., 2007; Yogurtcu et al., 2012). Glycolytic enzymes were found 
to be highly localized at lamellipodia, region where F-actin bundles were 
highly expressed, supplying localized ATP production at the energy hotspot 
(De Bock et al., 2013). Interestingly, downregulation of glycolysis by 
silencing the key glycolytic regulator enzyme phosphofructokinase (PFK) 
completely impaired filopodia and lamellipodia formation in endothelial cells.  
 Besides that, glycolytic metabolites from cancer cells too play 
important activation roles on endothelial cells. Lactate produced by cancer 
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cells was actively uptaken by surrounding endothelial cells through activation 
of monocarboxylate transporter (MCT)-1 (Végran et al., 2011). This led to 
inhibition of prolyl-hydroxylase domain protein 2, a negative regulator of 
HIF1a, thus promoted HIF1a-induced angiogenic pathway (De Saedeleer et al., 
2012). A significant increase in IL-8 production by endothelial cells was 
evidenced. This created an autocrine loop for endothelial activation and 
neovascular maturation (Polet and Feron, 2013). Taken together, it is clearly 
demonstrated by compiling evidences that metabolic crosstalk between cancer 
cells and endothelial cells, especially in the context of metabolic adaptation to 
glucose, is critical for cancer progression (Illus. 3). Thus, this area appears as a 




Illus. 3. Cancer metastasis and angiogenesis. Cancer metastasis requires 
cancer cells to be equipped with high motility, invasiveness and ability to 
proliferate under non-anchorage condition to establish distant colony. A 
glycolytic switch comparing between in situ cancer cells at primary tumor site 
and invaded cancer cells is evidenced. Cancer factors released by invasive 
cancer cells can also induce a glycolytic switch on endothelial cells that 




1.3.3 Targeting cancer metabolism and pH homeostasis to anti-cancer 
Given the glycolytic nature of cancer cells, tremendous efforts have been 
invested in developing metabolism targeted cancer therapy. The foremost 
logical idea is to block glucose metabolism in order to deprive bioenergetics of 
cancer cells. A phase-1 clinical trial using glycolytic inhibitor 2-deoxyglucose 
(2-DG) was conducted on 34 patients with advanced solid tumors (Raez et al., 
2013). A tolerated doses of 63 mg/kg/day 2-DG documented 32% of stable 
disease and 66% of progressive disease as the best response. Although all 
subjects showed hypoglycemia following 2-DG administration, only 1 patient 
showed partial response in solid tumor regression. Besides, an expected 
synergic effect of 2-DG with docetaxel was not observed. Utilization of 
glycolysis inhibitor 2-DG as a monotherapy does not seem to possess apparent 
effect as speculated. Nonetheless, some studies had reported an increase 
efficacy of other chemotherapy agents and radiotherapy in osteosarcoma, non-
small cell lung cancers and glioblastoma (Maschek et al., 2004; Singh et al., 
2005). 
 Asides 2-DG, an inhibitor of PFK, namely 3-(3-pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one (3PO) showed transient reduction of glycolysis and 
positive outcomes in anti-cancer (Schoors et al., 2014). 3PO inhibition on 
glycolysis was partial and reversible. Despite a general reduction in 
angiogenesis under health or disease conditions was observed, the author 
claimed that only high glycolytic cancer and cancer-activated endothelial cells 
were severely affected by inhibition of PFK by 3PO. Baseline glycolysis for 
homeostatic purposes was not affected (Schoors et al., 2014). More works are 
needed to evaluate the safety perspective and efficiency of these glycolysis 
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blockers as some essential organs such as brain and eyes are also reply highly 
on glycolysis for energy production.  
 On the other hand, manipulation of pH homeostasis in cancer cells may 
be a worth-explored field in anti-cancer. Principally, altering systemic 
buffering pH particularly by increasing extracellular pH may directly impact 
on tumor growth. Orally intake of bicarbonate did not cause obvious change in 
plasma pH but was able to elevate subnormal pH of tumor microenvironment 
(Robey et al., 2009). In nude mice harboring breast tumor, oral administration 
of sodium bicarbonate significantly reduced metastasis occurrences to nearby 
lymph nodes and distal lung organ. Yet, no regression in primary tumor 
growth was observed. When translated into a human with weight of 70 kg, a 
daily dosage as high as 31.75 g of sodium bicarbonate is required for the 
alkalinizing therapy and this may cause temporary nausea and diarrhea 
(Requena et al., 2005). Therefore, chronic administration of bicarbonate was 
implemented instead.  
An alternative to disrupt cancer pH homeostasis is to target pH 
regulators so to achieve pHi acidification. Sulphonamides and coumarin based 
derivatives have been developed to target tumor associated carbonic 
anhydrase-9 and -12 (Carta et al., 2012; Ekinci et al., 2012; M Monti et al., 
2012; Supuran, 2012). 4,4’-diisothiocyano-2,2’-stilbenedisulphonic acid 
(DIDS) and cariporide inhibit AEs and NHEs activity respectively (Jessen et 
al., 1986; Masereel et al., 2003). Yamagata and coworker demonstrated that 
ionophore nigericin induced time-dependent anti-cell viability under pHe 6.8 
in murine KHT and EMT-6 tumor cell line (Yamagata and Tannock, 1996). A 
72 hours continuous infusion of DIDS and nigericin showed an enhanced anti-
51 
 
tumor activity, with only 0.002 surviving fraction as compared to 0.1 in 
nigericin treatment alone. Besides, pretreatment with pH regulator inhibitors 
prior to delivery of chemotherapeutic agents resulted in greater apoptotic 
events in gastric cancer SGC7901 (Chen et al., 2012). This demonstrated that 
pH regulator inhibitor can potentiate anti-cancer therapy.  
Disappointedly, clinical development of these pH regulator inhibitory 
compounds proved to be unsuccessful (Theroux et al., 2000; Yamagata and 
Tannock, 1996). A large scale clinical trial in assessing potential of using 
cariporide as NHE inhibitor in preventing myocardial infraction reported 4.8% 
to 6.6% drug discontinuation due to adverse events. Small occurrence of liver 
and kidney toxicity were also evidenced in treatment group. Owing to the 
toxicity, alternative approaches that target cancer cell pH would serve as a 
better anti-cancer strategy. 
 
1.4 Aims of Study 
Development of effective anti-cancer therapeutic agent with low toxicity on 
non-cancer cells is an on-going effort. We had previously reported using the 
slow-releasing H2S donor GYY4137, cell viability of cancer but not non-
cancer cells was significantly reduced (Lee et al., 2011). The exciting results 
suggest that H2S may potentially be used as a selective anti-cancer agent that 
spares non-cancer cells. At the same time, intriguingly, the sulfide salt NaHS 
did not affect cell viability regardless of cell type. Examining their H2S-
releasing profiles, it was evidenced that NaHS releases H2S acutely but 
sustains only for a short period of time (< 2 hours). GYY4137 on the other 
hand exhibits low amount but sustained-release of H2S over days. This leads 
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us to hypothesize that continual exposure to low concentration of H2S may 
possess selective anti-cancer cell viability effect. We thence (i) examined 
H2S effect on cell viability of cancer and non-cancer cells. As long known that 
cancer cells are highly dependent on the glucose metabolism and an efficient 
pH homeostatic system for survival, we also (ii) explored mechanism of action 
by H2S on cancer cell glucose metabolism and pH regulation. To explore 
further the potential of using H2S as an anti-cancer agent, we (iii) investigated 
H2S effect on metastatic activity of glycolytic adapted invasive cancers and (iv) 
possible intervention by H2S on cancer angiogenesis, particularly the interplay 
between invasive cancer and endothelial cell. Last but not least, we developed 
an allograft tumor model to (v) investigate anti-cancer activity by H2S in vivo. 
The findings may greatly enhance our current knowledge on H2S as a 
biologically active gas molecule especially in cancer biology. Moreover, 
possible novel and innovative therapeutic strategy can be developed in future 




CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell culture  
Standard cell culture procedures and methods following ATCC Animal Cell 
Culture Guide (American Type Culture Collection, 2012) were used unless 
otherwise stated. Cell culture was maintained in a 37 ⁰C incubator supplied 
with 5% carbon dioxide. Anchorage dependent monolayer cell lines were 
subcultured when reaching 70% to 90% confluent. Culture media was 
removed and monolayer cells were rinsed once with pre-warmed phosphate 
buffered saline [PBS, 137 mM NaCl (Scheldelco, S0119-1), 2.7 mM KCl 
(Sigma, #7447-40-7), 10 mM Na2HPO4 (Sigma, #71640), 1.8 mM KH2PO4 
(Merck, #2389213)]. PBS was removed and 0.5% trypsin-EDTA solution 
(Invitrogen, #15400-054) was added onto monolayer cells. Cell dissociation 
from growth surface of culture flasks was monitored under light microscope. 
Trypsin was inactivated with at least 3 volumes of complete growth media. 
Remaining cells were washed and collected into tubes. Collected suspension 
was centrifuged at 125 × g for 3 min. Supernatant was removed and cell pellet 
was dispersed in fresh complete growth media. Cell lines were maintained into 
new culture flasks according to their respective split ratio. Suspension cell 
lines at 2 to 5 × 10
6
 cells/ml density were diluted with fresh media to 2 × 10
5
 





Table 2. Cell lines and culturing condition 





4T1-Luc RPMI/10% FBS  1:8 CRL-2539 
MCF7 DMEM/10% FBS 1:8 HTB-22 
MDA-MB-231 DMEM/10% FBS 1:5 HTB-26 
Prostate Carcinoma 
LnCaP RPMI/10% FBS 1:5 CRL-1740 
DU145 DMEM/10% FBS 1:8 HTB-81 




H1299 RPMI/10% FBS 1:6 CRL-5803 
A549 DMEM/10% FBS 1:8 CCL-185 
Epithelial Ovarian Cancer 
OVCAR3 RPMI/20% FBS 1:4 HTB-161 
OVCA433 DMEM/10% FBS 1:5  
SKOV3 DMEM/10% FBS 1:5 HTB-77 
A2780P DMEM/10% FBS 1:8  
OVCAR10 DMEM/10% FBS 1:5  
HeyA8 RPMI/10% FBS 1:5  
Cervical Adenocarcinoma 
HeLa DMEM/10% FBS 1:5 CCL-2 
SiHa DMEM/10% FBS 1:5 HTB-35 
Hepatocellular Carcinoma 
HepG2 DMEM/10% FBS 1:6 HB-8065 
Colorectal Carcinoma 
HCT116 DMEM/10% FBS 1:6 CCL-247 
Osteosarcoma 
U2OS DMEM/10% FBS 1:5 HTB-96 




SNU5 DMEM/20% FBS  CRL-5973 
SNU1 RPMI/10% FBS  CRL-5971 
Leukemia 
HL60 DMEM/10% FBS  CCL-240 
MV4-11 RPMI/10% FBS  CRL-9591 
Neuroblastoma 






Non-cancer Cell Lines 
WI38 DMEM/10% FBS 1:4 CCL-75 
IMR90 DMEM/10% FBS 1:4 CCL-186 
MCF10A MEBM BulletKit (Lonza, CC-
3150)/10% FBS, 100 ng/ml 
cholera toxin (Sigma, C8052) 
1:5 CRL-
10317 
PBMC RPMI/10% FBS   
Primary 
Keratinocyte 
Complete keratinocytes media 
(Life Tech, #17005-042) 
1:4  
293T DMEM/10% FBS 1:8 CRL-3216 
Endothelial Cell 
EA.hy926 DMEM/10% FBS 1:5 CRL-2922 
* RPMI (PAA, E15-842); DMEM (Sigma, D1152); Fetal bovine serum (FBS, 
HyClone, SV30160.03) 
 
2.2 Compound treatments 
Synthesis of GYY4137, ZYJ1122 and SZJ2263 
20 mmol of morpholine was added dropwise into 4 mmol of 2,4-bis(4-
methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane in a total volume of 
12 ml methyl chloride. Reaction mixture was stirred at RT for 2 hours. 
GYY4137 formed as 67% yield was suction filtered and washed with methyl 
chloride solvent. To prepare ZYJ1122, 2 mmol of morpholine was added 
dropwise into 1 mmol of diphenylphosphinic acid in dichloromethane. 
Reaction was stirred at RT for 1 hours and product white solid obtained as 56% 
yield was collected. For SZJ2263 synthesis, 15 mmol of morpholine was 
added with 2M HCl ether solution and morpholine hydrochloride formed was 
collected. 1 mmol of morpholine hydrochloride and 1 mmol of morpholine 
were dissolved in anhydrous methanol and stirred at RT for 1 hr. Excess 
methanol was evaporated and product precipitated was collected as 93% yield. 
Chemical synthesis of these compounds was performed and provided by A/P 




H2S donors including sodium hydrosulfide (NaHS) and GYY4137 were 
freshly prepared in DMEM prior to every treatment. Other compounds were 
dissolved in corresponding solvents according to manufacturers’ instruction at 
indicated stock concentration tabulated in Table 3.  
 
Illus. 4. Molecular structure of GYY4137, ZYJ1122 and SZJ2263. 
GYY4137 is a morpholino salt containing sulfur atoms that produces H2S in 
aqueous via hydrolysis. ZYJ1122 and SZJ2263 are structural analogs of 
GYY4137 that lacked of sulfur atom hence without H2S-release property. The 
negative analog was included in the study to demonstrate the specific activity 
by H2S. 
 
Table 3. Compounds preparation 
Compound Solvent Stock Source 
H2S donors and negative analogs 
Sodium hydrosulfide 
(NaHS) 
DMEM 80 mM Sigma, 
#161527 
GYY4137 DMEM 80 mM  
ZYJ1122 PBS 80 mM  
SZJ2263 PBS 80 mM  
Mitochondrial complex inhibitors 
Rotenone (Rot) Ethanol/H2O 1:1 10 mM Sigma, R8875 
Antimycin A (AA) Ethanol/H2O 1:1 10 mM Sigma, A8674 
pH regulator inhibitors 







PBS 10 mM Sigma, D3514 
Glycolysis inhibitor 
2-deoxyglucose (2-DG) PBS 100 mM Sigma, D8375 
Ionophore 
Nigericin (Nig) Ethanol 10 mM Sigma, N7143 
Monocarboxylate inhibitors 





1 M Tocris, #5029 
Glycolysis booster 
Metformin (Met) PBS 100 mM Fluka, 
PHR1084 
 
2.3 Cell viability assays 
Cell viability was examined using crystal violet (Bonnekoh et al., 1989), 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, 
M5655) colorimetric assay or trypan blue (Sigma, T6146) exclusion cell count. 
Adherent cells were first fixed with absolute methanol at room temperature 
(RT) for 10 min and then stained with 0.2% w/v crystal violet solution (Fluka, 
#61135) for 15 min. Excess staining solution was washed by immersing 
stained plates into beaker of tap water. Washed plates were dried in 50 ⁰C 
oven. Crystal violet stain was solubilized with 1% v/v sodium dodecyl sulfate 
solution (SDS, Vivantis, PB0640) and absorbance 570 nm was read using 
microplate spectrophotometer (Tecan Ultra 384). To assess cell viability using 
MTT colorimetric assay, media was removed and cells were rinsed once using 
PBS. MTT solution (0.25 mg/ml in DMEM) was incubated on cells at 37 ⁰C 
for 1 hour. Excess MTT solution was removed and purple formazan formed 
was dissolved with dimethyl sulfoxide (DMSO, Sigma, #47230). Absorbance 
570 nm was read. For suspension cells, cells were collected into fresh tubes 
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and were pelleted down by centrifugation at 125 × g for 3 min. Supernatant 
was removed and cell pellet was dispersed in fresh media. 10 μl of cell 
suspension was added with equal volume of trypan blue solution and loaded 
onto a hemocytometer for cell counting. Only viable cells with intact and 
bright membrane periphery were counted. Cell viability was normalized to 
non-treatment control in corresponding experiment setup.  
 
2.4 Glucose uptake measurement 
Cellular glucose uptake was measured using [
3
H]-labelled 2-deoxyglucose (2-
DG, Perkin Elmer, NET328) intracellular retention assay (Alexander et al., 
1981). Cells were incubated with 2.5 μCi [3H]-2-DG for 30 min in DMEM. 
Culture media was rinsed off with PBS and cells were lysed using RIPA lysis 
buffer (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 0.1% v/v SDS, 0.5% w/v 
sodium deoxycholate, 1% v/v Triton X-100, 2 mM EDTA). Lysate was pre-
cleared from cell debris by centrifugation at 10 000 × g, 5 min. Lysate was 
then mixed with biodegradable scintillation liquid (rpi, #111195) and [
3
H] 
signal was detected and measured with a liquid scintillation counter (LSC, 
Beckman Coulter, LS 6500). For non-radioactive glucose uptake assay, cells 
were incubated with 1 μM XenoLight 2-DG-750 probe (Perkin Elmer, 
#760561) in glucose-free media for 3 hours. Excess probe was washed off 
with PBS and fluorescence signal was read at Ex. 745/Em. 820 nm using 




2.5 Glucose utilization assay 
Cellular glucose utilization was determined using [
3
H]-labelled glucose (Hom 
et al., 1984). [
3
H]-glucose gets channeled into glycolytic pathways and 
produces [
3
H]-H2O that is excreted to extracellular compartments. Amount of 
[
3
H]-H2O presents in extracellular compartment corresponds to cellular 
glucose utilization rate. Cells were first incubated with 10 μCi [3H]-glucose in 
glucose-free media for 1 hour. Culture media was then removed and changed 
with fresh media. Media sample was collected at indicated time points and [
3
H] 
signal was measured using liquid scintillation counter.  
 
2.6 Quantitative reverse-transcription PCR (qRT-PCR) 
Cells were lysed in situ on culture plate using TRIzol reagent (0.5 ml per 6 
well, ThermoFisher Scientific, #15596018) with gentle rinsing using pipette. 
TRIzol samples were stored at -80 °C till use. To extract total RNA, 0.1 ml of 
chloroform (Sigma, C7559) per 0.5 ml of TRIzol used was added and mixed 
vigorously for 15 seconds. Mixture was allowed to sit at RT for 3 min. Phase 
separation was achieved by centrifugation at 12 000 × g, 15 min at 4 ⁰C. 200 
μl of upper aqueous phase was collected into fresh tube. 250 μl of absolute 
isopropanol (Sigma, I9516) was added and mixed well then was allowed to sit 
at RT for 10 min. RNA pellet was centrifuged down at 12 000 × g, 10 min at 4 
⁰C. Supernatant was removed and 0.5 ml of 75% ethanol (Sigma, E7023) was 
added. RNA pellet was washed by gentle vortex. After centrifugation at 7500 
× g, 5 min at 4 ⁰C, RNA pellet was air-dried and solubilized in nuclease-free 
water (ThermoFisher Scientific, AM9930). 1 μg of total RNA was used for 
cDNA synthesis using oligo(dT)20 primer with iScript Select cDNA synthesis 
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kit (Bio-Rad, #1708896). qPCR was performed using iTaq universal SYBR 
green supermix (Bio-Rad, #1125121) with iQ5 Multicolor Real-time PCR 
detection system (Bio-Rad, #1709780).  
 
Table 4. Genes and qPCR primers 
Gene Accession No. Primer Sequences* 
RPL13A NM_012423 82F: GGAGGTGCAGGTCCTGGTGC 
242R: CAGGTACTTCAACTTGTTTCTGTAG 






























CA9 NM_001216 775F: TTTGCCAGAGTTGACGAGGC 
871R: GCTCATAGGCACTGTTTTCTTCC 






















2.7 Glycolytic enzymatic activity assays 
Cells were lysed using Passive Lysis Buffer (Promega, E194) and lysate was 
pre-cleared from cell debris by centrifugation at 10 000 × g for 3 min at 4 ⁰C. 
Protein concentration was determined using Bradford protein assay (Bio-Rad, 
#500-0006) with a standard curve constructed using bovine serum albumin 
(BSA, Santz Cruz, sc-2323). A total of 30 μg total protein lysate was used in 
each enzymatic assay. To assess hexokinase (HK) activity, lysate was added 
with 80 mM glucose (Sigma, G7021), 16.5 mM ATP (Duchefa, A1335), 6.8 
mM NAD (Sigma, N8285) and 300 U/ml glucose-6-phosphate dehydrogenase 
(Sigma, G6378) in 50 mM Tris-HCl (Bio-Rad, #161-0719), 13.3 mM MgCl2 
(Sigma, M3634), pH 8.0 buffer (De la Fuente et al., 1958). Absorbance at 340 
nm was recorded by microplate spectrophotometer with 30 seconds interval 
for 7 min. Phosphofructokinase (PFK) activity was examined in 50 mM Tris-
HCl, 6 mM MgCl2, 2.5 mM dithiothreitol (DTT, Promega, P1178), pH 7.0 
buffer with 4 mM fructose-6-phosphate (Sigma, F1502), 1 mM ATP, 0.2 mM 
NADH (Sigma, N1630), 1 U/ml aldolase (Sigma, A2714) and 2.5 U/ml triose-
glycerolphosphate dehydrogenase (Sigma, G1881). Change in absorbance at 
340 nm was monitored with 30 seconds interval up to 20 min (Mansour, 1972). 
Pyruvate kinase (PK) activity was determined using commercially available 
assay kit (Biovision, K709). Colorimetric change was detected at absorbance 
570 nm. Enzyme activity was determined from the initial linear portion of 




2.8 Cellular bioenergetics analysis 
Mitochondrial activities were examined using Mito Stress Test Kit with XF96 
Extracellular Flux Analyzer (Nicholls et al., 2010). Cells were sequentially 
challenged with oligomycin (1 μM), carbonyl cyanide-p-trifluoromethoxy-
phenylhydrazone (FCCP, 1.5 μM) and rotenone/antimycin A (Rot/AA, 1 μM). 
Real time Oxygen Consumption Rate (OCR) was measured with a 3 min mix-
3 min measure cycle (Seahorse Bioscience). In cancer pair study, basal 
Extracellular Acidification Rate (ECAR) and OCR were measured using 
XFe24 Extracellular Flux Analyzer. ECAR and OCR values were normalized 
to number of cells and ECAR/OCR ratio was calculated as an indicator of 
glycolytic adaptation of the cell line.  
 
2.9 Lactate measurement 
To measure extracellular media, 200 μl media was collected into fresh tube 
containing 100 μl 6% perchloric acid (Sigma, #244252). Sample was vortexed 
and centrifuged at 10 000 × g for 3 min at RT. Supernatant was transferred 
into new tube and neutralized using 33.3 μl of 2M Na2CO3 (Sigma, S2127). 
Neutralization was completed by vortex and centrifugation at 10 000 × g for 3 
min at RT. Processed media was transferred into new tubes and was ready for 
assay or was stored frozen till use. Enzymatic reaction was carried out in 0.4 
M hydrazine (Sigma, #309400), 0.5 M glycine (Bio-Rad, #1610718), pH 9.0 
buffer with 2 mM NAD and 2 U/ml lactate dehydrogenase (Sigma, L2500). 
Absorbance at 340 nm was measured with 2 min interval for 15 cycles. Tumor 
tissue harvested was homogenated in 2% perchloric acid solution and then 
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neutralized with Na2CO3. Lactate measurement was carried out following the 
abovementioned protocol.  
 
To measure intracellular lactate, cells were trypsinized and pelleted down in 
PBS by centrifugation at 125 × g for 3 min at 4 ⁰C. Supernatant was removed 
and cell pellet was snapped frozen in -80 ⁰C for at least 30 min. Frozen cell 
pellet was then lysed instantaneously with H2O (40 μl per 6-well cells) with 
aid of 3 pulses of 5 sec 20% amplitude sonication. 1 μl of pre-cleared lysate 
was diluted into 19 μl H2O to make 20 × diluted protein sample for Bradford 
protein assay. 20 μl of 6% perchloric acid was added into remaining lysate to 
precipitate proteins and was then neutralized with 6.7 μl 2 M Na2CO3. After 
centrifugation, processed lysate was ready for assay. Enzymatic reaction was 
performed in 0.5 M glycine, pH 9.0 buffer with 2 mM NAD, 2 U/ml lactate 
dehydrogenase, 0.05 mg/ml MTT and 0.1 mM phenazine thiosulfate (PES, 
Sigma, P4544). Absorbance at 570 nm was monitored with 2 min interval for 
15 cycles. Initial velocity gradient was determined from the linear portion of 
kinetic curve. Lactate concentration was calculated from a lactate standard 
curve (Extracellular lactate: 0 - 10 mM range; Intracellular lactate: 0 - 400 μM 
range; R
2
 ≥ 0.99) constructed using sodium lactate solution (Sigma, L7022).  
 
2.10 Ratiometric pHi measurement 
Intracellular pH (pHi) was determined by ratiometric fluorescence analysis 
using confocal microscopy (Zeiss, LSM 710) or microplate spectrophotometer 
(Rink et al., 1982; Wang and Kurtz, 1990). Cells were incubated at RT with 2 
μM 2’,7’-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF-AM, 
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Invitrogen, B1170) in mammalian Ringer’s solution [154 mM NaCl, 2.2 mM 
CaCl2 (Sigma, #223506), 5.6 mM KCl, 2.4 mM NaHCO3 (Sigma, S5761), 2 
mM Tris-Cl, pH 7.4] for 10 min at RT. Excess probe was then washed off with 
Ringer’s solution. Cells were excited at pH-insensitive 405 nm and pH-
sensitive 488 nm while emission was detected at 500 nm.  A 3-points in situ 
calibration of pH 6.5, 7.0 and 7.5 (adjusted using HCl or KOH) was performed 
on cells in 125 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 20 mM HEPES (Sigma, 
H4034) sodium-free calibration buffer, added with 10 μM nigericin (Sigma, 
N7143). For microplate setup, cells were seeded into 96-well culture plate and 
incubated with BCECF as mentioned. Emission at 500 nm was read with a 3 × 
3 area scanning, with excitation at 405 nm and 488 nm respectively. 488/405 
ratio corresponded to pHi was calculated from the calibration curve. 
Intratumoral pH was measured using Micro pH Electrode (ThermoFisher 
Scientific, Orion 9863BN). 
 
2.11 pH regulator activity assays 
pH regulator activity was examined with alkali or acid loading assay. Cells 
were seeded in 35 mm fluorodish (World Precision Instruments, FD35-100) 
and were stained with BCECF. Basal resting pHi was measured in mammalian 
Ringer’s solution using real-time mode. Continuous changes in pHi was 
monitored with alkali loading using ammonium chloride buffer [20 mM 
NH4Cl (Sigma, #213330), 20 mM HEPES, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM glucose]. Alkali peak response represented anion-exchanger 
(AE) activity (Alonso et al., 1993). On the other hand, cells were changed to 
acid loading buffer (20 mM HEPES, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 
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10 mM Glucose, pH 6.0) to induce intracellular acidification (Jang et al., 
2006). Na
+
 buffer (20 mM HEPES, 150 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 
mM MgCl2, 10 mM glucose, pH 7.4) was reintroduced and pHi recovery was 
monitored. Slope of pHi recovery represented sodium/proton exchanger (NHE) 
activity.  
 
2.12 Protein oligomer detection assay 
Cloning of Glut1 into pXJ40-Flag plasmid 
Glucose transporter 1 (NM_006516) coding sequence (CDS) was amplified 
from MDA-MB-231 cDNA using Platinum Pfx DNA polymerase 
(ThermoFisher Scientific, #11708013). CDS amplified was purified using 
QIAquick PCR Purification Kit (QIAGEN, #28104) and restriction digested 
using HindIII and KpnI restriction enzymes (New England Biolabs). pXJ40-
Flag plasmid was also digested at 37 ⁰C for 2 hours using the same restriction 
enzymes to create hanging sticky end. 1 μl of alkaline phosphatase (New 
England Biolabs, M0290S) was added into plasmid restriction mix and 
incubated at 37 ⁰C for 1 hour. Cut plasmid and insert was run on DNA gel 
electrophoresis and purified using QIAquick Gel Extraction Kit (QIAGEN, 
#28704). Insert and plasmid was ligated at 10:1 molar mass ratio and ligation 
product was heat shock transformed into DH5α competent bacteria cells. A 
single positive clone was selected and inoculated for plasmid production. 
Plasmid was extracted using E.Z.N.A. Plasmid Midi Kit (OMEGA bio-tek, 
D6904).  
 
Transfection of pXJ40-Flag-Glut1 and protein oligomer cross-linking 
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293T cells were seeded in 24-well culture plate and transfected with pXJ40-
flag-Glut1 plasmid by calcium phosphate transfection method [400 ng plasmid 
DNA, 2 μl 2.5 M CaCl2, 20 μl HEPES-buffered saline (HBS, 50 mM HEPES, 
280 mM NaCl, 1.5 mM Na2HPO4), top up with sterile H2O to total of 40 
μl/well] for 48 hours and treated with compound for 24 hours. Culture media 
was removed and cells were rinsed once with PBS. 1% v/v formaldehyde 
solution (FA, 300 μl per 24-well, Sigma, F1635) was added to cross-link 
proteins with gentle rotation (15 rotations per min) on a side-way rotator for 
15 min at RT. FA solution was then removed and cross-linking was quenched 
by addition of 125 mM glycine solution and incubated for 5 min with rotation 
at RT. Cells were then lysed with RIPA lysis buffer supplemented with 
inhibitors 1 mM phenyl methanesulfonyl fluoride (PMSF, Sigma P7626), 2 
µg/ml leupeptin (Sigma, L2884), 2 µg/ml aprotinin (Sigma, A1153), 1 µg/ml 
pepstatin A (Sigma, P4265), 20 mM NaF (Sigma, #201154), 20 mM Na3VO4 
(Sigma, S6508) and 20 mM β-glycerophosphate (Sigma, G9422). Cell lysate 
was pre-cleared from cell debris by centrifugation at 10 000 × g, 10 min at 4 
⁰C. Protein concentration was determined with Bradford protein assay. 1 
volume of 2 × Laemmli sample buffer [4% v/v SDS, 20% v/v glycerol (Sigma, 
G5516), 120 mM Tris-HCl, 0.02% w/v bromophenol blue (Bio-Rad, 
#1610404)] was added into 1 volume of lysate and samples were heated at 65 





2.13 Cysteine sulfide-linkage derivation 
Cells were lysed using 1% w/v SDS solution (1 ml per 60 mm culture dish) 
supplemented with inhibitors. Lysate was collected into tubes and was 
sonicated for 10 pulses, 5 sec each pulse of 20% amplitude to facilitate lysis. 
Lysate was centrifuged at 10 000 × g, 5 min at RT to pre-clear from cell debris. 
For positive control (Pos), 25 mM DTT was added and incubated with rotation 
for 1 hour at RT. Other samples were added with 2 mM N-ethylmaleimide 
(NEM, Sigma, E3876) and incubated with rotation for at least 2 hours at RT. 
After incubation, samples were acetone precipitated to remove excess 
blocking reagent. 3 volumes of ice cold absolute acetone (Merck, 
#158.00104.198) was added into 1 volume of sample and the mix was kept in -
20 ⁰C for at least 30 min. Protein pellet was collected by centrifugation at 
2000 × g for 5 min at 4 ⁰C. Supernatant was removed and protein pellet was 
rinsed once with ice cold 70% v/v acetone. 1% v/v SDS solution was used to 
resolubilize protein pellet. Negative control (Neg) was added with H2O. For 
other samples, 25 mM DTT was added and incubated with rotation for 1 hour 
at RT followed by acetone precipitation. Resolubilized samples were then 
incubated with 0.4 mM biotin-maleimide (Sigma, B1267) with rotation for 3 
hours at RT. Streptavidin-conjugated beads (5 μl per sample, Cell Signaling 
Technology, #3419) was first dispersed into 1% v/v SDS solution and then 
added into samples (50 μl per sample) and was incubated with rotation for at 
least 1 hour at RT. To collect immunoprecipitated (IP) beads, mix was 
centrifuged at 800 × g, 1 min at RT. IP beads were washed with 1% v/v SDS 
solution thrice. 2 × Laemmli sample buffer/ DTT mix (200 mM DTT) was 
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added (50 μl per sample) and processed sample was heated at 95 ⁰C for 3 min 
to elute IP sample. IP samples were ready for SDS-PAGE.  
 
2.14 Western Blot protein analysis 
10 μg of total protein was separated using SDS running buffer (25 mM Tris, 
192 mM glycine, 0.1% v/v SDS) on 8% SDS-polyacrylamide gel. Proteins 
were transferred onto polyvinylidene difluoride (PVDF) membrane by 
constant 140 mA for 2 hours. No SDS was added into polyacrylamide gel and 
running buffer for native PAGE. 5% w/v skim milk in TBS (50 mM Tris, 150 
mM NaCl, pH 7.4) was used as blocking buffer. Mouse anti-FLAG (1:2000 
Sigma, F3165), rabbit anti-Glut1 (1:2000, Millipore, #07-1401), rabbit anti-
VEGFA (1:200, Santa Cruz, sc152) and rabbit anti-GAPDH (1:2500, Santa 
Cruz, sc25778) diluted using 2.5% w/v skim milk in TBS were used for 
immunoblot. Secondary antibody anti-mouse (1:10000, ThermoFisher 
Scientific, #31436) and anti-rabbit (1:10000, GE Healthcare, NA934V) were 
incubated for at least 1 hour at RT. Blots were washed after antibody 
incubation with 0.1% w/v Tween-20 (Sigma, P1379) in TBS thrice, 10 min 
each wash. Chemiluminescent signal developed by Lumigen ECL Ultra 
(TMA-6) was detected using ChemiDoc MP System (Bio-Rad, #1708280). 
 
2.15 2-Dimentional (2D) gap closure migration assay 
Invasive cancer cells MDA-MB-231 and HeyA8 were seeded into culture 
insets (ibidi, #80209) overnight. Culture insets were removed creating distinct 
gap in between two pools of cells. Cells were allowed to migrate to fill in the 
gap. Cell migration was monitored over time and microscopy pictures were 
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taken using inverted light microscope (Olympus, IX81). Distance migrated 
(arbitrary unit, a.u.) by the cells were measured and analyzed using Image-Pro 
Analyzer software (Olympus).  
 
2.16 Transwell migration assay 
Collagen (1 mg/ml in PBS) was coated onto upper chamber of 8.0 μm pore 
size, 6.5 mm diameter, 24-well plate hanging polycarbonate transwell 
(Corning, #3422). Culture plate with transwells was incubated in a 37 ⁰C 
incubator for at least 1 hour to allow collagen layer to solidify. Cancer cells 
dispersed in serum-free media (SFM) were then seeded into upper chamber 
with 20% FBS media as chemoattractant in lower chamber. Transwell 
migration was incubated for 24 hours. Cells remained on upper chamber and 
those migrated into lower chamber were harvested and counted. Transwell 
migratory index (%) was calculated by formula:  
Cell number in lower chamber
Cell number in lower chamber+Cell number in upper chamber
 × 100%. 
For endothelial cell (EC) migration assay, cancer spheroids were used as 
chemoattractant in lower chamber of transwell. Cancer cells were seeded into 
96-well ultra-low adherent culture plate (Corning Costar, CLS7007) to form 
spheroids over 3 days incubation. The cancer spheroids formed were carefully 
transferred into lower chamber of transwell using sterile Pasteur pipette. EC 
cells were pre-loaded with CMFDA green fluorescence cell tracker dye (2 μM 
in DMEM, ThermoFisher Scientific, C7025) for 15 min before seeded into 
upper chamber. Transwell migration was quantified by measuring green 
fluorescence intensity in lower chamber using microplate spectrophotometer. 
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Trans-migratory index (%) was calculated and normalized to signal intensity 
read in non-treatment control.  
 
2.17 3D non-anchorage soft agar assay 
Base agar (1% w/v in sterile H2O, 1 ml/well, First Base, BIO-1000-500g) was 
evenly added into 6-well culture plate and allowed to solidify in tissue culture 
hood for at least 10 min. Top agar (0.7% w/v in serum-free DMEM, 
Affymetrix, #10907-100GM) was dissolved and kept at 42 ⁰C water bath till 
use. Cells were trypsinized and dispersed in 20% serum media. 4000 cells in 
0.5 ml of 20% FBS media suspension was quickly mixed with 0.5 ml of 0.7% 
w/v top agar solution to make 10% FBS/0.35% agar cell mix. The mix was 
loaded onto base agar evenly and allowed for solidification for at least 15 min 
in 37 ⁰C incubator. Cells were fed with complete growth media (2 ml/well) 
and incubated for 14 days. 1.5 ml of culture media was removed and 
replenished with fresh media every 4 or 5 days. At the end of experiment, 
colony diameter was measured using Image-Pro Analyzer software. Colony 
number within grid (1 mm × 1 mm) was visually counted under microscopy. 
Data distribution was analyzed and represented with boxplot.  
 
2.18 Enzyme-linked immunosorbent assay (ELISA) 
Cancer conditioned media (CM) collected was stored at -20 °C till use. For ex 
vivo treatment of CM, NaHS or GYY4137 was added into CM for 1 hour prior 
to assay. ELISA was performed using Human VEGF Standard ELISA 
Development Kit (PeproTech, #900-K10). 96-well assay plate was coated with 
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100 μl/well of 0.5 µg/ml VEGF capture antibody overnight. Excess coating 
antibody was removed and assay well was washed 4 times with 0.05% Tween-
20/PBS. 100 µl of blocking buffer (1% BSA/PBS) was added into each well 
and assay plate was incubated for at least 1 hr at RT. After 4 times washing 
with 0.05% Tween-20/PBS, 100 µl of cancer CM sample was added. Sample 
was incubated in assay well for at least 2 hr at RT. Assay plate was then 
washed and added with 100 μl of 0.25 µg/ml detection antibody. Antibody 
conjugation was allowed for at least 2 hr at RT. Assay well was washed 4 
times with 0.05% Tween-20/PBS and incubated with avidin peroxidase 1:2000 
for at least 45 min at RT. 100 µl of ABTS substrate (Sigma, A3219) was 
added into each well. Absorbance at 405 nm was read after 15 min incubation. 
 
2.19 Endothelial tube differentiation assay 
Matrigel (50 μl/well, Gibco Geltrex A1413202) was added into 48-well 
culture plate and allowed to solidify in 37 ⁰C incubator for at least 30 min. EC 
(25 000 cells/cm
2
) was seeded into culture well in either DMEM or MDA-
MB-231 cancer-conditioned media (CM). CM was collected from a 24-hours 
confluent culture of MDA-MB-231. Tube differentiation was monitored for 16 
hours. For ex vivo treatment of CM, NaHS was added into CM for 1 hour prior 
induction of EC tube differentiation. Microscopy pictures were taken using an 
inverted light microscope. Number of nodes and tubes formed were analyzed 




2.20 In vivo mouse tumor model 
Mouse breast adenocarcinoma 4T1-Luc allograft tumor model was established 
to study anti-cancer effects of H2S in vivo. 4T1-Luc cells were harvested from 
monolayer culture and dispersed in PBS to a concentration of 10 × 10
6
 
cells/ml. 1 × 10
6
 cells/mouse were injected into left flank mammary fat pad of 
BALB/C female nude mice. Cancer cells were inoculated for 14 days to form 
palpable tumor (≥ 150 mm3). Mice were randomly assigned into non-treatment 
or treatment groups. GYY4137 was administered intra-peritoneally at 300 or 
500 mg/kg daily for 14 days. Tumor growth was monitored daily by 
measuring tumor length (L) and width (W) and tumor volume (V, mm
3
) was 
calculated using formula: (L × W
2
)/2. On 14 days after compound 
administration, mice were injected intra-peritoneally with luciferin solution 
(15 mg/ml, 100 μl/mouse, Caliper Life Sciences, #119222) and were subjected 
to In Vivo Imaging System (IVIS) to image for bioluminescence. Mice were 
euthanized by carbon dioxide and tumor was harvested. Tumor gross mass 
(mg) was recorded. Tumor tissue was divided into several portions for 
subsequent immunohistochemistry, tumor sulfide and tumor lactate 
measurement and were processed accordingly.  
For the large number study, 0.5 × 10
6
 cells/mouse were injected into 
left flank mammary fat pad of BALB/C female nude mice. A total of 15 mice 
were divided into 3 groups: 0, 150 and 300 mg/kg (n=5 per group). Compound 
administration was started as the primary tumor volume achieved ≥ 100 mm3 




2.21 Sulfide measurement in blood plasma and tumor or organ tissue 
homogenate 
Mouse blood was collected into tubes containing 0.5 M EDTA (10 μl per tube, 
Amresco, #0322-500G) and 1% w/v zinc acetate (200 μl per tube, Sigma, 
#383058) by facial vein prick method (Golde et al., 2005). Blood sample was 
mix well by gentle inversion. Blood cells were pelleted down by 
centrifugation at 2000 × g for 10 min at 4 ⁰C. 200 μl blood plasma was 
transferred into fresh tube on ice and added with 50 μl 10% w/v trichloroacetic 
acid (TCA, Sigma, T6399) to precipitate hemoglobin and plasma proteins. 
Sample was centrifuged at 10 000 × g for 5 min at 4 ⁰C. 90 μl of processed 
plasma was transferred into 2 fresh tubes, one served as blank. In blank, 30 μl 
28 mM FeCl3 (dissolved in 1.2 M HCl, Sigma, #451649) and 30 μl 7.2 M HCl 
were added and mixed by vortex. In sample, 30 μl 28 mM FeCl3 and 30 μl 20 
mM N,N-dimethyl-p-phenylenediamine (N,NDPD, dissolved in 7.2 M HCl, 
Sigma D5004) were added instead. The mix was centrifuged at 10 000 × g for 
3 min at RT. 100 μl derived supernatant was transferred into 96-well assay 
plate. Absorbance at 670 nm was read using microplate spectrophotometer.  
Tumor or organ tissue portion was weighted and mass (M, mg) was 
recorded. 1 M of tissue was homogenized with 4 volumes (V, μl) of 1:1 v/v 
HEPES (250 mM HEPES, pH 7.4)/1% w/v zinc acetate buffer. Homogenate 
was centrifuged at 3000 × g for 5 min at 4 ⁰C to pre-clear tissue debris. 
Supernatant was transferred into fresh tube and centrifuged at 13 000 × g for 
30 min at 4 ⁰C. 150 μl cleared homogenate was added with 50 μl 10% w/v 
trichloroacetic acid and mixed by vortex. Protein was precipitated by 
centrifugation at 10 000 × g for 3 min at 4 ⁰C. 150 μl processed homogenate 
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was added with 50 μl 28 mM FeCl3 and 30 μl 20 mM N,NDPD. Mix was 
centrifuged and supernatant was transferred into 96-well assay plate. 
Absorbance at 670 nm was read. 
 
2.22 Immunohistochemistry 
Immunohistochemistry (IHC) was carried out following abcam IHC-paraffin 
protocol. Tumor tissue was fixed with 10% v/v neutral phosphate-buffered 
formalin, pH 7.0 for 24 hours with gentle inverted rotation at RT. Tissue was 
washed once with PBS after fixation and dehydrated in 70% v/v ethanol 
(EtOH) overnight with rotation at RT. Tissue was then changed into fresh 70%, 
95%, 100% absolute EtOH and xylene (Sigma, #534056) sequentially, before 
mounted onto cassette holder in paraffin. Tissue block was sectioned and 
adhered onto polysine coated slides (ThermoFisher Scientific, P4981) and the 
slides were dried overnight. Before staining, slides were rehydrated and 
subjected to antigen retrieval using citrate acid buffer [10 mM citric acid 
(Sigma, C0759), 0.05% w/v Tween-20, pH 6] heated at 95 ⁰C for 25 min. 
Samples were incubated with primary antibody and then stained with 
secondary antibody using ImmunoCruz rabbit or mouse ABS staining kit 
(Santa Cruz, sc-2018, sc-2017). Hematoxylin staining was developed using 
bluing solution (0.1% w/v sodium bicarbonate, pH 8). Processed slides were 
observed using phase contrast microscope.  
 
2.23 Statistical analysis 
Data was consolidated using EXCEL (Microsoft Office) and was shown as 
mean ± standard deviation in plots. Unless otherwise stated, experiments were 
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with at least triplicate. Statistical comparisons were analyzed using two-tailed, 
one-way ANOVA (XLSTAT). P < 0.05 was applied as statistically significant 






CHAPTER 3: H2S targets on cancer glucose 
metabolism and pHi homeostasis to decrease cancer 
cell viability 
 
3.1 Continual exposure to low concentration of H2S possesses selective 
cytotoxicity on cancer cells 
Our previous study showed that GYY4137 but not single exposure of NaHS 
selectively decreased cancer cell viability (Lee et al., 2011). The differential 
effects between GYY4137 and NaHS were speculated to be due to their 
different H2S-releasing property. 400 μM of NaHS released H2S into solution 
instantaneously, peaked at or before 30 min and had no detectable sulfide after 
2 hours (Fig. 1). In contrast, a same concentration of GYY4137 released only 
much lower amount, measured at less than 30 μM sulfide. However, being a 
slow-releasing H2S donor, GYY4137 sustained continual sulfide release at 





Fig. 1. Differential H2S-release by NaHS and GYY4137. NaHS and 
GYY4137 were dissolved in culture media at 400 μM and the sulfide-released 
into culture media was examined over time. NaHS produced H2S 
instantaneously into media and no sulfide was detected after 2 hours. 
GYY4137 released very low amount but sustainable H2S up to 6 days in 
culture.  
 
In order to verify the effects of H2S on cell viability, we used simple 
sulfide salt NaHS as H2S donor and exposed hepatocellular carcinoma HepG2, 
breast adenocarcinoma MCF7, normal diploid lung fibroblast WI38 and breast 
epithelial MCF10A to either single or continual exposure of H2S. Treatment 
media was changed into fresh NaHS solution every 2 hours to maintain a 
continual exposure of H2S for 5 days. Cell viability was assessed using crystal 
violet colorimetric assay and concentration response curves were fit plotted 
using Origin 8.5 (OriginLab) analysis software.  
Single exposure to H2S did not affect cell viability of all the four cell 
lines tested (Fig. 2A). Intriguingly, continual exposure to H2S showed anti-cell 
viability effect on the cell lines but the effects were comparatively stronger in 
cancer cells. Low concentrations (5, 10 and 20 μM, Log2 = 2.32, 3.32, 4.32; 
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region shaded in grey) of NaHS significantly reduced cell viability of HepG2 
and MCF7 but lesser extent to WI38 and MCF10A. 5 μM NaHS maintained at 
least 91% of cell viability of WI38 and MCF10A while decreased cell viability 
of HepG2 and MCF7 to 68%. Apparent reduction of cell viability to 45% and 
55% in HepG2 and MCF7 respectively was observed after continual exposure 
to 10 μM NaHS. Exposure to 20 μM of NaHS strikingly reduced cell viability 
to 27% and 31% in HepG2 and MCF7 respectively while WI38 and MCF10A 
maintained at least 75% survival (Fig. 2A).  
 The data strongly indicated that H2S exhibited a selective anti-cell 
viability effect on cancer cells within concentration range of 5 - 20 μM. 
Concentration greater than 80 μM (Log2 = 6.32) lost the selectivity effect on 
cancer cells, drastically killing all the four cell lines tested. As only the low 
concentration and continual exposure to H2S showed cancer selectivity effect, 
we reasoned the slow H2S releasing donor GYY4137 may be a more practical 
reagent than addition of NaHS every 2 hours. We thence examined cell 
viability of the cell lines under treatment with increasing concentration of 
GYY4137. 
 GYY4137 similarly showed selective anti-cell viability effects on 
HepG2 and MCF7 within working concentration range of 200 - 800 μM 
(region shaded in grey, Log2 = 7.64, 8.64, 9.64) over 5 day incubation (Fig. 
2B). Cross referencing with concentration response curve generated using 
NaHS (Fig. 2A) and the known production level from 400 μM of GYY4137 
(Fig. 1), this working concentration range of GYY4137 was estimated to be 
corresponded with 5-20 μM of H2S release. Non-cancer cells WI38 and 
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MCF10A maintained at least 70% cell viability at 800 μM GYY4137. 
Significant reduction of cell viability in non-cancer cells was observed only at 
high concentration of GYY4137 (≥ 2000 μM, concentrations to the right of 
grey shading region).  
 
Fig. 2. Continual exposure to low concentration of H2S possesses selective 
cytotoxicity on cancer cells. (A) Cell viability of non-cancer (WI38 and 
MCF10A) and cancer (HepG2 and MCF7) cells were examined using crystal 
violet colorimetric assay after 5 day incubation with NaHS, either single or 
continual exposure. Cell culture media was changed with fresh NaHS solution 
every 2 hours to maintain continual exposure to H2S. Single exposure to H2S 
minimally affected cell viability while continual exposure decreased cell 
viability in a concentration-dependent manner. A selectivity to cancer cells 
was observed within low concentration ranges of NaHS (non-cancer cell ≥ 75% 
cell viability, region shaded in grey: 5, 10 and 20 µM; Log2 = 2.32, 3.32, 4.32). 
(B) Slow-releasing H2S donor GYY4137 decreased cancer cell viability within 
200 - 800 µM concentration range (region shaded grey; Log2 = 7.64, 8.64, 
9.64). Cell viability of non-cancer cells were significantly inhibited only at 




3.2 H2S decreases cell viability of cancer of various tissue origins but is 
minimal effects on non-cancer cells 
To further validate the anti-cancer cell viability potential of GYY4137, we 
expanded our study panels into a wide range of cell lines. Breast (MCF7, 
MDA-MB-231), prostate (LnCaP, DU145), lung (H1299, A549), epithelial 
ovarian (OVCAR3, A2780P, HeyA8), cervical (HeLa, SiHa), liver (HepG2), 
colon (HCT116), bone (U2OS, Saos 2) and gastric cancers (SNU5, SNU1), 
leukemia (HL60, MV4-11) and mouse neuroblastoma (N2A) cells were used 
to study effects of GYY4137 on their cell viability. In general, GYY4137 
(400-800 μM) effectively decreased cell viability of the cancer cell lines tested 
in a concentration dependent manner (Fig. 3).  Importantly, when tested on 
several other non-cancer cell lines including normal diploid lung fibroblast 
WI38 and IMR90, breast epithelial MCF10A, isolated peripheral blood 
mononuclear cell (PBMC) from two individuals (1 and 2) and primary 
keratinocyte (Ker.), GYY4137 possessed minimal effects on their cell viability. 
Taken together, GYY4137 showed a non-tissue specific anti-cell viability 




Fig. 3. H2S decreases cell viability of cancer of various tissue origins but has minimal effects on non-cancer cells. A wide range of cell lines 
were treated with increasing concentration of GYY4137 (μM) and cell viability was examined after 5 days incubation. Crystal violet 
colorimetric assay was used on anchorage-dependent monolayer cell lines while hemocytometer trypan blue exclusion cell count was performed 
on suspension cell lines to examine their cell viability. GYY4137 effectively decreased cell viability of breast, prostate, lung, ovarian, cervical, 
liver, colon, bone, gastric, leukemia and neuronal cancer cell lines. Non-cancer cell lines including normal diploid lung fibroblast, breast 
epithelial MCF10A, isolated peripheral blood mononuclear cell (PBMC) and primary keratinocyte (Ker.) were minimally affected by GYY4137. 
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3.3 H2S increases glucose uptake and utilization in cancer cells 
We observed that H2S is selective in anti-cell viability of cancer but spares 
non-cancer cells. As cancer cells depend highly on availability of glucose for 
bioenergetics and survival (Lunt and Vander Heiden, 2011), we next 
investigated if H2S may drive cancer cell death via interference with glucose 
metabolism. Hepatocellular carcinoma HepG2, breast adenocarcinoma MCF7, 
normal diploid lung fibroblast WI38 and breast epithelial MCF10A were 
cultured in either low (5 mM) or standard (Std. 25 mM) glucose media with 
GYY4137 treatment and their cell viability was examined. We anticipated that 
GYY4137 may exhibit greater reduction in cancer cell viability under low 
glucose condition.  
Surprisingly, greater decrement in cell viability was observed in cancer 
cells under Std. as compared to low glucose condition (Fig. 4A). At least 80% 
of cell viability was maintained in cancer cells at 400 μM GYY4137 under 
low glucose while only 50% cell viability was observed under Std. glucose 
media. 600 μM GYY4137 further decreased cancer cell viability to less than 
30% under Std. glucose whereas 50 - 60% cell viability was maintained under 
low glucose media. Non-cancer cells were minimally affected by GYY4137 
under both Std. and low glucose conditions, maintained at least 80% cell 
viability (Fig. 4B). Though opposed to what we speculated, the different 
extents of decreased cell viability by GYY4137 under different glucose 








Fig. 4. H2S exhibits greater anti-cancer cell viability effect under higher 
glucose culturing condition.  (A) Hepatocellular carcinoma HepG2 and 
breast adenocarcinoma MCF7 were treated with GYY4137 under either low (5 
mM) or standard (Std., 25 mM) glucose media for 5 days. Cell viability was 
assessed using crystal violet colorimetric assay. GYY4137 decreased cancer 
cell viability regardless in media of low or standard glucose concentration. 
Greater reduction of cell viability was observed in cancer cells treated in 
media of higher glucose concentration. (B) No significant differences in cell 
viability of non-cancer cells (lung fibroblast WI38 and breast epithelial 
MCF10A) treated with GYY4137 in media of low or standard glucose 





We next measured glucose transport into cells using [
3
H]-labelled 2-
deoxyglucose (2-DG). 2-DG is unable to get channeled into glycolytic 
pathway thus accumulates upon up taken by cells (Hom et al., 1984). Cancer 
cell MCF7 was incubated with [
3
H]-2-DG for 30 min and [
3
H] signal in cell 
lysate represented the amount of glucose uptake by the cells. To demonstrate 
that any changes observed was due to H2S but not molecular backbone of 
GYY4137, a structural analog ZYJ1122 lacks of sulfur atom was included as a 
negative control (molecular structure was shown in Section 2.2, Illus. 4). A 
mitochondrial complex inhibitor, Antimycin A (AA), which added into cells 
will block mitochondria thence will boost up glycolysis, was included as a 
positive control (Potter and Reif, 1952). A significant increase of 43% of [
3
H] 
scintillation signal was observed in GYY4137 treated cells showing enhanced 
glucose uptake as compared to non-treatment (NT) and ZYJ1122 control (Fig. 
5A). 





H]-glucose used by cells produces [
3
H]-H2O that gets excreted 
extracellularly. Measurement of [
3
H] scintillation signal from extracellular 
media collected over time represented glucose utilization rate by the cells. In 
parallel with higher glucose uptake, GYY4137 treatment increased glucose 
utilization in cancer cells (Fig. 5B). ZYJ1122 showed difference as compared 





Fig. 5. H2S increases glucose uptake and utilization in cancer cells.  (A) 
Cancer cell MCF7 was incubated with [
3
H]-labelled 2-deoxyglucose (2-DG) 
for 30 min. Cells were lysed and glucose uptake by cells was determined by 
measuring [
3
H] signal using liquid scintillation counter (LSC). GYY4137 
significantly increased glucose uptake in cancer cell. Structural analog lacking 
sulfur atom, ZYJ1122 was no different from non-treatment control (NT). 
Antimycin A (AA, 2 μM) was included as a positive control. (B) MCF7 was 
incubated with [
3
H]-labelled glucose for 1 hour and was then changed into 
fresh media. Extracellular media samples were collected at indicated time 
points and [
3
H] signal was measured. GYY4137 induced higher rate of 
glucose utilization as compared to NT. ZYJ1122, GYY4137; 400 μM. * P < 
0.05. 
 
 One of the renowned toxicity effects of H2S derives from its inhibition 
on cytochrome c oxidase activity in mitochondria (Dorman et al., 2002). 
Inhibition of mitochondria is known to lead to increase in glycolysis. As an 
increased in glucose uptake and utilization were observed in GYY4137-treated 
cancer cells, we asked if the current working concentration of GYY4137 
possibly affected mitochondrial activities. We examined the effects of 
GYY4137 on mitochondrial activities using XF96 Extracellular Flux Analyzer 
(Seahorse Bioscience) with Mito Stress Test Kit (Nicholls et al., 2010). 
Oxygen Consumption Rate (OCR) of MCF7 and MCF10A treated with 
GYY4137 was measured real-time as the cells were sequentially challenged 
with oligomycin, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
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(FCCP) and rotenone/antimycin A. Oligomycin is an inhibitor of 
mitochondrial ATP synthase (Knobeloch et al., 1990). Magnitude of 
decrement in OCR after oligomycin indicated the ATP production of the cells. 
Mitochondrial electron transport chain (ETC) uncoupler FCCP will maximize 
ETC then allowed the quantification of cellular spare respiratory capacity. On 
the other hand, addition of Rot/AA will result in a complete shutdown of ETC. 
The difference between OCR readings after addition of oligomycin and 
Rot/AA represented the proton leak by the cells. No significant differences 
were observed in the basal respiration, ATP production, spare respiratory 
capacity and proton leak in MCF7 or MCF10A cells between NT, ZYJ1122 
and GYY4137 treatments (Fig. 6A, B). This indicates that the H2S produced 
by current working concentration of GYY4137 does not affect mitochondrial 
functionality. Increased glucose uptake and utilization observed was not likely 







Fig. 6. GYY4137 at 400 μM working concentration does not affect cellular 
mitochondrial activities. Mitochondrial functions were evaluated using XF96 
Extracellular Flux Analyzer with Mito Stress Test Kit. 24 hours treatment of 
GYY4137 did not affect basal respiration, ATP production, spare respiratory 
capacity and proton leak of cancer cell MCF7 nor non-cancer cell MCF10A. 
Oxygen consumption rate, OCR. Oligomycin; 1 μM. Carbonyl cyanide-p-
trifluoromethoxyphenyl hydrazone (FCCP); 1.5 μM. Rotenone (Rot), 





3.4 H2S induces higher glycolytic enzyme activities in cancer cells 
To elucidate further the effects of GYY4137 on glycolysis, we first examined 
expression level of several enzymes along glycolysis pathway. Total RNA was 
extracted with TRIzol reagent and qRT-PCR was performed. Relative mRNA 
expression level of glucose transporter 1 (Glut1), hexokinase 2 (HK2), 
phosphofructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), phosphoglycerate kinase 1 (PGK1), pyruvate kinase (PK) and 
lactate dehydrogenase (LDHA, B) were quantified. No changes were observed 
in mRNA expression level of all the glycolytic enzymes checked (Fig. 7). The 
data showed that H2S did not induce glycolytic enzyme expression.  
 
Fig. 7. H2S does not change expression level of glycolytic enzymes in 
cancer cells. MCF7 cells treated with compounds for 5 days were harvested. 
Total RNA was extracted and qRT-PCR was performed to quantify mRNA 
expression level of several enzymes in glycolytic pathway. No changes were 
observed comparing non-treatment control (NT) and compound treatments. 
Glucose transporter 1, Glut1. Hexokinase 2, HK2. Phosphofructokinase, PFK. 
Glyceraldehyde-3-phosphate dehydrogenase, GAPDH. Phosphoglycerate 
kinase 1, PGK1. Pyruvate kinase, PK. Lactate dehydrogenase, LDH. 




We thus asked if H2S induced increased glycolysis via modulation of 
enzyme activity rather than expression levels. Enzymatic activities of three 
important regulatory enzymes in glycolytic pathway were measured using in 
vitro enzymatic assays. HepG2 and MCF7 treated with GYY4137 were lysed 
using Passive Lysis Buffer (Promega) to preserve intact enzymes and lysates 
were subjected to hexokinase (HK), phosphofructokinase (PFK) and pyruvate 
kinase (PK) enzymatic assays. Absorbance reading changes (∆A/min) that 
represented initial velocity of enzyme reactions were recorded using 
microplate spectrophotometer. All the three glycolytic enzymes showed higher 








Fig. 8. H2S induces higher glycolytic enzyme activities of cancer cells. 
HepG2 and MCF7 were treated with compounds for 5 days. Cells were lysed 
using Passive Lysis Buffer and lysate was used for hexokinase (HK), 
phosphofructokinase (PFK) and pyruvate kinase (PK) enzymatic assays. 
Absorbance readings were measured using microplate spectrophotometer. 
Enzyme activity was determined from initial linear slope of activity curve. 
GYY4137-treated cells exhibited higher glycolytic enzymes activity as 






3.5 H2S induces thiol-sensitive oligomerization of glucose transporter 1 
(Glut1) 
Thus far, an increase in glucose uptake and glycolysis observed in GYY4137 
treated cancer cells were not due to changes in expression level of glycolytic 
enzymes. We therefore hypothesized that H2S may modulate the very initial 
event of glycolysis; glucose transport into cell. Glucose transporter 1 (Glut1) 
is known to be associated with the cancer progression and malignancy (Airley 
et al., 2001; Brown and Wahl, 1993; Haber et al., 1997). Glut1 may exist in 
multiple oligomer forms and its activity is highly modulated by the protein 
oligomerization (Hebert and Carruthers, 1992; Pessino et al., 1991; Zottola et 
al., 1995). Dimeric or tetrameric forms of Glut1 possesses alternate glucose-
binding sites that enable the protein to uptake glucose continuously, thus 
exhibits higher glucose transport activity as compared to its monomeric form. 
Interestingly, Glut1 oligomerization is promoted by the formation of an 
intramolecular disulfide bond (Zottola et al., 1995). In view of this, we 
examined if H2S as a thiol may alter Glut1 oligomeric status that may induce 
changes in glucose uptake of the cells. 
Transfection of Glut1-EGFP plasmid into the 293T cells yielded 
approximately 70-90% efficiency as examined by fluorescence microscopy 
(data not shown). Thus, no drug selection was carried out in order to prevent 
negative impact on the cell status that may in turn affect Glut1 oligomeric 
status. Besides, to prevent possible interference on the protein oligomerization 
caused by the EGFP tag, Flag-Glut1 without conjugation with EGFP was 
expressed instead. 293T cells were transfected with pXJ40-Flag-Glut1 plasmid 
for 48 hours and were treated with increasing concentration of GYY4137 for 
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24 hours. In order to preserve the oligomeric forms of Glut1, cells were cross-
linked with 1% v/v formaldehyde before being lysed with non-reducing SDS 
lysis buffer. Lysate was heated at 65 ⁰C for 30 min before loaded into SDS-
PAGE. Flag-Glut1 was detected using anti-Flag antibody. Overexpressed 
Flag-Glut1 was found to exist as monomeric (predicted size approximately 45 
kDa), dimeric (90 kDa) and tetrameric forms (180 kDa, Fig. 9). Two distinct 
bands of monomer were detected with molecular weight of 37-50 kDa, 
suggesting possible post-translational modifications on Glut1. Not particularly 
distinguishing the two bands detected, we collectively considered the both 
bands as Glut1 monomer. Nonetheless, a decreasing monomeric form of Glut1 
was observed with increasing doses of GYY4137 treatment. Ratio of dimer or 
tetramer to monomer was calculated as an indication of the protein 
oligomerization. Increasing concentration of GYY4137 treatment induced 
greater proportion of dimeric and tetrameric Glut1. The data indicated that 





Fig. 9. H2S induces oligomerization of glucose transporter 1 (Glut1). 293T 
cells were transfected with pXJ40-Flag-Glut1 plasmid for 48 hours and treated 
with increasing concentration of GYY4137 for 24 hours. Cells were cross-
linked for 15 min using 1% v/v formaldehyde before being lysed with non-
reducing SDS lysis buffer. Expression level of oligomeric forms of Glut1 was 
examined by Western Blotting using anti-Flag antibody. Intensity of different 
oligomeric forms of Glut1 was quantified using ImageJ analysis software. 
Dimer or tetramer to monomer ratio in respective treatment group was plotted 
as concentration response curve. Increasing GYY4137 treatment induced 
increasing dimeric and tetrameric form of Glut1.  
 
 
Glut1 oligomers have been shown to confer higher glucose transport 
activity as compared to their monomers (Hebert and Carruthers, 1992). We 
next asked if the GYY4137-induced Glut1 oligomer formation brought to the 
changes in cellular glucose uptake. We treated the 293T cells that 
overexpressed Flag-Glut1 with increasing concentration of GYY4137 for 24 
hours to induce the protein oligomerization. The cells were then incubated 
with XenoLight 2-deoxyglucose (2-DG)-750 probe in glucose-free media for 3 
hours. The fluorescence unit (FU) read represented the amount of glucose 
uptake into the cells. GYY4137 treatment showed an increasing FU signal in a 
concentration dependent manner, indicating higher glucose transport activity 
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into the cells (Fig. 10). 500 μM GYY4137 increased 2-DG uptake by 69% 
while 1000 μM resulted in nearly 2.3 times of 2-DG uptake as compared to the 
non-treatment control. Hence, we concluded that H2S induced Glut1 
oligomerization that resulted in an increased glucose uptake by the cells. 
 
 
Fig. 10. Oligomerization of Glut1 promotes increased glucose uptake. 
293T overexpressing flag-Glut1 was treated with GYY4137 for 24 hours. 
Cells were changed with glucose-free media containing XenoLight 2-
Deoxyglucose (2-DG)-750 probe and were incubated for 3 hours. Media was 
removed and cells were rinsed with PBS once. Fluorescence unit (FU) read at 
Ex. 745/ Em. 820 nm represented 2-DG uptake inside cells. Increasing 
concentration of GYY4137 promoted increasing glucose uptake of the cells. * 
P < 0.05. 
 
GYY4137 is a sulfide donor and the oligomerization of Glut1 is 
postulated to be thiol sensitive (Zottola et al., 1995). Hence, we next 
investigated if alteration of thiol-redox status may induce changes on status of 
Glut1 oligomers. Firstly, the 293T cells overexpressing Flag-Glut1 treated 
with 500 μM GYY4137 showed increased dimeric and tetrameric forms of 
Glut1 (Fig. 11, Lane 1 and 2). Interestingly, cells treated with reduced 
glutathione (GSH) for 24 hours alone also showed increased dimeric and 
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tetrameric forms of Glut1, mimicking the effects of GYY4137 (Lane 5 and 6). 
Continual NaHS treatment also induced Glut1 oligomer (Lane 7). On the other 
hand, cells co-treated with GYY4137 and oxidized glutathione (GSSG) were 
found to exhibit abolished GYY4137-induced Glut1 protein oligomerization 
(Lane 3 and 4). The results clearly indicated that Glut1 protein oligomerization 
was modulated by thiol-redox status and was enhanced by thiol reductants 
such as GSH and sulfide. Exogenously added oxidant GSSG might consume 
the thiol reductants hence diminished GYY4137 effect. 
 
Fig. 11. Glut1 oligomerization is thiol-redox sensitive. 293T cells were 
transfected with pXJ40-Flag-Glut1 plasmid for 48 hours and incubated with 
reduced glutathione (GSH) or oxidized glutathione (GSSG) for 24 hours. 
NaHS was treated continually for 24 hours. Cells were cross-linked for 15 min 
using 1% v/v formaldehyde before being lysed with non-reducing SDS lysis 
buffer. Expression level of oligomeric forms of Glut1 was examined by 
Western Blotting using anti-Flag antibody. Increasing concentration of GSH 
induced increasing expression level of oligomeric forms of Glut1. GYY4137-
induced protein oligomerization of Glut1 was attenuated by co-treatment with 
GSSG. GYY4137; 500 μM. 
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To uncover the molecular mechanism of sulfide action, we performed 
sulfide-linkage derivation assay to characterize possible cysteine sulfide-
linkage changes by H2S on Glut1. H2S was postulated to interfere with sulfide-
linkage in Glut1 protein that resulted in changes of Glut1 glucose transport 
activity. MDA-MB-231 cells were treated with GYY4137 or SZJ2263 (a latest 
structural analog of GYY4137 lacking sulfur atom to be used as a negative 
control, refer Fig. 1A for molecule structure) for 24 hours. The cells were 
lysed with non-reducing SDS lysis buffer and the total lysate was derived for 
sulfide-linkage detection (Fig. 12A). The free thiol ends were blocked by 
NEM prior to DTT reduction of the S-S bond. Newly formed -SH end will be 
recognized by biotin-maleimide and immunoprecipitated with streptavidin-
conjugated beads. Sulfide-linkage formation in endogenous Glut1 was 
detected using Western Blotting probed with anti-Glut1 antibody. Absolute 
reduction of total lysate by DTT was included as a positive control (Pos) while 
H2O non-reduced sample served as a negative control (Neg). The Pos sample 
showed significant signal indicating the credibility of the derivation assay (Fig. 
12B, Lane 1). Neg control with no signal demonstrated the successful 
blocking of thiol ends by NEM thus any signal observed in H2S-treated sample 
should be derived from H2S activity on the sulfide-linkage of the protein (Fig. 
12B, Lane 5). GYY4137 treatment induced significant sulfide-linkage 
formation on the Glut1 protein as compared to non-treatment and SZJ2263 
controls (Fig. 12B, Lane 2-4). In an independent setup, cells were treated with 
increasing concentration of GYY4137 and derived for the sulfide-linkage. The 
formation of sulfide-linkage induced by GYY4137 was concentration 
dependent (Fig. 12C). Increasing sulfide-linkage signal was observed with 
97 
 
increasing concentration of GYY4137 treatment. Taken together, the data 
showed that GYY4137 acted as a thiol reductant inducing sulfide-linkage 
formation on Glut1 protein that promoted its oligomerization. The increased 
oligomeric forms of Glut1 exhibited greater glucose transport activity that 
resulted in increased glycolysis in cancer cells. 
 
Fig. 12. H2S induces sulfide-linkage formation of endogenous Glut1. (A) 
Workflow of cysteine sulfide-linkage derivation. Free thiol ends in total 
protein lysate are first blocked with NEM prior to S-S bond reduction using 
DTT. Newly formed –SH ends are labelled with biotin-maleimide which then 
immunoprecipitated using streptavidin-conjugated beads. Cysteine sulfide-
linkage derived samples are detected using SDS-PAGE. NEM, N-
ethylmaleimide; DTT, dithiothreitol. (B) Breast adenocarcinoma MDA-MB-
231 was incubated with compound treatment for 24 hours. Cells were then 
lysed with non-reducing SDS lysis buffer on culture plate. Total lysate was 
collected and pre-clear prior to sulfide-linkage derivation assay. Samples from 
derivation assay were examined with Western Blotting using Glut1 antibody. 
GAPDH in total lysate was used as loading control. GYY4137 treatment 
induced significant sulfide-linkage formation of Glut1 protein as compared to 
non-treatment control (NT) and structural analog lacking sulfur SZJ2263. 
GYY4137, SZJ2263; 500 μM. (C) 293T cells overexpressing Flag-Glut1 were 
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treated with increasing concentration of GYY4137 and cell lysate was 
collected for sulfide-linkage derivation assay. Sulfide-linkage formation of 
Flag-Glut1 increased in a GYY4137 concentration-dependent manner.  
 
3.6 H2S increases lactate production in cancer cells 
Lactate is the major end product from cancer glycolysis (Hirschhaeuser et al., 
2011). As our previous data indicated that H2S increased cancer glycolysis, we 
next moved on to measure the lactate production in cells treated with H2S. 
Extracellular media from culture of non-cancer cells WI38 and MCF10A 
treated with 400 μM GYY4137 for 5 days was collected. Lactate amount in 
the samples was determined using lactate dehydrogenase enzymatic activity 
assay and was normalized to their total protein. Despite under standard 25 mM 
glucose culture condition, no changes were observed comparing lactate 
amount of NT, ZYJ1122 and GYY4137 treatments (Fig. 13A). H2S thus did 
not change lactate production in non-cancer cells. In contrast, cancer cells 
HepG2 and MCF7 treated with GYY4137 produced drastically higher lactate 
amount excreted into extracellular media under standard glucose media 
condition, as compared to NT or ZYJ1122 (Fig. 13B). Nearly 2-3 folds 
increment was observed in HepG2 and MCF7 treated with GYY4137, 
respectively. The lactate increment was also observed in GYY4137 samples 
under the low glucose media culture condition, though at a lesser extent. 
Examination on lactate amount in media samples collected over 5-days 
duration also showed that GYY4137 treatment increased the lactate 
production rate in both HepG2 and MCF7. Therefore, it was evidenced here 





Fig. 13. H2S increases lactate production in cancer cells. (A) Non-cancer 
lung fibroblast WI38 and breast epithelial MCF10A were treated with 
compounds for 5 days. Extracellular media was collected and lactate amount 
was determined using lactate dehydrogenase enzymatic activity assay. Lactate 
amount was normalized to total protein. Structural analog ZYJ1122 was 
included as a control. No differences of lactate amount were observed among 
different treatments in WI38 and MCF10A. (B) Hepatocellular carcinoma 
HepG2 and breast adenocarcinoma MCF7 were incubated with compounds in 
standard (25 mM) or low (5 mM) glucose media for 5 days. Samples collected 
at the end of 5 days incubation was measured. Cancer cells treated with 
GYY4137 produced significantly higher lactate amount and larger lactate 
production as compared to non-treatment (NT) and ZYJ1122 controls. 




3.7 H2S induces intracellular acidification in cancer cells 
An enhanced glycolysis induced by H2S leads to metabolic acid lactate 
overproduction in cancer cells. We thus asked if the increase in lactate 
production may disturb intracellular pH (pHi) balance of the cancer cells. pHi 
of the cells was measured using 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein (BCECF,AM) dye with ratiometric confocal microscopy 
imaging. The dye got excited at a pH insensitive 405 nm and pH sensitive 488 
nm sequentially, and emission at 500 nm was detected. Emission intensity 
from the pH insensitive 405 nm excitation was used as internal control for 
each sample. Calculated 488/405 ratio represented the pHi of the cells. A 
three-point pH 6.5, 7.0 and 7.5 in situ calibration was performed for 
construction of pHi standard curve.  
 A neutral pHi was assigned with green pseudo-color while an acidic 
pHi appeared yellowish in color. Visually and quantitatively, 5 days 
incubation of GYY4137 significantly decreased pHi of HepG2 and MCF7 as 
compared to their respective NT and ZYJ1122 controls (Fig. 14A). The resting 
pHi of HepG2 at pH 7.21 drastically reduced to 6.58, while pHi 7.43 of MCF7 
reduced to 6.59 with GYY4137 treatment. In contrast, the pHi of non-cancer 
cells WI38 and MCF10A were of no change with treatment of ZYJ1122 or 
GYY4137 (Fig. 14B). The reduction in pHi was observed only in cancer but 
not non-cancer cells, corresponds well with the cancer selective increased 
lactate production and anti-cell viability effect of GYY4137.  







Fig. 14. H2S induces intracellular acidification in cancer cells. (A) 
Intracellular pH (pHi) of cancer cells HepG2 and MCF7 was measured using 
ratiometric confocal microscopy imaging. Cells treated with compounds for 5 
days were incubated with BCECF probes for 10 min prior imaging. Cells were 
imaged at Ex. 405 and Ex. 488/ Em. 500 nm. Ratio of 488/405 fluorescence 
intensity represented pHi was calculated from a 3-points pHi calibration curve 
of pH 6.5, 7.0 and 7.5. GYY4137-treated cancer cells showed significant 
intracellular acidification as compared with non-treatment (NT) and ZYJ1122 
controls. (B) Compound treatments did not cause changes in pHi of non-




In a separate experiment where the cells were continual exposed to 
NaHS treatment (fresh solution changed every 2 hours) for 5 days, pHi of 
HepG2 and MCF7 too showed a marked decrease in a concentration 
dependent manner (Fig. 15A). The continual exposure to 10 μM NaHS 
reduced pHi of HepG2 from pH 7.38 to 6.96 and pH 7.44 to 6.81 in MCF7. A 
higher concentration of 20 μM NaHS further decreased pHi of HepG2 to pH 
6.77 and of MCF7 to 6.61. No change in pHi was observed in WI38 and 
MCF10A that were continual exposed to NaHS (Fig. 15B). The results clearly 
demonstrated that the H2S released from GYY4137 or NaHS, but not any 
possible backbone remnant from GYY4137 degradation, was responsible for 
inducing the pHi reduction in cancer cells.  
 
 
Fig. 15. Continual exposure to NaHS induces pHi acidification. (A) Cancer 
cells HepG2 and MCF7 were treated with fresh NaHS solution every 2 hours 
for 5 days. pHi was measured by BCECF probe using ratiometric confocal 
microscopy imaging. Continual exposure to NaHS decreased pHi in a 
concentration dependent manner. (B) Continual exposure to NaHS did not 
change pHi of non-cancer cells WI38 and MCF10A. * P < 0.05. 
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To validate if the decrease in pHi was specifically induced by H2S but 
not a secondary phenomenon from the cell death, MCF7 cells were treated 
with several other cytotoxic agents correspondingly at their pharmacological 
concentration (IC50) and the pHi was measured (Fig. 16). Taxol treatment 
increased pHi of MCF7, while etoposide and camptothecin (CPT) did not 
change the pHi of the cells. In our interest, no significant intracellular 
acidification was observed in cells treated with these cytotoxic agents, as 
compared to what had been observed in GYY4137 treatment. Hence, a 
decrease in pHi was specifically induced only by H2S and not a secondary 
observation resulted from cell death. 
 
 
Fig. 16. Intracellular acidification is induced by H2S but not several other 
cytotoxic agents. MCF7 cells were treated with different cytotoxic agents at 
their pharmacological IC50 concentrations for 24 hours incubation time. pHi 
was measured by BCECF probe using ratiometric confocal microscopy 
imaging. No significant intracellular acidification was observed in taxol, 
etoposide and camptothecin (CPT) as compared to GYY4137 treatment. 
GYY4137; 400 μM. Taxol; 10 μg/ml. Etoposide; 200 μM. CPT; 20 μM. 




3.8 H2S impairs pH regulator activities of cancer cells 
Cancer cells with glycolytic adaptation are well equipped with an efficient pH 
regulatory mechanism to maintain their functional pHi balance (Neri and 
Supuran, 2011). It is unlikely to observe such a drastic decrease in pHi in the 
cancer cells if their pH regulation system is functionally well. Therefore, we 
anticipated that H2S may affect the pH homeostatic system of the cells to 
cause pHi acidification. We first examined the expression level of several 
cancer-associated pH regulators including carbonic anhydrases (CA), 
sodium/proton exchanger (NHE) and anion-exchanger (AE). Cancer cells 
HepG2 and MCF7 expressed much higher mRNA level of CA9 (5-10 folds), 
CA12 (10-20 folds), NHE1 (10-40 folds) and AE2 (20-30 folds) as compared 
to in the non-cancer cells WI38 and MCF10A (Fig. 17A). The high expression 
levels of these pH regulators in cancer as compared to in the non-cancer cells 
was a direct evidence showing a greater dependency on pH regulation by the 
cancer cells. However, there was no change in mRNA expression level was 









Fig. 17. H2S does not change expression level of pH regulators in cancer 
cells. (A) Total RNA was extracted and qRT-PCR was performed to quantify 
mRNA expression level of several important pH regulators. Cancer cells 
HepG2 and MCF7 expressed much higher level of pH regulators as compared 
to non-cancer WI38 and MCF10A. (B) No change in expression level of pH 
regulators was observed comparing non-treatment control (NT) and compound 
treatments. Carbonic anhydrase, CA. Sodium/proton exchanger, NHE. Anion 




With no change in the expression level of pH regulators, we speculated 
that H2S may affect the pH regulator activities of cancer cells. To assess this 
possibility, we assayed AE or NHE activity with alkali or acid loading 
respectively. Alkali loading of the cells with ammonium chloride (NH4Cl) 
caused an instant increase in pHi forming a spontaneous alkali peak (Fig. 18A, 
dotted line, indicated by arrow). This in turn activated AE activity to restore 
pHi back a new resting state. In the case of AE inhibition by DIDS, cells were 
absent of the signature alkali peak (Fig. 18A, solid line). On contrary, acid 
loading steadily reduced pHi of the cells (Fig. 18B). The acid loading buffer is 
sodium-free thus suppressed the NHE activity. Upon reintroduction of sodium 
buffer (Na
+
), NHE was activated restoring pHi to resting state (Fig. 18B, 
dotted line). Slope of the pHi response curve represented NHE activity. A 
marked reduced in pHi recovery response was observed in cariporide 
inhibition of NHE (Fig. 18B, solid line, indicated by triangle inset). 
 
  
Fig. 18. Typical responses of pH regulator activity with inhibition. (A) 
Cancer cells MCF7 was treated with anion-exchanger (AE) inhibitor DIDS, 1 
hour prior alkali load. DIDS inhibition diminished alkali peak response 
(indicated by arrow) of the cells upon ammonium chloride (NH4Cl) addition. 
(B) Sodium/proton exchanger (NHE) activity was inhibited by cariporide 
incubation. Cells treated with cariporide showed marked reduced pHi recovery 







In NT and ZYJ1122-treated HepG2 and MCF7 cells, a typical alkali 
peak response was observed upon NH4Cl loading but the response was barely 
apparent in the GYY4137 treated cells (Fig. 19A, indicated by arrows). NT 
and ZYJ1122-treated HepG2 showed less visible alkali peak as compared to 
the typical one observed in MCF7. Yet, an obviously impaired response was 
visible in GYY4137-treated HepG2. Loss of the typical alkali peak was 
undoubtedly observed in GYY4137-treated MCF7 cells. The data 
demonstrated that GYY4137 treatment impaired activity of the alkali loader 
AE. On the other hand, a significantly slower and minimal recovery of pHi 
was observed in GYY4137-treated cells as compared to NT and ZYJ1122 
upon reintroduction of Na
+
 buffer in acid loading assay (Fig. 19B, indicated by 
triangle inset). It was therefore evidenced that GYY4137 treatment resulted in 








Fig. 19. H2S impairs pH regulator activities of cancer cell. (A) Cancer cells 
HepG2 and MCF7 treated with compounds for 5 days were subjected to alkali 
load to examine anion-exchanger (AE) activity. Ammonium chloride (NH4Cl) 
induced a spike increase of intracellular pH (pHi) that triggered AE activity to 
restore pHi back to stable state. GYY4137-treated cancer cells lacked of 
signature alkali peak (indicated by arrow) as observed in non-treatment (NT) 
and ZYJ1122 controls. (B) Cancer cells were loaded with acid loading buffer 
to induce steady decrease in pHi. Addition of sodium buffer (Na
+
) activated 
sodium/proton exchanger (NHE) to restore pHi. GYY4137-treated cancer cells 
showed slower and minimal recovery of pHi (indicated by triangle inset) as 






Non-cancer cells WI38 and MCF10A showed different pHi response 
profiles from that typically observed in the cancer cells, further supporting the 
differences in pH regulatory mechanism between the two cell types. 
Importantly, no differences were observed comparing alkali responses and 
acid recovery in WI38 and MCF10A between the different treatments (Fig. 
20A, B). This implied that H2S impaired pH regulation in the cancer but not 




Fig. 20. H2S does not alter pH regulator activity of non-cancer cells. (A) 
Non-cancer cell WI38 and MCF10A were treated with compounds for 5 days 
and subjected to ammonium chloride (NH4Cl) alkali load. No differences were 
observed comparing alkali responses of cells with GYY4137 treatment and 
non-treatment (NT) and ZYJ1122 controls. (B) Acid load induced reduction in 
pHi of non-cancer cells. Reintroduction of sodium buffer (Na
+
) recovered pHi 
in WI38 but pHi recovery was minimal in MCF10A. No differences were 
observed between different treatments. ZYJ1122, GYY4137; 400 μM. 
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3.9 Neither lactate overproduction nor pH regulator inhibition alone is 
sufficient to induce pHi acidification and cancer cell death 
Thus far, we showed that the H2S (i) increased metabolic acid production and 
(ii) impaired pH regulation in the cancer cells, of which both may contribute 
their important part in causing pHi acidification. To further elucidate the 
interplay between these two components, we first asked if lactate 
overproduction alone is sufficient to induce intracellular acidification in 
cancer cells. We treated MCF7 cells with mitochondrial complex inhibitor 
rotenone (Rot) and/or antimycin A (AA), either one was known to boost 
glycolysis (Dickman and Mandel, 1990). Rot or AA strikingly caused nearly 3 
times higher lactate production in MCF7, yet no significant reduction in pHi 
was observed (Fig. 21A).  
 We then treated cancer cells HepG2 and MCF7 with increasing 
concentration of pH regulator inhibitors DIDS and/or cariporide (Cari) and 
examined if inhibition of the pH regulator activity alone may be sufficient in 
decreasing cancer cell viability. Intriguingly, inhibition of AE and/or NHE 
showed no observable effects on cancer cell viability (Fig. 21B). Cancer cell 
viability was maintained at more than 80% across the concentration range 
tested. The pHi of the cancer cells treated with Cari, DIDS or in combination 
of both inhibitors was also measured so to examine the relationship between 
pHi with cell viability (Fig. 21C). Of which, the combinatorial treatment of 
Cari and DIDS was able to reduced pHi of HepG2 to pH 6.98, statistically 
significant as compared to a resting pH 7.26. Cari treatment alone too reduced 
pHi of MCF7 to pH 7.13 as compared to a resting pH 7.43. However, the 
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reduction in pHi observed was of much lesser extent as compared to the 
intense intracellular acidification observed in GYY4137 (> 0.5 unit, Fig. 14).  
 
 
Fig. 21. Neither lactate over-production nor pH regulator inhibition alone 
is sufficient to induce pHi acidification and cancer cell death. (A) pHi of 
MCF7 cells treated with mitochondrial complex inhibitors rotenone (Rot) and 
antimycin A (AA) was measured using ratiometric confocal microscopy 
imaging. Mitochondrial complex inhibitor caused significantly high lactate 
production but not intracellular acidification in MCF7. Rot, AA; 2 μM. (B) 
Cell viability of cancer cells HepG2 and MCF7 treated for 5 days with 
increasing concentration of pH regulator inhibitors DIDS and cariporide (Cari) 
was examined using crystal violet colorimetric assay. pH regulator inhibition 
did not affect cell viability of cancer cells. (C) Cancer cells treated with pH 
regulator inhibitors did not show intense intracellular acidification (> 0.5 unit). 





 The data suggests that increased lactate production alone is not 
sufficient to cause significant intracellular acidification in cancer cells. 
Inhibition of pH regulator activities though causes pHi changes (small extent) 
but alone, is insufficient to induce significant cancer cell death. Concurrent 
overproduction of metabolic acid from glycolysis and impairment in pH 
regulatory system induced by H2S were necessary to induce intracellular 
acidification to trigger cancer cell death. 
 
3.10 Inhibition of glycolysis or restoration of pHi partially rescues cancer 
cell viability 
We next investigated the possibility of rescuing H2S-induced cancer cell death 
by glycolysis inhibition or pHi restoration. Cancer cells HepG2 and MCF7 
were co-treated with GYY4137 and the competitive inhibitor of glucose, 2-
deoxyglucose (2-DG) for 5 days. 2-DG up taken by cells is unable to be 
hydrolyzed further thus inhibits glycolysis process (Wick et al., 1957). The 
cell viability was examined using crystal violet colorimetric assay, comparing 
between GYY4137 treatment alone and co-treatment. Co-treatment of 
GYY4137 with 1 mM 2-DG significantly rescued cell viability of HepG2 
from 41% to 78%, while 0.5 mM 2-DG rescued cell viability of MCF7 from 
58% to 90% (Fig. 22A). The results supported our previous findings and 
clearly indicated that the anti-cancer cell viability effect of H2S was driven by 
glycolysis.  
Next, we evaluated whether a restoration in pHi may rescue cancer cell 
viability. To do so, cancer cells were first treated with GYY4137 for 3 days to 
allow H2S-induced pHi acidification to take place. The cells were then co-
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treated with ionophore nigericin for additional 2 days. Nigericin creates ion-
diffusible pores on the cell membrane allowing free proton exchange between 
the intracellular and extracellular compartments (Alonso and Carrasco, 1981). 
This disruption of membrane integrity partially restored the pHi acidification 
caused by GYY4137 in HepG2 and MCF7 cells. Increasing concentration of 
nigericin gradually restored acidic pHi 6.58 to 7.02 in HepG2 and pH 6.64 to 
7.04 in MCF7 (Fig. 22B, line graph, right y-axis). The gradual restoration of 
pHi was coupled with increasing cell viability in both cancer cell models (Fig. 
22B, bar graph, left y-axis). Thus far, our results clearly showed that H2S 
triggered cancer cell death by inducing intracellular acidification driven by 
combination effects of an enhanced glycolysis and an impaired pH regulation. 
This mechanism was minimally active in non-cancer cells thus making H2S 








Fig. 22. Inhibition of glycolysis or restoration of pHi partially rescues 
cancer cell survival. (A) Cancer cells HepG2 and MCF7 were co-treated with 
GYY4137 and glycolysis inhibitor 2-deoxyglucose (2-DG) for 5 days and cell 
viability was examined using crystal violet colorimetric assay. Increasing 
concentration of 2-DG gradually restored cancer cell viability. (B) Cancer 
cells were treated with GYY4137 for 3 days and then co-treated with 
ionophore nigericin (Nig) for additional 2 days. Cell viability and pHi were 
determined after a total of 5 days incubation. Co-treatment of nigericin 
partially rescued cell viability of HepG2 and MCF7 (left axis, bar chart) in 
parallel with partial restoration of pHi (right axis, line graph). GYY4137; 400 





3.11 Invasive cancers exhibit glycolytic adaptation 
We now know that H2S caused cancer cell death by inducing accumulation of 
metabolic acid lactate leading to intracellular acidification. Cancer glycolysis 
is the predominant source of lactate and the high glycolytic activity is reported 
to confer aggressive behavior of invasive cancers (Gatenby and Gillies, 2004; 
Lisanti et al., 2013; Lunt and Vander Heiden, 2011). Integrating the ideas of 
high glycolytic nature of invasive cancers and increased glycolysis induced by 
H2S to trigger cancer cell death, we hypothesized that H2S may exhibit greater 
anti-cancer activity on invasive cancers.  
We first studied the relationship between cancer cell invasiveness and 
their glycolytic adaptation in response to H2S. From the wide range of cancer 
cell lines that we had tested for H2S effects (Fig. 3), we selected 5 pairs of 
cancer cell line originated from different tissue as the study models. Cancer 
cell invasiveness was characterized using 2D gap closure assay. Cancer cell 
migration was monitored over time and the distance migrated by the cells 
indicated their invasiveness (Fig. 23A). MDA-MB-231, DU145, A549, 
HeyA8 and SiHa appeared as the faster-migration cell lines, in comparison 
with the slower-migration MCF7, LnCaP, H1299, A2780P and HeLa in breast, 
prostate, lung, ovarian and cervical cancer cell pair, respectively.  
 Cell viability of the cancer pairs treated with GYY4137 was then being 
examined. A consistent result was observed across all the 5 pairs of cancer cell 
lines. The slower-migration cell line showed a greater sensitivity to H2S as 
compared to their faster-migration pair (Fig. 23B). The observation was 
opposed to what we initially anticipated. We thus postulated that the 
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differential sensitivity of the invasive cancer cell lines to H2S may be due to 
their different dependency on glycolysis.  
 
Fig. 23. Invasive cancers are less sensitive to H2S. (A) Cancer cell pairs 
were seeded into culture insets with constant gap in between. Culture insets 
were removed and cells were allowed to migrate to fill in the gap. Cell 
migration was monitored and microscopy pictures were taken at indicated 
times. Distance migrated (arbitrary unit, a.u.) was measured and calculated 
using Image-Pro Analyzer software. (B) Cell viability of cancer cell pairs 
treated with increasing concentration of GYY4137 was determined and plotted 
as concentration response curve. Slower-migration cell line showed greater 
sensitivity toward GYY4137.  
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We moved on to characterize glycolysis dependency of the cancer cell 
lines by measuring intracellular lactate production and bioenergetics profile of 
the cell lines. Intracellular lactate production of the cancer cell pairs was 
determined using lactate dehydrogenase enzymatic activity assay and was 
normalized comparison to their corresponding slower-migration cell line. A 
higher lactate production suggested a higher glycolysis by the cell line. 
Consistent trend was observed across all the 5 pairs of cancer cell line (Fig. 
24A). The faster-migration cell line produced relatively higher lactate as 
compared to their slower-migration pair albeit dissimilar extends of difference 
was observed across cell line pairs (Fig. 24A) 
 To confirm further the glycolytic behavior of the cancer pairs, we used 
XFe24 Extracellular Flux Analyzer (Seahorse Bioscience) to measure basal 
Extracellular Acidification Rate (ECAR) and Oxygen Consumption Rate 
(OCR) of the cancer cells. ECAR and OCR represented the glycolytic rate and 
mitochondrial activity respectively. The metabolic parameter ECAR/OCR 
ratio was calculated to represent the cellular metabolic activity. A higher 
ECAR/OCR ratio indicated a greater glycolytic adaptation by the cell. In tight 
correlation with higher intracellular lactate production, the faster-migration 
cell line exhibited higher ECAR/OCR ratio as compared to their 
corresponding slower-migration pair (Fig. 24B). Analysis of intracellular 
lactate production and ECAR/OCR ratio clearly demonstrated a glycolytic 






Fig. 24. Invasive cancers exhibit higher intracellular lactate production 
and ECAR/OCR. (A) Intracellular lactate of cancer cell pairs was determined 
using lactate dehydrogenase enzymatic assay and was expressed with 
normalization to corresponding slower-migration cell line. Faster-migration 
cell lines were found to produce relatively higher lactate as compared to their 
slower-migration pair. (B) Basal Extracellular Acidification Rate (ECAR) and 
Oxygen Consumption Rate (OCR) of cancer cells were measured using XFe24 
Extracellular Flux Analyzer. ECAR/OCR ratio was calculated to represent 
cellular metabolic activity. The faster-migration cancer cell line exhibited 






3.12 H2S induces intracellular lactate overproduction and pHi 
acidification in invasive cancers 
We next investigated the H2S effects on intracellular lactate production and 
possible pHi decrease upon GYY4137 treatment in the cancer cell pair. The 
cancer cell lines were treated with GYY4137 for 3 days and the cells were 
lysed for intracellular lactate measurement. 500 μM GYY4137 was treated on 
the slower-migration cell lines while 500 μM and higher concentration of 1000 
μM was used on the faster-migration cell lines. The different concentrations of 
GYY4137 used on the pairs of cancer cell lines was based on their differential 
sensitivity to H2S (Fig. 23B). 1000 μM GYY4137 was not included for the 
slower-migration cancer cell lines as this high concentration would have kill 
most of the cells. A significant increase in lactate production was measured in 
cancer cells treated with GYY4137 as compared to NT (Fig. 25A). While 500 
μM GYY4137 was able to induce significant increase in intracellular lactate 
production of the slower-migration cell lines (MCF7, LnCaP, H1299, A2780P 
and HeLa; grey bars), higher concentration of 1000 μM GYY4137 was needed 
to induce lactate over-production in the faster-migration cell lines (black bars).  
 At the same time, the pHi of the 5 cancer pairs under treatment of 
increasing concentration of GYY4137 was measured. A significant and drastic 
intracellular acidification was observed at concentration of 500 μM GYY4137 
treatment on the slower-migration cell lines; in contrast to the faster-migration 
cell lines which showed an obvious pHi reduction only at the higher 
concentration of 1000 μM (Fig. 25B). A higher concentration of GYY4137 
was needed to induce intracellular lactate overproduction and pHi acidification 
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in the faster-migration cell line, suggested that the greater glycolytic 
adaptation by invasive cancers conferred their lower sensitivity to H2S.  
 
 
Fig. 25. H2S induces intracellular lactate over-production and pHi 
acidification in invasive cancers. (A) Intracellular lactate of GYY4137-
treated cancer cell was measured using lactate dehydrogenase enzymatic 
activity assay. GYY4137 treatment induced significant lactate over-production 
in all cancer cell lines but higher concentration was needed for faster-
migration pair (MCF7, LnCaP, H1299, A2780P, HeLa; 500 μM. MDA-MB-
231, DU145, A549, HeyA8, SiHa; 1000 μM). (B)  pHi was measured using 
ratiometric fluorescence microplate assay. GYY4137 reduced pHi in a 
concentration dependent manner. pHi reduction was obvious for faster-




3.13 Magnitude of pHi acidification determines sensitivity to H2S 
To demonstrate the correlation between the pHi acidification and the anti-
cancer cell viability effects of H2S on the 5 cancer pairs, we presented the 
magnitude of decrement in pHi (∆pHi) induced by GYY4137. ∆pHi in all the 
5 pairs of cancer cell lines was GYY4137-concentration dependent (Fig. 25B, 
26). Importantly, the slower-migration cell line exhibited a greater ∆pHi at the 
same concentration as compared to their corresponding faster-migration pair 
(Fig. 26). For example, in breast cancer cell pair, MCF7 showed 0.30, 0.58 
and 0.80 unit of pHi reduction with 250, 500 and 1000 μM GYY4137 
treatment correspondingly. MDA-MB-231, resembles the more invasive 
cancer cell line, showed only a significant reduction of 0.34 unit pHi at 1000 
μM. Likewise, LnCaP showed 0.15, 0.37 and 0.75 unit of pHi reduction while 
DU145 showed only 0.05, 0.24 and 0.31 unit of pHi decrease with increasing 
GYY4137 concentration. The magnitude of ∆pHi showed parallel trend with 
the concentration responses of the cancer pairs to GYY4137 (Fig. 23B, 26). 
Thus, we concluded that the invasive cancers with higher basal glycolytic 
adaptation were less sensitive to H2S-induced intracellular lactate production 
and pHi acidification. The magnitude of pHi acidification determined the 





Fig. 26. Magnitude of pHi acidification determined sensitivity of invasive 
cancer cells toward H2S. Decrement in pHi of cancer cells as compared to 
resting pHi of non-treatment control (∆pHi) was calculated. GYY4137 
induced concentration dependent decrease in pHi. ∆pHi was greater in slower-
migration cell line as compared to their corresponding faster-migration pair.  
 
 
3.14 Perturbation of lactate accumulation increases cancer sensitivity to 
H2S 
We were now revealed that the magnitude of pHi acidification induced by H2S 
modulated the cancer sensitivity to H2S. The pHi acidification was a result 
from the lactate overproduction and accumulation inside the cancer cells. Yet, 
the possible contribution of H2S-induced pH regulator impairment was not 
particularly examined in this setting, as the complicated yet comprehensive pH 
homeostasis networks may cross-talk and compensate each other (Reshkin et 
al., 2014). Instead, manipulation of intracellular lactate accumulation is 
focused. Lactate is transported into or out from cells by the monocarboxylate 
transporter (MCT). The two major MCTs, MCT1 which functioned as a 
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lactate importer and MCT4 which predominantly acted as a lactate exporter 
were known to work antagonistically in regulating lactate distribution 
(Halestrap and Price, 1999; Hirschhaeuser et al., 2011). We hereby asked if 
the co-treatment of GYY4137 with a MCT1 inhibitor α-cyano-4-
hydroxycinnamate (CHC) or MCT4 inhibitor simvastatin may enhance H2S 
effects on the invasive cancer cells (Kobayashi et al., 2006; Sonveaux et al., 
2008). Besides, glycolysis booster metformin that can partially increase 
glycolysis was also tested for its possible synergy effects (Viollet et al., 2012).  
We treated MDA-MB-231 and DU145 with GYY4137 alone, or with 
co-treatment with MCT1 inhibitor α-cyano-4-hydroxycinnamate (G+CHC), 
MCT4 inhibitor simvastatin (G+Sim), or glycolysis booster metformin 
(G+Met) and examined the cell viability after 3 days incubation. The working 
concentration used for Sim (1 μM), CHC (1 mM) and Met (1 mM) did not 
cause detrimental effect on cell viability (Fig. 27A). These nonlethal 
concentrations of compound were chosen in purpose to avoid discrepancy in 
subsequent interpretation of possible synergy effects with GYY4137. The 
combinatorial treatment of GYY4137 and Sim or Met resulted in an enhanced 
sensitivity of invasive cancers as compared to GYY4137 treatment alone (Fig. 
27B). At 600 μM GYY4137, the cell viability of MDA-MB-231 reduced 
further from 69% to 48% with Sim, and 52% with Met combined treatment. A 
further decrease of 17% and 21% in cell viability of MDA-MB-231 was 
observed at 800 μM GYY4137 combined treatment with Sim and Met 
respectively. Likewise, Sim combination with 600 μM GYY4137 reduced cell 
viability of DU145 from 76% to 60%. Increased sensitivity in Met 
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combination with GYY4137 was observed in DU145 but only at higher 
concentration of 800 and 1000 μM GYY4137.  
To verify that the enhanced sensitivity to H2S observed in combined 
treatment of GYY4137 with Sim or Met was due to the lactate accumulation, 
we measured the intracellular lactate production in MDA-MB-231 cells. Sim 
or Met treatment alone slightly increased the lactate production in MDA-MB-
231 (Fig. 27C). Sim induced 19% increase while Met induced 32% increase of 
lactate production as compared to the NT. GYY4137 treatment alone 
efficiently increased 2.5 folds of lactate production in the cells. Strikingly, 
nearly 4-5 folds increment of lactate production was measured in Sim and Met 
combined treatment with GYY4137, respectively. The huge increment in the 
lactate production induced by the combination treatment was corresponding to 
the enhanced sensitivity to H2S. The results hereby showed the possibility to 
increase sensitivity of invasive cancer to H2S by perturbing lactate 
accumulation in cancer cells with, but not limiting to MCT inhibitor and 
glycolysis booster. Though not measured in this setup, we postulated that the 
combined treatment may result in enhanced pHi acidification as compared to 
GYY4137 treatment alone.  
In summary, we demonstrated that H2S selectively increased cancer 
glycolysis that resulted in the lactate overproduction. The effect was partly 
contributed by a H2S-induced protein oligomerization of Glut1. H2S also 
impaired pH regulator activity. Combined effect of these both components 
caused pHi acidification in cancer cells that triggered cancer cell death. 
Perturbation of intracellular lactate accumulation possessed potential to 





Fig. 27. Perturbation of lactate accumulation increases cancer sensitivity 
to H2S. (A) Cell viability of MDA-MB-231 and DU145 were examined after 3 
day incubation with monocarboxylate transporter (MCT) inhibitor simvastatin 
(Sim, 1 μM), α-cyano-4-hydroxycinnamate (CHC, 1 mM) and glycolysis 
booster metformin (Met, 1 mM) using MTT colorimetric assay. No significant 
reduction of cancer cell viability was observed at the indicated working 
concentration. (B) Cancer cells were co-treated with GYY4137 and indicated 
compounds for 3 days. Cell viability was examined using MTT colorimetric 
assay. Combinatorial treatment of GYY4137 and Sim or Met caused greater 
reduction in cell viability as compared to GYY4137 treatment alone. (C) 
MDA-MB-231 cancer cells with single or combinatorial treatment of 
GYY4137 and Sim or Met were harvested and lysed with 2% v/v perchloric 
acid solution. Lactate concentration was determined by lactate dehydrogenase 
enzymatic activity assay. Sim or Met treatment alone slightly increased lactate 
concentration of the cells. Combinatorial treatment of GYY4137 with Sim or 
Met significantly increased lactate concentration. The increment was greater 
as compared to GYY4137 treatment alone. GYY4137; 600 μM. * P < 0.05.  
126 
 
CHAPTER 4: Anti-cancer metastasis and angiogenesis 
activity of H2S on glycolytic-adapted invasive cancer-
activated endothelial cells 
 
4.1 H2S inhibits cancer cell migration and transwell chemoinvasion 
Invasive cancer cells that show glycolytic adaptation are known to possess 
hostile metastatic behaviors (Bettum et al., 2015). We had showed that H2S 
was capable to induce invasive cancer cell death by pHi acidification. We 
thence continued to explore the potential of using H2S to anti-cancer 
metastasis. Cancer metastasis requires cancer cells to be equipped with high 
cell motility and ability to degrade membrane matrix for extravasation then 
proliferate to colonize at distant sites (Germanov et al., 2006; Leber and 
Efferth, 2009). We examined the effects of GYY4137 on each of these 
properties of cancer metastasis using the highly invasive breast 
adenocarcinoma MDA-MB-231 and epithelial ovarian cancer HeyA8 as study 
models.  
 To assess cancer cell motility, MDA-MB-231 and HeyA8 were seeded 
into culture insets with a constant gap in between overnight. Cell culture insets 
were removed and cells were monitored as they migrated to fill in the gap. 
Microscopy pictures were taken after 24 hours of migration in MDA-MB-231 
and after 12 hours in HeyA8 (Fig. 28). As the migration assays were examined 
only within 24 hours after GYY4137 treatment, no anti-cell viability was 
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expected therefore whatever effects observed were solely due to inhibitory 
activity by H2S on cell motility. The distance migrated by the cells within the 
indicated duration of time was measured and calculated using Image-Pro 
Analyzer software. In the both invasive cancer models, 250 μM GYY4137 
showed visible decrease of cell migration as compared to non-treatment 
control. Greater gap distance was quantified with increasing concentration of 
GYY4137 treatment. The data indicates that GYY4137 decreases cell motility 
of invasive cancer.  
 
 
Fig. 28. H2S decreases cancer cell migration in 2D gap closure assay. 
Breast adenocarcinoma MDA-MB-231 and epithelial ovarian cancer HeyA8 
were seeded into culture inset with a constant gap in between. Cells were 
allowed to migrate to fill in the gap over time. Microscopy pictures were taken 
after cell migration (t=24 hr for MDA-MB-231; t=12 hr for HeyA8) and 
distance migrated (arbitrary unit, a.u.) was measured using Image-Pro 
Analyzer software. GYY4137 inhibited cancer cell 2D migration in a 




In a separate setting to examine the cancer cell chemoinvasiness, 
MDA-MB-231 and HeyA8 cells were seeded into the upper chamber of 
transwell coated with 1 mg/ml of collagen as a membrane matrix mimic, in 
serum-free media (SFM, Fig. 29, inset illustration). 20% serum media was 
added into the lower chamber to act as the chemoattractant. GYY4137 was 
added into both the upper and lower chambers so to avoid interpretation 
discrepancy. With the presence of H2S in the both sides, any differences 
observed between the non-treated control and treated group would not be due 
to the chemoattractive or chemorepulsive property of H2S. Serum gradient 
between the upper and lower chambers attracts cancer cells to degrade the 
membrane matrix and migrate towards the lower chamber. The cells migrated 
into the lower chamber after 24 hours of incubation were harvested and 
quantified. Nearly 30 - 35% of MDA-MB-231 and HeyA8 cells migrated into 
the lower chamber after 24 hours in response to the serum attraction (Fig. 29). 
250 μM GYY4137 significantly inhibited the cancer cell chemoinvasion to 
only 15% in MDA-MB-231 and 20% in HeyA8. A further increase in 
GYY4137 concentration showed a greater decrease in the cancer transwell 





Fig. 29. H2S inhibits cancer transwell chemoinvasion. Cancer cell MDA-
MB-231 and HeyA8 were seeded into upper chamber of transwell in serum-
free media (SFM) and were allowed to migrate across collagen-coated 
membrane in attraction to 20% FBS media. Cells migrated into lower chamber 
of transwell were harvested after 24 hours and cell number was quantified. 
Increasing concentration of GYY4137 showed decreasing transwell migratory 
index. * P < 0.05. 
 
4.2 H2S suppresses cancer tumorigenicity under non-anchorage condition 
A crucial step in the cancer metastasis is the successful establishment of new 
colonies at distant site (Leber and Efferth, 2009). The ability of a single cancer 
cell to form a distinct colony refers to its tumorigenicity. The whole process 
possesses extreme stress to the cancer cells when the isolated cancer cells need 
to colonize at a different niche to form the survival colonies. This stress is 
repeatedly observed in vitro as not every cancer cell line is able to form 
survival colonies under the non-anchorage 3-dimentional culture (Fidler, 
2003). To assess this, we suspended and singly embedded MDA-MB-231 and 
HeyA8 cancer cells in 0.35% agarose, fed with GYY4137 incubation for a 
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total of 14 days. Fresh media was changed every 3 or 4 days to ensure the 
adequate supply of nutrients. Microscopy pictures were taken under random 
view fields and the colony diameter was measured using Image-Pro Analyzer 
software. The number of colonies formed within grid was visually counted 
under microscope and was normalized to colony number per mm
2
. Results 
were presented as scattered dotplot. 
Distinct and varied sizes of MDA-MB-231 and HeyA8 colonies were 
measured in non-treatment control (Fig. 30). Nonetheless, increasing 
concentration of GYY4137 treatment significantly suppressed the colony 
growth. Using mean (○) as a representative of the whole colony population, 
colony diameter decreased by 39%, 54% and 78% in MDA-MB-231 with 250, 
500 and 1000 µM GYY4137 treatment, respectively. A marked reduction in 
colony number was also quantified. 250 µM GYY4137 decreased MDA-MB-
231 colony number by 61%, as compared to non-treated control. A further 
decrease of 79% and 94% was observed with 500 and 1000 µM GYY4137 
treatment. Notably, a stronger inhibitory effect on cancer colony growth by 
H2S was observed in the 3D culture as compared to in monolayer cell culture 
(comparing effective concentrations for MDA-MB-231 and HeyA8 in Fig. 23 
and 30). This was possibly due to a larger surface area exposure to H2S 
accessibility under 3D condition. In conclusion, GYY4137 effectively 
inhibited the invasive cancer 2D cell migration, transwell chemoinvasion and 








 Fig. 30. H2S suppresses cancer tumorigenicity under non-anchorage 
condition. Cancer cell MDA-MB-231 and HeyA8 were trypsinized from 
culture and singly embedded in 0.35% agarose. Cells were incubated for 14 
days with GYY4137-treated media changed every 4 or 5 days. Colony 
diameter was measured using Image-Pro Analyzer software and colony 
number within grid was visually counted. Boxplot represented distribution of 




4.3 Cancer-conditioned media (CM)-activated endothelial cells (EC) 
exhibit glycolytic adaptation 
Another pathophysiological process that contributes to carcinogenesis is the 
formation of new blood vessels to supply the tumor mass with nutrients 
(Carmeliet and Jain, 2000). Endothelial cell (EC) is the most important player 
in cancer angiogenesis (Polet and Feron, 2013). Cancer cells produced and 
released cancer-associated factors into extracellular compartment that 
activated EC to initiate cancer angiogenesis (Gerhardt, 2008; Keeley et al., 
2010). An interesting feature of the cancer-activated EC was a metabolic 
switch to glycolysis (De Bock et al., 2013; Gerhardt, 2008). This glycolytic 
switch was shown to be greatly driven by vascular endothelial growth factor 
(VEGF). 
To study the effects of H2S on endothelial cell, we used the endothelial 
hybridoma cell line EA.hy926 as the EC model. EA.hy926 is a somatic 
hybridoma of primary human umbilical vein cells (HUVEC) and A549 lung 
adenocarcinoma. EA.hy926 is transformed thus immortalized, but preserved 
important characteristics of primary endothelial cell (Ahn et al., 1995). The 
cell line is commonly used to study endothelial functions as this avoids 
possible batch-to-batch variation and limited lifespan of primary endothelial 
cells (Bouïs et al., 2001). In order to study cancer-context EC functionality, we 
collected cancer-conditioned media (CM) from highly invasive breast 
adenocarcinoma MDA-MB-231 and used it to activate EC, establishing a 
cancer CM-activated endothelial cell (CM-EC) model (Fig. 31Aii). A 24-hour 
culture media collected from confluent MDA-MB-231 cancer cells was pre-
cleared from cell debris and used as cancer CM. In contrast, EC cultured with 
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fresh DMEM (DMEM-EC) was used as control cell model (Fig. 31Ai), 
representing non-activated EC in physiology. Foremost, no distinct difference 
in the growth rate was observed comparing EC cultured under either DMEM 
or CM. Since a glycolytic switch was reported in cancer-activated EC, we 
asked if this was indeed true in our EC system. Extracellular lactate 
production by EC cultured under either normal DMEM or cancer CM was 
measured using lactate dehydrogenase enzymatic activity assay. Fresh DMEM 
or the cancer CM collected was used as the assay blank respectively, so to 
ensure the lactate amount detected was truly produced by EC under each 
culturing condition. Interestingly, cancer CM-EC produced nearly 50% higher 
amount of lactate as compared to the DMEM-EC (Fig. 31B), clearly indicated 
a glycolytic switch in EC when it was activated by cancer CM.  
 
Fig. 31. Cancer-conditioned media (CM)-activated endothelial cells 
exhibit glycolytic switch. (A) Culture media from a confluent MDA-MB-231 
cancer cells was collected as cancer CM. Pre-cleared cancer CM was used to 
activate endothelial cell (EC) EA.hy926. Fresh DMEM cultured EC was used 
as a non-activated control. (B) Lactate concentration in media samples 
collected from a 3 days culture of EC under either fresh DMEM or cancer CM 
was determined using lactate dehydrogenase enzymatic activity assay. Lactate 
concentration was normalized to total protein amount. Cancer CM-EC 
produced significantly higher lactate as compared to DMEM-EC. * P < 0.05.  
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4.4 H2S decreases cell viability of cancer-conditioned media activated 
endothelial cell (CM-EC) 
Next, EC cell viability in exposed to H2S was examined. The EC cells were 
first seeded in fresh DMEM into culture plate and were allowed to attach 
overnight. GYY4137 treatment was carried out in either fresh DMEM or 
cancer CM, and the cells were incubated for 72 hours. The cell viability was 
examined by MTT colorimetric cell viability assay. GYY4137 minimally 
affected cell viability of the DMEM-EC up to 2000 μM, maintaining at nearly 
70% cell viability (Fig. 32, dotted line). Interestingly, within the same 
concentration range, in particular, 800 and 1000 μM GYY4137 significantly 
reduced the cell viability of cancer CM-EC to 73% and 65% respectively (Fig. 
32, solid line). The decrease in cell viability of cancer CM-EC was GYY4137 
centration dependent. However, at high concentration of GYY4137 (> 2000 
μM), a marked reduction in cell viability was observed in both DMEM- and 
cancer CM-EC. This may possibly due to the mitochondrial toxicity action of 
high exposure to H2S (Dorman et al., 2004). In order to avoid possible 
discrepancy that resulted from non-cancer selective H2S toxicity, subsequent 
studies on EC functionality were performed using GYY4137 below 
concentrations of 1000 μM. Conclusively, the data showed that H2S exhibited 
anti-cell viability activity on EC only under cancer-activated context but not 




Fig. 32. H2S decreases cell viability of CM-EC. Endothelial cell EA.hy926 
was treated with increasing concentration of GYY4137 under normal culture 
media (DMEM) or cancer-conditioned media (CM). Cell viability was 
assessed after 72 hours incubation of GYY4137 using MTT colorimetric assay. 
GYY4137 significantly decreased cell viability of CM-EC but to a lesser 
extent of DMEM-EC. Cell viability reduction was observed at high 
concentration (> 2000 μM) treatment.  
  
4.5 H2S induces lactate overproduction and pHi acidification in cancer-
conditioned media cultured endothelial cell (CM-EC) 
We had known that H2S acts via increasing metabolic acid lactate production 
and causing pHi acidification to reduce cell viability. Hereby, we examined if 
the same mechanisms took place in cancer CM-EC treated with H2S. 
Extracellular and intracellular lactate produced by EA.hy926 cells, cultured 
under either normal DMEM or cancer CM for 72 hours, were analyzed. An 
increase of basal lactate production was observed comparing between the 
cancer CM-EC and DMEM-EC (Fig. 33A, white bar), indicated the glycolytic 
switch by EC under cancer CM activation. GYY4137 did not cause changes in 
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extracellular and intracellular lactate production of the DMEM-EC. 
Interestingly, a GYY4137-concentration dependent increase in lactate 
production was observed in the cancer CM-EC (Fig. 33A, black bar).  
The pHi of EC under either DMEM or CM condition was measured by 
ratiometric pHi measurement using confocal microscopy. The basal resting 
pHi of DMEM-EC was pH 7.47. No change in pHi was observed in DMEM-
EC with GYY4137 treatment (Fig. 33B, dotted line). This indicated that H2S 
did not affect pHi of EC under a non-activated condition. However, the resting 
pHi in cancer CM-activated EC was measured at pH 7.11 as compared to pH 
7.47 in the non-activated DMEM-EC. This suggested that an activation of EC 
by cancer CM induced glycolytic switch that resulted in a lower resting pHi in 
the cells. Already existed at lower resting pHi, a GYY4137-concentration 
dependent decrease in pHi was further observed in cancer CM-EC (Fig. 33B, 
dashed line). 500 μM GYY4137 decreased pHi of cancer CM-EC to pH 6.85 
while 1000 μM resulted in pHi 6.65. Taken together, these data suggested that 
H2S-induced intracellular acidification was similarly active in EC and was 








Fig. 33. H2S induced lactate over-production and pHi acidification in CM-
EC. (A) Endothelial cell (EC) EA.hy926 was treated with GYY4137 using 
either normal DMEM or media collected from cultured MDA-MB-231 cancer 
cell line (cancer conditioned media, CM) for 3 days. Extracellular lactate was 
determined from media samples while intracellular lactate was measured from 
2% perchloric acid cell lysate using lactate dehydrogenase enzymatic activity 
assay. Lactate concentration was normalized to total protein amount. 
GYY4137 induced increased lactate production only in CM-EC but not 
DMEM-EC. (B) pHi of EC treated with GYY4137 was measured using 
BCECF probe with ratiometric confocal microscopy imaging. Intense 






We also calculated the magnitude of pHi reduction (∆pHi) in EC. 
Shown in Fig. 34, under cancer CM condition, 500 μM GYY4137 caused a 
reduction of 0.26 unit pHi. 0.45 unit pHi reduction was measured with 1000 
μM GYY4137 treatment. The data thus clearly demonstrated that the pHi 
acidification caused by H2S was corresponded to its anti-cell viability activity. 
The cancer context specific condition suggested possible anti-cancer 
angiogenesis property by H2S that possessed low cytotoxicity effect on non-
activated endothelial cell.  
 
 
Fig. 34. H2S induces greater reduction in pHi in CM-EC but not DMEM-
EC. pHi of EC treated with GYY4137 was measured using BCECF probe 
with ratiometric confocal microscopy imaging. Decrement in pHi as compared 
to resting pHi of non-treatment control (∆pHi) was calculated. GYY4137 
induced concentration dependent decrease in pHi under CM but no effect 





4.6 H2S inhibits EC migration in response to cancer spheroid attraction 
and EC tube differentiation 
Having known an active cross-talk between the cancer and endothelial cells, 
we thus established a co-culture system of cancer spheroids with EC to 
represent cancer physiology. Cancer cell MDA-MB-231 and HeyA8 were first 
cultured in ultra-low adherence culture plate for 3 days to form spheroids. 
Cancer spheroids were used to resemble an intact solid tumor mass that 
consists of a normoxic periphery and hypoxic tumor core, as compared to a 
less physiological relevant, uniform monolayer cell culture (Kimlin et al., 
2013). The spheroids were then transferred into the lower chamber of 
transwell to act as in situ chemoattractant. The EC preloaded with green 
fluorescence cell tracker dye was seeded onto the upper chamber and transwell 
migration was incubated for 24 hours (Fig. 35, inset illustration). A transwell 
setting examined the crosstalk between cancer and EC via interaction through 
soluble factors released by the cancer cells. Trans-migratory index represented 
by green fluorescence intensity measured in the lower chamber was 
normalized to their corresponding non-treatment control. DMEM media 
contained no cancer spheroid was included as the negative control. Very low 
migration activity was observed under DMEM and GYY4137 exhibited no 
effect on EC cell migration in DMEM media control (Fig. 35A, grey bars). 
Interestingly, 500 μM GYY4137 reduced trans-migratory index of the 
EC by 35% in MDA-MB-231 and 23% in HeyA8 spheroid systems (Fig. 35A, 
yellow bars). A 56% - 65% decrement of trans-migration was observed with 
1000 μM GYY4137. The results clearly demonstrated a selective inhibitory 
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effect of GYY4137 on the EC migration only when co-cultured together with 
the cancer spheroids.  
 On the other hand, we examined the cancer CM-induced endothelial 
tube differentiation. Endothelial tube maturation is the determinant process in 
cancer angiogenesis (Carmeliet and Jain, 2000). The cell culture wells were 
coated with Geltrex matrigel for 1 hour in 37 ⁰C incubator. EC were seeded 
onto solidified matrigel and tube differentiation was induced with MDA-MB-
231 cancer CM for 16 hours. In contrast, DMEM media was used as the 
negative control. No tube differentiation occurred in DMEM control while 
cancer CM induced enclosed and intact tube formation (Fig. 35B). The 
obvious activation by cancer CM indicated the successful experiment setup. 
Besides, this observation was in line with previous reports showing that cancer 
CM contained necessary factors for EC tube differentiation driving cancer 
angiogenesis (Carmeliet, 2005; Shahi and Pineda, 2008). Quantified using 
ImageJ analysis software, GYY4137 resulted in leaked and contracted tubes 
with marked reduction in the number of nodes and tubes formation under 
cancer CM induction. A 500 μM GYY4137 treatment had significantly 
reduced the number of nodes and tubes formation by 77% and 83%, 
respectively. Taken together, we hereby provided evidences that GYY4137 
was an effective anti-cancer angiogenesis agent inhibiting cancer-activated 





Fig. 35. H2S inhibits EC migration in response to cancer spheroid 
attraction and EC tube differentiation. (A) Cancer cell MDA-MB-231 and 
HeyA8 were seeded into ultra-low adherence culture plate to form spheroids 
over 3 days incubation. Cancer spheroids formed were transferred into lower 
chamber of transwell to act as in situ attractants of EC. Control contained only 
DMEM media without spheroid. Endothelial cell EA.hy926 was loaded with 
green fluorescence cell tracker dye prior seeding into upper chamber of 
transwell. Transwell migration was incubated for 24 hours. Migratory 
responses were quantified by green fluorescence intensity reading in the lower 
chamber. Readings were normalized to their corresponding non-treated control. 
No significant migratory responses under DMEM while GYY4137 
significantly inhibited EC transwell migration in response to cancer spheroid 
attraction. (B) Basal gel matrix was coated onto culture well and incubated at 
37 ⁰C incubator for 1 hour to allow solidification. EC was seeded onto gel 
matrix in MDA-MB-231 conditioned media (CM) with GYY4137 treatment. 
EC tube differentiation was monitored after 16 hours and number of nodes and 
tubes formed were quantified using ImageJ analysis software. No tube 
differentiation was observed in DMEM control. CM induced significant and 
intact tube differentiation. GYY4137 reduced number of nodes and tubes 
formed. * P < 0.05.  
142 
 
4.7 H2S decreases vascular endothelial growth factor (VEGF) in ELISA 
Vascular endothelial growth factor (VEGF) is one of the major angiogenic 
factors released by cancer to its surrounding microenvironment (Carmeliet, 
2005; Gerhardt, 2008). An enhanced production of cancer VEGF is associated 
with the hostile behavior of malignant tumors and neovascularization at tumor 
site. We therefore examined if the inhibitory effect of H2S on cancer 
metastasis and angiogenesis was related with a decrease in VEGF production. 
We examined the expression level of VEGF using ELISA and qRT-PCR. 
Cancer media of MDA-MB-231 was collected after incubation with GYY4137 
for 24 hours. VEGF amount presented in the media was detected and 
measured by ELISA. Approximately 40% and 60% reduction in ELISA 
reading was measured with 500 and 1000 μM GYY4137 treatment as 
compared to the non-treated control (Fig. 36A). Intriguingly, no detectable 
change was observed in the mRNA expression level of VEGF and its well-
known transcription factor, HIF1a (Fig. 36B). The ELISA and qRT-PCR 
measured the soluble protein and mRNA expression level respectively. The 
ambiguous result led us to hypothesize that H2S may affect VEGF binding 






Fig. 36. H2S decreases vascular endothelial growth factor (VEGF) ELISA 
in cancer CM but not its expression level. (A) MDA-MB-231 cancer cells 
were treated with GYY4137 for 24 hours. Conditioned-media was collected 
and subjected to ELISA. GYY4137 significantly decreased vascular 
endothelial growth factor (VEGF) concentration detected in CM. (B) Total 
RNA was extracted and qRT-PCR was performed to quantify mRNA 
expression level of hypoxia-inducible factor 1-alpha (HIF1a) and VEGFA. No 
changes was observed with GYY4137 treatment. GYY4137; 1000 μM.  
 
4.8 H2S reduces sulfide-linkage in VEGF 
VEGF protein structure is regulated by cystine-knots that preserve its 
homology among different isoforms (Iyer and Acharya, 2011; Muller et al., 
1997). Disruption of these cystine-knots greatly affects its receptor binding 
activity and demolishes VEGF activation on angiogenesis. We hence 
postulated that H2S being thiol reductant may interfere with cysteine sulfide-
linkages in VEGF thus alters its activity. Total protein from MDA-MB-231 
conditioned media was acetone precipitated and subjected to cysteine sulfide-
linkage derivation (refer to Section 2.13 for detailed procedures). Thiol ends 
of the total protein were blocked with NEM and any S-S bonds present in the 
protein were then reduced by using reductant DTT. The newly formed free 
thiol ends were labelled by biotin-maleimide and immunoprecipitated using 
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streptavidin-conjugated beads. A sample with total reduction by DTT without 
NEM blocking was included as the positive control (Pos). The Pos sample 
showed strong sulfide-linkage signal indicated a successful derivation 
procedures (Fig. 37A, Lane 1). Non-treated control (NT) showed a moderate 
sulfide-linkage signal as opposed to a significant reduction of signal from 
GYY4137-treated sample (Fig. 37A, Lane 2 and 3). Multiple forms of the 
VEGF were detected on the SDS-PAGE (monomer 21 kDa; oligomer 37-50 
kDa). Nonetheless, GYY4137 appeared to reduce the sulfide-linkage 
formation in VEGF regardless of its monomeric or oligomeric form.  
VEGF conformation is tightly maintained by its cystine-knots (Muller 
et al., 1997). A reduction in sulfide-linkage caused by H2S was thought to 
affect its conformation. To examine this possibility, native PAGE was run. 
Depending on their folding and molecular charges, proteins with different 
conformation will display different motility patterns on native PAGE (Wittig 
and Schägger, 2005). Cancer CM with or without GYY4137 treatment was 
collected and concentrated by using Amicon ultra spin column. The 
concentrated media was added with bromophenol blue sample buffer without 
SDS denaturant or DTT reductant, and was separated on a native PAGE. 
Interestingly, VEGF presented in GYY4137-treated cancer CM displayed a 
significantly slower motility as compared to that in NT (Fig. 37B). Combining 
these evidences, we proposed that the H2S produced by GYY4137 induced 
sulfide-linkage reduction and conformational change in the cancer-derived 
VEGF. The modification may in turn alter VEGF activity, possibly reducing 








Fig. 37. H2S reduces sulfide-linkage formation of VEGF. (A) Breast 
adenocarcinoma MDA-MB-231 was incubated with compound treatment for 
24 hours. Conditioned media was acetone precipitated and extracellular 
proteins were subjected to sulfide-linkage derivation assay. Samples from 
derivation assay were examined with Western Blotting using anti-VEGF 
antibody. GAPDH in total cell lysate was used as the loading control. 
GYY4137 treatment reduced the sulfide-linkage formation of VEGF protein as 
compared to the non-treatment control (NT). (B) Conditioned media was 
concentrated and loaded on native non-denaturing PAGE. VEGF treated with 





4.9 Ex vivo H2S treatment reduces cancer VEGF binding affinity and 
activation on EC 
In attempt to demonstrate that the H2S-induced conformational changes in 
cancer VEGF led to a reduced functionality of the VEGF on endothelial 
activation, we ex vivo treated the cancer CM with NaHS. NaHS was expected 
to instantaneously release H2S that was diminished within a short period of 
time (less than 1 hour, Fig. 1B). The short-sustained H2S release enabled us to 
exclude the possibility of any remnant effect from the GYY4137 presented in 
the cancer CM to act on the EC. Any changes observed could only be coming 
from the H2S activity on cancer CM, ie. cancer-produced VEGF; rather than 
on the EC. The CM collected from MDA-MB-231 was incubated with either 
NaHS or GYY4137 ex vivo for 1 hour and was then used for VEGF ELISA or 
EC tube differentiation assay (Fig. 38A, B, inset illustrations). 
 Remarkably, a drastic reduction in VEGF ELISA reading was also 
measured in GYY4137 or NaHS ex vivo treated cancer CM (Fig. 38A). 500 
μM ex vivo treatment of GYY4137 reduced the ELISA reading by 40% while 
1000 μM showed a decrease of 81%. NaHS treatment was less potent than 
GYY4137 but still resulted in 26% and 55% reduction in ELISA reading with 
50 and 100 μM respectively. The data clearly indicated that H2S was capable 
to impair VEGF binding affinity. The same ex vivo NaHS-treated cancer CM 
was used to examine its activation on EC tube differentiation. In conjunction 
with the reduced VEGF binding affinity, ex vivo NaHS-treated CM failed to 
induce EC tube differentiation on matrigel (Fig. 38B). A marked reduction in 
the number of nodes and tubes formation was quantified. 50 µM of ex vivo 
NaHS treatment significantly reduced number of nodes and tubes formation by 
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more than 70%. Taken together, we concluded that H2S inhibition on cancer 
metastasis and angiogenesis was at least partly caused by its alteration on 
VEGF functional conformation via the reduction of sulfide-linkage. Reduced 
binding affinity of VEGF by H2S may not only decrease cancer autocrine for 
metastasis, but also its activation on endothelial cells to drive angiogenesis 
(Carmeliet, 2005; Gerhardt, 2008).  
 
Fig. 38. Ex vivo H2S decreases VEGF affinity binding reducing CM-
induced EC tube differentiation. (A) MDA-MB-231 cancer cells were 
treated with GYY4137 for 24 hours. Conditioned-media was collected and 
incubated with indicated concentration of GYY4137 or NaHS for 1 hour. 
VEGF binding was examined using ELISA. H2S treatment significantly 
decreased VEGF binding affinity detected using ELISA. (B) EC was seeded 
onto gel matrix in NaHS ex vivo treated CM. EC tube differentiation was 
monitored after 16 hours and number of nodes and tubes formed were 
quantified using ImageJ analysis software. Ex vivo NaHS-CM showed 
significantly reduced number of nodes and tubes formed. * P < 0.05.  
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CHAPTER 5: H2S donor as an anti-cancer agent in in 
vivo tumor model 
 
5.1 GYY4137 produces sulfide in mouse circulation and allograft tumor 
To validate the anti-cancer activity of H2S in vivo, we established a mouse 
breast adenocarcinoma 4T1-Luc allograft tumor model and tested GYY4137 
effect in a pilot study. 4T1 is a stage 4, highly aggressive mouse breast 
adenocarcinoma cell line. The cancer cells were inoculated into mouse 
mammary fat pad. The establishment of allograft breast adenocarcinoma 
tumor within mouse mammary fat pad enables tumor study under a natural 
microenvironment and proper niche of the cancer cells as compared to the 
other subcutaneous tumor models. Besides, the aggressive behavior of 4T1 
cancer cells allows us to study the effects of H2S on primary tumor growth and 
cancer metastasis using a single mouse tumor model. The growth of palpable 
primary tumor (approximately 150 mm
3
, 14 days) was monitored. Daily 
GYY4137 administration was then carried out intra-peritoneally for 14 days.  
5 mice were included in this small-scale pilot study. We first evaluated 
the sulfide release by GYY4137 in the animal model. Mouse blood samples 
were collected by facial vein prick method before and up to 120 min after 
GYY4137 administration (Golde et al., 2005). Blood sample was collected 
into a fresh tube containing 1% w/v zinc acetate solution to quench the sulfide 
and EDTA as the anticoagulant. Methylene blue derivation assay was used to 
quantify the sulfide concentration (Fig. 39A). Hemolysis is common during 
the process of blood sample collection. Therefore, a corresponding blank 
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without addition of color derivator N,NDPD was included for each blood 
sample to avoid sample-sample variation. The total sulfide concentration in 
the blood samples was calculated from a sulfide standard curve constructed 
using NaHS solution (R
2
 > 0.99). Basal total plasma sulfide measured in 
mouse blood samples was about 20 μM. 300 mg/kg GYY4137 increased the 
plasma sulfide to nearly 30 μM while 500 mg/kg increased plasma sulfide to 
50 μM, peaked at or before 30 min after compound administration (Fig. 39B). 
It was noted that the plasma sulfide concentration continued to maintain at a 
higher level in treated groups up to 120 min after compound administration. 
The results demonstrated that GYY4137 produced H2S in vivo and 
significantly increased the sulfide concentration in animal circulation.  
 GYY4137 was administered intra-peritoneally daily over 14 days. The 
tumors were harvested nearly 4 hours after GYY4137 administration and the 
sulfide concentration in tumor homogenates was measured. Homogenates 
were deproteinized by 10% w/v trichloroacetic acid precipitation prior to 
methylene blue derivation. Consistent with what we had observed in mouse 
blood plasma, the tumor sulfide concentration increased with GYY4137 
administration (Fig. 39C). The tumor sulfide remained high after 4 hours 
suggested that GYY4137 may be up taken by the animal tissues and continued 







Fig. 39. GYY4137 produces sulfide in mouse circulation and allograft 
tumor. (A) Mouse blood was collected by facial vein prick prior (t=0) and 
after GYY4137 administration intra-peritoneally. Total sulfide presence in 
samples was quenched with 1% w/v zinc acetate solution and quantified using 
methylene blue derivation assay. Total sulfide concentration was calculated 
based on a standard curve constructed using NaHS solution. (B) GYY4137 
increased total sulfide concentration in mouse circulation peaked at or before 
30 min after compound administration. Higher sulfide level was observed 
within 120 min in a GYY4137-concentration dependent manner. (C) Mouse 
breast adenocarcinoma 4T1-Luc allograft tumor was harvested and 
homogenized 4 hours after GYY4137 administration intra-peritoneally. Total 
sulfide in tumor homogenate was quantified. Increasing concentration of 
GYY4137 showed increasingly higher total sulfide concentration in tumor. (0 





5.2 GYY4137 inhibits tumor growth and metastasis 
The tumor growth was monitored and measured over time of study. Length 
and width of the tumors were measured and tumor volume was calculated. The 
4T1-Luc breast adenocarcinoma cells stably expressed luciferase as a reporter 
protein. Therefore, mice were imaged for bioluminescence signal using the in 
vivo imaging system (IVIS) following injection with luciferin solution. 
Bioluminescence signal produced by the primary tumor or other 
macrometastatic sites was recorded. GYY4137 treated mice exhibited 
significant retarded tumor growth as shown by reduced tumor volume and 
reduction in tumor gross mass (Fig. 40A, B). High intensity of 
bioluminescence was observed from primary tumor in the non-treatment group 
while GYY4137 treatment resulted in a smaller primary tumor size with lower 
bioluminescence signal (Fig. 40C). Moreover, mice in the non-treatment group 
showed bioluminescence signal from chest region indicated lung 
macrometastasis.  No bioluminescence signal was observed from chest region 
in GYY4137 treatment group. Tumor sections of GYY4137-treated groups too 
showed reduced staining of proliferation markers Ki67 and PCNA as 
compared to non-treatment group (Fig. 40D). Importantly, hematoxylin 
staining of lung tissue sections from non-treatment group contained 
macrometastasized tumor nodule which was absent in the GYY4137-treated 
groups. The cumulative evidences showed clearly the anti-tumor and anti-








Fig. 40. H2S donor as an anti-cancer agent in in vivo tumor model. (A) 
Mouse breast adenocarcinoma 4T1-Luc cells were inoculated for 14 days into 
mammary fat pad of BALB/C nude female mice. GYY4137 was administered 
intra-peritoneally daily over 14 days. Tumor growth was monitored and tumor 
was harvested after the administration course-time. (B) Gross mass of 
harvested tumors was weighted. GYY4137 treatment decreased gross mass of 
4T1-Luc allograft tumor. (0 mg/kg, n=2; 300 mg/kg, n=2; 500 mg/kg, n=1). 
(C) Mice harboring 4T1-Luc allograft tumor were imaged using in vivo 
imaging system (IVIS) after intra-peritoneal injection of luciferin solution. 
Control mouse exhibited larger tumor size and greater bioluminescence signal 
from primary tumor. Mice in treatment groups showed reduced tumor size and 
lower bioluminescence signal. Bioluminescence signal was detected in chest 
region in control mouse but not in mice in treatment groups. (D) Tumor 
harvested was sectioned and subjected to immunohistochemistry probing for 
proliferation markers Ki67 and PCNA. Tumor sections from treatment groups 
showed reduced Ki67 and PCNA expression with increasing GYY4137 
dosage. Hematoxylin staining of lung tissue sections showed macrometastasis 
of cancer cell forming tumor nodule (area marked with #) in non-treatment but 
not GYY4137 treated groups.   
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5.3 Higher lactate production in GYY437-treated mouse tumor 
We also measured the lactate amount in 4T1-Luc tumors harvested from the 
allograft tumor mice to evaluate if the in vitro H2S activity similarly occurred 
in in vivo. The tumor tissues were homogenized in 2% v/v perchloric acid 
solution to precipitate all the proteins present and to preclear the homogenates. 
After neutralization, samples were subjected to lactate dehydrogenase 
enzymatic activity assay. Lactate amount measured was normalized to the 
mass of tissue homogenated. Tumor homogenates from GYY4137-treated 
mice contained signifcantly higher intratumoral lactate concentration as 
compared to that measured in the control mice (Fig. 41). Moreover, lactate 
concentration measured in allograft tumors showed increment with increasing 
GYY4137 dosages administered. We hereby provided evidences that H2S-
induced overproduction of lactate in vivo.  
 
Fig. 41. Higher lactate production in H2S-treated mouse tumor. 4T1-Luc 
allograft tumor harvested was homogenized in 2% v/v perchloric acid solution. 
Pre-cleared homogenates were neutralized with 2M sodium bicarbonate and 
lactate amount in samples were determined by lactate dehydrogenase 
enzymatic activity assay. Tumor in GYY4137-treated groups produced higher 





5.4 Larger number animal study of in vivo allograft tumor  
A. Optimization of study setting 
Promising results from the small-number pilot study encouraged us to expand 
our animal work to a larger number animal study (n=15, 5 mice per group). A 
few modified settings were employed in the setup of this study.  
 
I) 0.5 million cells/mouse was inoculated at inguinal mammary fat pad 
A lower number of 4T1-Luc cells were used for primary tumor inoculation. 1 
million cells/mouse density used in the previous small-number pilot study 
resulted in a very large primary tumor, especially in the non-treated control 
group mice (˃ 5000 mm3 at the end of experiment). The large tumor growth 
was a burden and exerted significant stress to the animal. Due to ethical 
concern, reduced cancer cell number was used instead.  
 
II) Dosage groupings of 0, 150 and 300 mg/kg (n=5 per group) 
5 mice were included per group to provide adequate statistical power for result 
analysis. Though 500 mg/kg dose of GYY4137 previously used did not exert 
any significant toxicity to the animal, reduced dosages of 150 and 300 mg/kg 
were used in this large number study. This was to further ensure that the 
observable anti-tumor effect of GYY4137 was not due to possible negative 
impacts on the animal physiology. Compound administration was carried out 
when a palpable tumor volume of 100 mm
3




III) Longer monitoring of blood plasma sulfide kinetics 
Previous measurement of blood plasma sulfide showed that GYY4137-treated 
mice remained higher level of sulfide after 120 min post administration. We 
hereby extended the blood sample collection up to 240 min to monitor the 
sustainability of GYY4137 in animal circulation. 
 
B. Blood plasma sulfide kinetic and intratumoral sulfide measurement 
with GYY4137 administration 
Foremost, we measured the blood plasma sulfide kinetics over 4 hours after 
GYY4137 administration. Plasma sulfide was measured using methylene blue 
assay (detailed procedures were described in Section 2.21 and illustrated in 
Fig. 39A). Consistent with previous finding, intra-peritoneal administration of 
GYY4137 was rapidly absorbed into animal systemic circulation, with higher 
sulfide concentration detected after 15 min (Fig. 42A). The sulfide 
concentration peaked at or before 30 min after compound administration. 
Blood plasma sulfide dropped back to the basal level after 3 hour. The kinetic 
study demonstrates increase in circulatory sulfide concentration by GYY4137 
that sustains adequate duration of time (hours). Similarly, the intratumoral 
sulfide measurement showed an increased sulfide concentration in the tumors 
from GYY4137-treated mice. The data showed that GYY4137 was, at least 




Fig. 42. GYY4137 increases sulfide concentration. (A) Animal blood 
samples were collected over course of time up to 4 hours after GYY4137 
administration. Total sulfide presence in animal blood plasma was measured 
with methylene blue derivation assay and calculated based on a NaHS-
constructed standard curve. GYY4137 increased total sulfide concentration in 
mouse circulation, peaked at 30 min and continued to be detected within 2 
hour. (B) Mouse breast adenocarcinoma 4T1-Luc allograft tumor harvested 
was homogenized and subjected to total sulfide measurement. A significant 
and GYY4137-concentration dependent increase in total sulfide in tumor was 
observed. (n=5 per group). * P < 0.05. 
 
C. H2S donor decreases tumor growth, volume and gross mass with 
increased intratumoral lactate and decreased intratumoral pH 
Allograft 4T1-Luc tumor growth was monitored over the course of animal 
study. The tumor volume was calculated and plotted as growth curve. 
Endpoint tumor volume was presented as scattered dot plot. Filled diamond 
dots (♦) represented each individual mouse within a group while the empty 
rounded dots (○) represented the mean value of the group. GYY4137-treated 
group showed retarded tumor growth with concentration-dependent effect (Fig. 
43B). Furthermore, GYY4137 resulted in marked reduction of tumor gross 
mass, proliferation markers Ki67 and PCNA (Fig. 43C, D). All the 5 mice in 
control group showed lung macrometastatic tumor nodules while nonce was 
observed in treated groups (Fig. 43D). Lastly, intratumoral lactate was 
measured and GYY4137-treated mice harbored tumor with significantly 
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higher intratumoral lactate concentration (Fig. 44A). Using pH microelectrode, 
intratumoral pH of the treated groups was significantly lower as compared to 
control group. Thus far, our allograft tumor animal study validated the H2S-
release by GYY4137 in animal system and H2S-induced lactate 
overproduction and pH acidification seen in in vitro study was evidenced in 






Fig. 43. H2S donor decreases tumor growth, volume and gross mass with 
decreased lung macrometastasis. (A) Mouse breast adenocarcinoma 4T1-
Luc cells were inoculated for 10 days into mammary fat pad of BALB/C nude 
female mice and GYY4137 was administered intra-peritoneally daily over 14 
days. Tumor was harvested at the end of experiment and examined for tumor 
mass, sulfide and lactate concetration. (B) GYY4137 treated groups showed 
retarded tumor growth. Scattered dot plot showed distribution of tumor 
volume of all the mice in the study. ○ indicated mean of the group. − 
represented median of the group. (C) Gross mass of harvested tumors was 
weighted as presented as scattered dot plot. ○ indicated mean of the group. − 
represented median of the group. (D) GYY4137 treated groups exhibited 
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significantly decreased intensity of proliferation markers Ki67 and PCNA with 
no lung macrometastasis. (n=5 per group). 
 
 
Fig 44. GYY4137 increased intratumoral lactate production and 
decreased pH. (A) Intratumoral lactate in 4T1-Luc allograft tumor harvested 
was determined by lactate dehydrogenase enzymatic activity assay. A 
significant increase in intratumoral lactate was measured with GYY4137 
treatment as compared to control. (B) GYY4137 treatment significantly 
decreased intratumoral pH. (n=5 per group). *, # P < 0.05  
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CHAPTER 6: DISCUSSIONS AND FUTURE 
WORKS 
6.1 Concluding Remarks 
In current study, we examined if H2S possesses anti-cell viability property and 
if this effect was selective on cancer. Our data showed that a continual 
exposure to H2S released by NaHS exhibited anti-cell viability property. The 
effect was selective on cancer at low concentration range (≤ 20 μM, Fig. 2), 
but displayed no selectivity at high concentration of H2S (≥ 80 μM). This was 
possibly due to the strong inhibitory action by continual exposure to high 
concentration of H2S on mitochondrial cytochrome c oxidase. The inhibition 
of mitochondria complex was detrimental to both cancer and non-cancer cell 
types (Dorman et al., 2002). Thus, the continual exposure to low concentration 
of H2S appeared to be the key approach to achieve a selective anti-cancer 
outcome. We observed that H2S treatment significantly increased glycolysis 
and lactate production in the cancer cells (Fig. 13). Additionally, impairment 
on the pH regulator activities induced by H2S resulted in the accumulation of 
metabolic acid intracellularly thus acidified the cancer cells (Fig. 14, 19). The 
uncontrolled intracellular acidification led to the cancer cell death (Illus. 5). 
Prominently, the two mechanisms, an increased glycolysis and an impaired pH 
regulator activity, did not apply on non-cancer cells. Thus, H2S exhibited 
minimal cytotoxicity on the non-cancer cells.  
Invasive cancer cells are recognized to exhibit increased glycolytic 
activity that confers their high motility and resistance to chemo drugs (Bettum 
et al., 2015; Gatenby and Gillies, 2004). In view of this, H2S that targeted on 
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the cancer glucose metabolism was thought to be greatly effective in inhibiting 
viability of invasive cancers. Oppositely, the invasive cancers were found to 
be less sensitive to H2S (Fig. 23). Higher concentration of GYY4137 was 
required to induce intracellular lactate overproduction and pHi acidification in 
invasive cancer cell lines (Fig. 25, 26). It was then identified that the 
accumulation of intracellular lactate led to different magnitudes of pHi 
acidification in the cancer cells determined their sensitivity to H2S. Principally, 
compounds that can increase intracellular lactate accumulation may sensitize 
cancer cells to H2S. Indeed, by co-treatment of GYY4137 with MCT4 
inhibitor simvastatin, or glycolysis booster metformin, an enhanced sensitivity 
to H2S was observed (Fig. 27). We hereby conclude that H2S selectively and 
effectively decreased cancer cell viability by causing intracellular acidification 
in cancer cells. 
 
Illus. 5. Mechanistic action by H2S to trigger cancer cell death. H2S 
increases glucose uptake by cancer cells that enhances glycolysis. 
Overproduction of lactate from glycolysis couples with an impaired pH 
regulator activity results in accumulation of metabolic acid intracellularly. 
Intracellular acidification thence triggers cancer cell death.  
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Using MDA-MB-231 and HeyA8 invasive cancer cell line models, 
H2S treatment was shown to significantly suppressed cancer cell migration, 
transwell chemoinvasion and tumorigenicity (Fig. 28-30), demonstrating 
promising anti-metastasis property. Moreover, H2S significantly reduced the 
cell viability of cancer-activated endothelial cells by inducing intracellular 
lactate overproduction and pHi acidification (Fig. 32-34, Illus. 6). H2S caused 
neither pHi acidification nor significant cell death in endothelial cell under 
normal culture condition, indicating the cancer-context specific action of H2S. 
H2S too showed an inhibitory effect on cancer spheroid-attracted endothelial 
cell migration and cancer-activated endothelial tube differentiation. The data 
showed an anti-cancer angiogenesis activity by H2S. Importantly, the anti-
cancer activity of H2S was validated in vivo. GYY4137 administration 
increased sulfide concentration in the animal circulation and in the tumor. A 
retarded tumor growth and reduced tumor volume and gross mass were 
measured in GYY4137-treated mice as compared to non-treated control group. 
Lung macrometastasis events happened in non-treated control mice but were 
absent in GYY4137-treated group. Taken together, we provide direct 
evidences of using a single agent H2S, it is possible to inhibit the tumor 




Illus. 6. Potential of using H2S as an anti-cancer agent. H2S targeting on 
glucose metabolism and pH homeostasis that leading to intracellular 
acidification. The unique mechanism by H2S makes H2S donor a potential 
cancer therapeutic agent systemically inhibits tumor growth, cancer metastasis 
and cancer angiogenesis.  
 
6.2 Discussions and Future Works 
A. Low concentration but sustained-release of sulfide to anti-cancer 
Sulfide acting as an anti-cancer agent was claimed by other studies that had 
used organosulfurs or HS-NSAIDs as the H2S donors (Chattopadhyay et al., 
2012; Thomson and Ali, 2003). However, none had systematically 
demonstrated that H2S was the exact sulfur species that possessed anti-cancer 
activity. In this study, we used the simplest sodium salt of sulfide, NaHS as 
the H2S donor and studied its effect on cancer. A single administration of 
NaHS, even though at the high concentrations (> 80μM) was not effective in 
reducing cancer cell viability (Fig. 2). Oppositely, continual NaHS treatment 
by changing into fresh NaHS solution every 2 hours caused significant 
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reduction in cell viability. However, continual, high concentration of NaHS 
exposure non-selectively killed both cancer and non-cancer cells. It appeared 
that the cancer-selective concentration window was within 5-20 μM of NaHS. 
This was the first study that clearly showed that a prolonged exposure to low 
concentration, of H2S, was the key to achieve selective anti-cancer effect using 
H2S. It was unrealistic to constantly provide fresh H2S solution in clinic to 
anti-cancer. Hence, the slow-releasing H2S donor GYY4137 that is able to 
sustain long H2S-release is a valuable tool. Moreover, using GYY4137 at the 
working concentrations that effectively killed cancer cells yet produced only 
low amount of H2S, did not detrimentally affect mitochondrial functionality 
thence possessed low toxicity on non-cancer cells (Dorman et al., 2002; 
Dorman et al., 2004). Based on the knowledge gathered from this study, 
sulfide donors that are able to release H2S at a low concentration and sustained 
manner will be useful as an anti-cancer agent. Of interest, bioactive 
compounds extracted from food and cysteine-activated sulfide donors hold 
great potential for further development (Zhao et al., 2010).  
 
B. H2S targeting on glycolytic adaptation of cancers 
Targeted therapy or personalized medicine based on genetic alterations 
identified in cancer, such as the up-regulation of pro-survival signaling Akt 
pathway, tyrosine kinase activated pathways or growth factor dependent 
pathways, had gained huge interest in the past decades (Green, 2004; Sawyers, 
2004). Though producing promising outcomes, relapse of compound-
resistance cancer cases were not uncommon. This may partly contributed by 
the heterogeneity in tumor and the clonal selection from the use of the targeted 
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compounds. In most of the relapse cases, the tumor appeared to be more 
aggressive and difficult to treat (Nahta et al., 2006; Rini and Atkins, 2009). It 
was increasingly clear now that many of those altered signaling pathways 
harbored by cancer cells converged into a glycolytic phenotype that conferred 
the tumor growth and metastasis (Zhao et al., 2013). The same switch to an 
enhanced glycolysis was also evidenced in the cancer-activated endothelial 
cells, promoting cancer angiogenesis (Polet and Feron, 2013). The fact that 
H2S targeted on this common phenotypic changes by cancer and cancer-
activated endothelial cells made H2S an effective agent to anti-cancer cell 
viability and angiogenesis. In comparison to targeted therapy, H2S may show 
efficacy on pan-general cancers regardless of its tissue origin or genetic 
signatures. It was also noteworthy that cancer stem cells which were usually 
resistant to chemo- or radiotherapy exhibited high reliance on the glucose 
metabolism for their energy supply (Shen et al., 2015). Studying the effects of 
H2S on cancer stem cell is an interesting area worth to explore in the future.  
 
C. Manipulating intracellular lactate accumulation to increase H2S 
sensitivity 
Interfering with the lactate accumulation inside cancer cells is a plausible 
approach to enhance sensitivity of the cancer cells to H2S. An attempt to use 
monocarboxylate transporter (MCT) inhibitor to anti-cancer was not a new 
idea. Instead, several in vitro models had demonstrated positive results from 
inhibition of activity or silencing of expression of MCT. Treatment of siRNA 
targeting MCT4 significantly suppressed MDA-MB-231 transwell migration, 
mediated by disruption of matrix metalloproteinase release from the cancer 
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cells (Gallagher et al., 2007). Inhibition of MCT1 also resulted in cell death of 
human glioblastoma, and an increased apoptosis and necrosis were observed 
in conjunction with silencing of MCT2 expression (Mathupala et al., 2004). 
However, when translated into systemic physiology, toxicity of MCT 
inhibition on normal tissues was a big concern. Systemic delivery of MCT 
inhibitor affected many organs especially cardiac and skeletal muscles 
(Fishbein, 1986). An obvious muscle fatigue and inability to tolerate high-
intensity exercises were symptoms due to the accumulation of lactate in the 
muscles. In worse cases, cardiac dysfunction caused from intracellular build-
up of proton was possible. Our combinatorial treatment of GYY4137 with 
MCT4 inhibitor simvastatin resulted in greater cancer cell sensitivity to H2S 
(Fig. 27). The non-lethal concentration of simvastatin used warranted low to 
no toxicity on normal tissues. Metformin is a generic drug used to treat 
patients with Type-2 diabetes. It acts by partially blocking mitochondrial 
complex I and activating AMPK to increase glucose utilization in periphery 
tissues (Viollet et al., 2012). An enhanced sensitivity to H2S in cancers was 
also observed with co-treatment of GYY4137 with metformin. These 
promising data opens up a new, worth-to-explore field in developing 
combinatorial treatment regime with GYY4137. Repurposing of the existing 
approved drugs in combination with GYY4137, especially those known to 





D. Exploiting pHi homeostasis by H2S to anti-cancer 
Cancer cells are particularly vulnerable to the harmful effects of accumulation 
of metabolic acid produced from their glucose metabolism (McCarty and 
Whitaker, 2010; Neri and Supuran, 2011; Reshkin et al., 2014). Thence, they 
evolve extensive pH regulatory mechanisms to maintain an alkaline 
physiological pHi for their survival. Theoretically applicable, pHi acidification 
can be achieved by either increasing metabolic acid production or inhibiting 
pH regulators. One possible way to do so was to use mitochondrial inhibitors 
to increase glycolysis thus to induce pHi acidification. However, from our 
present work, it was clear that solely by increasing lactate production was 
insufficient to trigger cancer cell death (Fig. 21). Alternatively, inhibition of 
pH regulators such as carbonic anhydrases, sodium/proton exchangers (NHE) 
and anion exchangers (AE) may result in pHi imbalance. Yet, the systemic use 
of the inhibitors remained subtle. Our data showed that inhibition of NHE and 
AE was unable to induce significant decrease in pHi, possibly due to 
compensation by other pH regulators that were highly expressed by cancer 
cells (McCarty and Whitaker, 2010). In fact, mitochondrial inhibitors and pH 
regulator inhibitors alone, and presumably in combination; possessed high 
toxicity in physiology (Knobeloch et al., 1990; Swarnkar et al., 2013; Theroux 
et al., 2000; Yamagata and Tannock, 1996). Under this context, H2S that 
concurrently increased metabolic acid production and impaired pH regulation 




E. Tumor-specific delivery of sulfide using thio-sugar 
In view of the glycolytic nature of cancers, H2S donors with glucose moiety 
such as thio-glucose may be preferentially taken up by cancer cells. This 
makes cancer-targeted delivery possible. The localized production of H2S by 
thio-glucose in tumor was believed to enable in situ anti-cancer activity by 
H2S. Furthermore, the glucose backbone formed after sulfide release exhibits 
no toxicity, relieving concerns of formation of side products that may cause 
adverse effects in chemotherapy. The glucose backbone can then be channeled 
into H2S-induced increased glycolysis to worsen the pHi acidification in 
cancer cells. The idea of using thio-conjugated sugars as a therapeutic agent 
was previously shown. In particular, S-glycan oligosaccharide was designed to 
be used as a mimic of cell adhesion molecule selectin (Dey PM, Witczak ZJ 
2003). Selectin is an antigen molecule highly expressed on metastatic colon 
and pancreatic cancers. Neutralization of selectin using these S-glycan mimics 
possessed anti-metastatic potential. Many other thiol-glycosides were naturally 
found or synthesized for their biological activities in antimicrobial and 
antifungal (Witczak and Culhane, 2005). These thiol-glycosides were able to 
conjugate with glycan side chains abundantly present on the membrane of 
bacteria then action on site. Applying similar concept, thio-sugars that can 
conjugate with cancer-specific membrane glycans may be designed hence 




F. Anti-cancer metastasis and angiogenesis by H2S: VEGF as the central 
player 
It is well described that the important cross talk via soluble factors between 
cancer cells and endothelial cells facilitates cancer metastasis and 
angiogenesis in dual directions (Shahi and Pineda, 2008). VEGF is one of, if 
not, the most important cancer-released factors that involves in these two 
carcinogenic processes (Carmeliet, 2005). A positive VEGF autocrine 
signaling is essential in oncogenic transformation. The cancer stem cells were 
found to up-regulate the Hedgehog target GLI family zinc finger 1 (GLI1) and 
the Polycomb group repressor BMI1 to maintain a consecutively active 
production of the VEGF to drive angiogenesis in nascent tumors (Chatterjee et 
al., 2013). An increased endothelium permeability and interendothelial 
junctions induced by VEGF too promoted cancer extravasation (Monsky et al., 
1999).  
VEGF is belongs to a growth factor family with signature cystine-knot 
motif (Iyer and Acharya, 2011). The six family members of VEGF (-A, -B, -C, 
-D, -E and placenta growth factor PlGF) shared little sequence homology but 
preserved common structural architecture that was maintained by intrachain 
and interchain disulfide bonds. Conventionally, VEGF is biologically active as 
a dimeric ligand. Disruption of the cystine-knot caused dramatic changes on 
the protein conformation and abolished its dimerization or binding onto VEGF 
receptor (Muller et al., 1997). H2S produced by GYY4137 was found to 
reduce cysteine sulfide-linkage in cancer-released VEGF and caused 
conformational change of the protein (Fig. 37). The disruptive effect of H2S on 
VEGF structure and its binding activity explained the H2S bioactivity in 
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inhibiting cancer cell metastasis and angiogenesis. However, in our current 
experiment, we could not exclude the possibility that H2S might interfere with 
VEGF protein synthesis or excretion out from the cell. Possibly, this can be 
assessed by quantifying expression of intracellular and extracellular GFP-
tagged VEGF protein with treatment of GYY4137. If H2S is to interfere with 
VEGF excretion, we would expect a marked reduction of intracellular green 
fluorescence signal. Notably, the existence of cystine-knot is not specific only 
on VEGF, but appears to be an important feature of many other cytokine 
proteins. In particular, other growth factor cystine-knots (GFCK) -containing 
proteins such as the platelet-derived growth factor (PDGF), nerve growth 
factor (NGF), transforming growth factor-b (TGF-b), and glycoprotein 
hormones (GPHs) may possibly affected by H2S too (Iyer and Acharya, 2011). 
These cytokine molecules are also involving in the cancer metastasis and 
angiogenesis. Future works to elucidate possible alteration of activity on these 
growth factors by H2S will enhance the potential of using H2S in various 
pathologies.  
 
G. Molecular modification by H2S: Sulfhydration 
A major challenge in developing H2S as an anti-cancer agent is the 
identification of its molecular targets. H2S is lipophilic in nature thus is freely 
permeable through plasma membrane (Cuevasanta et al., 2012). This implies 
that the transport of H2S into cells does not require facilitation of any protein 
transporter. It is therefore difficult to estimate its distribution and to identify 
its exact site of actions. Using hexane organic solvent and octanol as biomimic 
plasma bilayer membranes, H2S was found to be highly soluble within the 
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hydrophobic core (Cuevasanta et al., 2012). With the higher solubility in lipid 
than in aqueous, H2S may likely to accumulate within the plasma membrane 
bilayer. Thence, membrane-bound proteins such as glucose transporter (Glut1) 
and transmembrane pH regulators may be some of those protein candidates 
that are being regulated by H2S.  
Under physiological pH, dissociation constant of H2S indicates that 
about two-third of the gas exists as sulfide (HS
-
) ions (Cuevasanta et al., 
2012). HS
-
 species is a strong nucleophile that can covalently link with sulfur 
atom of a partially positively charged cysteine amino acid residue, forming S-
SH bond. This novel post-translational modification is termed as sulfhydration 
(Mustafa et al., 2009). Sulfhydration had been reported to occur in 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and actin. Addition of 
SH
-
 modulated the protein activity of GAPDH and actin (Paul and Snyder, 
2012). Alternatively, H2S may reduce disulfide linkage between two cysteine 
residues. Cys1045-1024 disulfide bond of VEGFR2 was reported to be labile 
and was susceptible to H2S-mediated reduction to form S-SH modification 
(Tao et al., 2013a). The reduction of sulfide bond increased activation of 
VEGFR signaling pathway that contributed to a pro-angiogenic effect of 
NaHS.  
In our study, we employed a modified sulfide-linkage derivation assay 
that detects possible sulfide modification on cysteine residue of a protein 
(detailed procedures described in Section 2.13). The blocking of all thiol ends 
with NEM following with reduction of S-S bonds using high concentration of 
DTT enabled us to derive sulfide-linkages present on the proteins, regardless 
of per- (S-S) or polysulfide [(S-S)n] linkages. It was clearly shown that H2S 
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from GYY4137 induced the formation of sulfide-linkage in Glut1 that led to 
the oligomerization of the protein. The Glut1 oligomers were higher in activity 
and promoted increased glucose uptake of the cells (Hebert and Carruthers, 
1992; Zottola et al., 1995). On the other hand, GYY4137 reduced sulfide-
linkage formation in cancer VEGF that induced conformational disruption of 
the important angiogenic factor. The alteration on protein sulfide-linkages, at 
least in Glut1 and VEGF, demonstrated the possible molecular modification 
induced by H2S. Potentially, H2S may also induce sulfide-linkage changes on 
the other proteins of interest, particularly transmembrane pH regulators. This 
remains a big area for further exploration.  
The cysteine sulfide-linkage derivation assay used in current study 
enabled detection of any sulfide-linkages present in a protein. Yet, limitation 
exists as the assay was unable to distinguish between per- (S-S) or polysulfide 
[(S-S)n] modifications. In order to identify the exact modification caused by 
H2S, mass spectrometry approach would be a good consideration (Murray and 
Van Eyk, 2012). The method based on switching labile sulfide modification to 
stable labelling can sensitively detect mass changes in protein peptide with 
H2S treatment. Moreover, quantitative proteomic approaches such as iTRAQ 
and SILAC can be combined with the sulfide labelling prior to mass 
spectrometry analysis so to relatively quantify the abundancy of cysteine 
modification (Ong et al., 2002; Ross et al., 2004). Cysteine residues involve in 
the sulfide modification can also be identified using mass spectrometry. This 
approach will be particularly useful to identify cysteine entity modulated by 




H. Active species from H2S: Sulfide or polysulfide? 
Sulfur species that is responsible for the abovementioned physiological 
responses remains subtle. The query was raised based on the lability of HS
-
 
ion and volatility of the intact H2S gas molecule. It was therefore unlikely for 
H2S to exert such bioactivities, and even if it was, the responses would be 
short-lived. Moreover, H2S was the sulfur species with the lowest oxidation 
state thus was not active enough to lead to oxidative thiol modification on 
protein (Greiner et al., 2013). The research group analyzed many different H2S 
donors including NaHS, Na2S and GYY4137, and detected formation of 
polysulfide in the prepared aqueous solution. These polysulfides were with 
high reactivity and were found to be able to readily modified proteins inside 
the cells.  
A major endogenous pool of sulfide is the bound sulfane sulfur 
(Ogasawara et al., 1994). These sulfides are bound to protein as storage. The 
release of sulfide from bound sulfane pool requires reducing condition, such as 
addition of reductant DTT, suggesting that the stored sulfide must be existed 
as oxidized forms (per- or polysulfide). Though unable to detect polysulfide 
release from astrocyte lysate, Kimura reported that Na2S3, Na2S4, H2S3 and 
H2S4-derived polysulfide, as compared to NaHS, was much more potent in 
activating TRPA1 channels in rat astrocytes (Kimura et al., 2013). Moreover, 
dissolution of elemental sulfur in NaHS solution yielded a yellow color 
solution that was potently activated astrocytes. It was speculated that the 
yellow solution containing H2Sn species, of particular Na2S3 and sodium 
pentasulfide (Searcy and Lee, 1998). Polysulfides were also higher in stability 
and longer lived in solution to exert biological actions. The author thus 
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concluded that polysulfide was the active entity that mediated sulfide 
signaling. Identification of the signaling molecules responsible for sulfide 
action will greatly advance our knowledge and greater potency sulfide 
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